Document:

Asset Purchase Agreement between the Company and GMN, Inc.

 Exhibit 10.6 
 CONFIDENTIAL PROVISIONS REDACTED 
 ASSET PURCHASE AGREEMENT 
 BY AND BETWEEN 
 PDL BIOPHARMA, INC., 

 a Delaware corporation 
 and

 GMN, INC., 
 a Delaware
corporation 
 Dated as of February 21, 2008 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 TABLE OF CONTENTS 
  

					
	  	  	 	  	Page
	 ARTICLE 1 DEFINITIONS
	  	1
		
	 ARTICLE 2 TRANSFER OF ASSETS; LICENSE AND SUBLICENSE
	  	9
	 2.1
	  	 Purchase and Sale of Assets
	  	9
	 2.2
	  	 Excluded Assets
	  	10
	 2.3
	  	 Assumed Liabilities
	  	10
	 2.4
	  	 Excluded Liabilities
	  	11
	 2.5
	  	 Risk of Loss
	  	11
		
	 ARTICLE 3 CONSIDERATION
	  	11
	 3.1
	  	 Purchase Price
	  	11
	 3.2
	  	 Method of Payment
	  	11
	 3.3
	  	 Allocation of Purchase Price
	  	12
		
	 ARTICLE 4 CLOSING
	  	12
	 4.1
	  	 Closing
	  	12
	 4.2
	  	 Actions at Closing
	  	12
	 4.3
	  	 Prorations
	  	15
		
	 ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF SELLER
	  	16
	 5.1
	  	 Organization and Authority
	  	16
	 5.2
	  	 No Violation or Conflict
	  	17
	 5.3
	  	 Consents and Approvals
	  	17
	 5.4
	  	 Assumed Contracts
	  	17
	 5.5
	  	 Compliance with Legal Requirements; Governmental Authorizations
	  	18
	 5.6
	  	 Legal Proceedings; Orders
	  	20
	 5.7
	  	 Environmental Matters
	  	20
	 5.8
	  	 Title to Assets; Real Property, Equipment and Supplies
	  	21
	 5.9
	  	 Sufficiency of Assets
	  	22
	 5.10
	  	 Condition of Tangible Personal Property
	  	22
	 5.11
	  	 Supplies
	  	22
	 5.12
	  	 Trade Secrets
	  	23
	 5.13
	  	 Brokers and Finders
	  	23
	 5.14
	  	 No Implied Warranty
	  	23
	 5.15
	  	 Condition of Facilities
	  	23
	 5.16
	  	 Disclosure
	  	24
	 5.17
	  	 Product Liability
	  	24
	 5.18
	  	 Suppliers
	  	24
	 5.19
	  	 Employees
	  	24
	 5.20
	  	 Insurance
	  	25
		
	 ARTICLE 6 REPRESENTATIONS AND WARRANTIES OF BUYER
	  	25
	 6.1
	  	 Organization and Authority
	  	25
	 6.2
	  	 No Conflict or Violation
	  	25

  

 CONFIDENTIAL TREATMENT REQUESTED 
 i 

 TABLE OF CONTENTS 
 (continued) 
  

					
	  	  	 	  	Page
	 6.3
	  	 Consents and Approvals
	  	25
	 6.4
	  	 Cash Resources
	  	26
	 6.5
	  	 Seller’s Records
	  	26
	 6.6
	  	 Environmental Governmental Authorizations
	  	26
	 6.7
	  	 Litigation
	  	26
	 6.8
	  	 Brokers and Finders
	  	26
	 6.9
	  	 Buyer Due Diligence
	  	26
		
	 ARTICLE 7 PRE-CLOSING COVENANTS
	  	27
	 7.1
	  	 Governmental Filings
	  	27
	 7.2
	  	 Conduct of Operations
	  	27
	 7.3
	  	 Obtaining Necessary Consents and Lease Extensions
	  	27
	 7.4
	  	 No Solicitation
	  	28
	 7.5
	  	 Access
	  	28
	 7.6
	  	 Title Insurance
	  	29
	 7.7
	  	 Inspections
	  	30
	 7.8
	  	 Employees
	  	31
	 7.9
	  	 Bulk Transfer Laws
	  	32
	 7.10
	  	 Brokers and Finders
	  	32
		
	 ARTICLE 8 CONDITIONS TO CLOSING
	  	32
	 8.1
	  	 Conditions to Obligations of Buyer
	  	32
	 8.2
	  	 Conditions to Obligations of Seller
	  	33
		
	 ARTICLE 9 POST-CLOSING COVENANTS
	  	34
	 9.1
	  	 Further Assurances
	  	34
		
	 ARTICLE 10 CONFIDENTIALITY
	  	34
	 10.1
	  	 Confidentiality
	  	34
	 10.2
	  	 Publicity
	  	34
		
	 ARTICLE 11 TERM AND TERMINATION
	  	35
	 11.1
	  	 Termination
	  	35
	 11.2
	  	 [****]*
	  	36
	 11.3
	  	 Consequences of Termination
	  	36
	 11.4
	  	 Effectiveness
	  	36
		
	 ARTICLE 12 INDEMNIFICATION
	  	36
	 12.1
	  	 Survivability of Representations and Warranties
	  	36
	 12.2
	  	 Indemnification by Buyer
	  	37
	 12.3
	  	 Indemnification by Seller
	  	37
	 12.4
	  	 Claims
	  	37

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 ii 

 TABLE OF CONTENTS 
 (continued) 
  

					
	  	  	 	  	Page
	 12.5
	  	 Assertion of Claims
	  	38
	 12.6
	  	 Payment of Claims; Limitation on Indemnification
	  	38
	 12.7
	  	 Limitation; Exclusivity
	  	38
		
	 ARTICLE 13 MISCELLANEOUS
	  	38
	 13.1
	  	 No Third Party Beneficiaries
	  	38
	 13.2
	  	 Governing Law; Jurisdiction; Dispute Resolution and Arbitration
	  	39
	 13.3
	  	 Severability
	  	39
	 13.4
	  	 Entire Agreement
	  	40
	 13.5
	  	 Amendment
	  	40
	 13.6
	  	 Notices
	  	40
	 13.7
	  	 Assignment
	  	41
	 13.8
	  	 No Agency
	  	41
	 13.9
	  	 Construction
	  	41
	 13.10
	  	 Payment of Expenses
	  	42
	 13.11
	  	 Counterparts
	  	42

  

 CONFIDENTIAL TREATMENT REQUESTED 
 iii 

 LIST OF EXHIBITS, ATTACHMENT AND SCHEDULES 
 EXHIBITS 
  

			
	 Exhibit A
	  	 General Assignment and Bill of Sale

	 Exhibit B
	  	 Limited Warranty Deed

	 Exhibit C
	  	 Assignment and Assumption Agreement

	 Exhibit D
	  	 Lease Assignment and Assumption Agreement

	 Exhibit E
	  	 Note Assignment

	 Exhibit F
	  	 Clinical Drug Substance Supply Agreement

	 Exhibit G
	  	 Transition Services Agreement

	 Exhibit H
	  	 Form of Third Party Consent

 ATTACHMENTS 
  

			
	 Attachment 1.30
	  	 Environmental Governmental Authorizations

	 Attachment 1.52
	  	 Knowledge Employees

	 Attachment 2.1(d)
	  	 Equipment

	 Attachment 2.1(e)
	  	 List of Assumed Contracts

	 Attachment 4.2(a)
	  	 List of Third Party Consents

		
	 SCHEDULES
	  	
		
	 Schedule 5.3
	  	 Seller’s Required Consents

	 Schedule 5.4(a)
	  	 Status of Assumed Contracts

	 Schedule 5.4(b)
	  	 Third Party Consents

	 Schedule 5.4(c)
	  	 Compliance with Contracts/Leases

	 Schedule 5.5(a)
	  	 Compliance with Legal Requirements

	 Schedule 5.5(b)
	  	 Governmental Authorizations

	 Schedule 5.6(a)
	  	 Proceedings

	 Schedule 5.6(b)
	  	 Orders

	 Schedule 5.7
	  	 Environmental Matters

	 Schedule 5.8(a)
	  	 Tangible Personal Property

	 Schedule 5.8(d)(i)
	  	 Description of Real Property

	 Schedule 5.8(d)(ii)
	  	 Title to Real Property

	 Schedule 5.9
	  	 Sufficiency of Assets

	 Schedule 5.10
	  	 Ownership of Tangible Personal Property

	 Schedule 5.12
	  	 Employee Inventions, etc.

	 Schedule 5.13
	  	 Seller’s Brokers

	 Schedule 5.18
	  	 Suppliers

	 Schedule 5.19
	  	 Operations Employees

	 Schedule 6.3
	  	 Buyer’s Required Consents

	 Schedule 6.8
	  	 Buyer’s Brokers

	 Schedule 7.8(a)
	  	 Seller’s Retained Employees

  

 CONFIDENTIAL TREATMENT REQUESTED 
 iv 

 ASSET PURCHASE AGREEMENT 
 This Asset Purchase Agreement (this “Agreement”) is entered into as of February 21, 2008 (the “Effective Date”)
between PDL BioPharma, Inc., a Delaware corporation (“Seller”), and GMN, Inc., a Delaware corporation (“Buyer”), a wholly owned subsidiary of Genmab A/S, a corporation existing under the laws of Denmark. 

RECITALS 
 A. Seller is engaged in,
among other businesses, the Operations. 
 B. Seller desires to sell, transfer and assign to Buyer, and Buyer wishes to acquire, all right,
title and interest in and to the Assets, in exchange for consideration consisting of cash and the assumption of certain Liabilities related to the Assets, pursuant to the terms and conditions set forth in this Agreement. 
 C. Concurrently with the execution and delivery of this Agreement, Buyer and Seller are executing and delivering that certain Clinical Drug Substance
Supply Agreement in the form attached hereto as Exhibit F, to be effective as of the Closing Date. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration, the
sufficiency and receipt of which are hereby acknowledged, the parties to this Agreement agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 1.1 “3750
Lease” means that certain Lease Agreement between St. Paul Properties, Inc., as landlord, and Seller, as tenant, dated March 7, 1996, as amended February 28, 1999 and September 12, 2003 covering approximately 2,034 square
feet of space at premises known as 3750 Annapolis Lane, Plymouth, MN 55447. 
 1.2 “3850 Lease” means that certain Lease
Agreement between St. Paul Properties, Inc., as landlord, and Seller, as tenant, dated May 31, 2001 covering approximately 27,259 square feet of space at premises known as 3850 Annapolis Lane, Plymouth, MN 55447. 
 1.3 “Affiliate” with respect to any party shall mean any entity that is directly or indirectly controlling, controlled by or under
common control with such party. 
 1.4 “Agreement” shall have the meaning given in the preamble above. 
 1.5 “Arbitration Notice” shall have the meaning given in Section 13.2. 
 1.6 “Assets” shall have the meaning given in Section 2.1. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 1.7 “Assignment and Assumption Agreement” shall have the meaning given in
Section 4.2(a)(iv). 
 1.8 “Assumed Contracts” shall have the meaning given in Section 2.1(e). 
 1.9 “Assumed Liabilities” shall have the meaning given in Section 2.3. 
 1.10 “[****]*” shall have the meaning given in Section 11.2. 
 1.11 “Buyer Indemnitees” shall have the meaning given in Section 12.3. 
 1.12 “Buyer Notice Deadline” shall have the meaning given in Section 7.7(a). 
 1.13 “Buyer Termination Deadline” shall have the meaning given in Section 7.7(b). 
 1.14 “Claim” shall have the meaning given in Section 12.4. 
 1.15 “Clinical Drug Substance Supply Agreement” shall mean the agreement entered into by Buyer and Seller effective as of the Closing
Date relating to manufacture and supply of certain products. 
 1.16 “Closing” and “Closing Date” shall
have the respective meanings given in Section 4.1. 
 1.17 “Confidential Information” shall have the meaning ascribed
to it in the Confidentiality Agreement. 
 1.18 “Confidentiality Agreement” shall mean that certain Mutual Confidentiality
Agreement between Buyer and Seller dated November 13, 2007, as amended. 
 1.19 “Consent” means any approval, consent,
ratification, waiver or other authorization. 
 1.20 “Contemplated Transactions” shall mean the transactions contemplated by
this Agreement, including all transactions contemplated by the other agreements contemplated by this Agreement. 
 1.21
“Contract” means any agreement, contract, lease, covenant, promise or undertaking (whether written or oral and whether express or implied). 
 1.22 “Cure Notice Deadline” shall have the meaning given in Section 7.6. 
 1.23
“Current Survey” shall mean an ALTA Non-Topographical Survey prepared by a surveyor approved by Seller and licensed to perform surveying work in the State of Minnesota certified to Buyer and the Title Company and with such other
certification as may be reasonably required by Title Company, meeting the minimum detail standard requirements adopted by ALTA in 2005. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 2 

 1.24 Development Agreement” shall have the meaning given in Section 2.1(e). 

1.25 “Effective Date” shall have the meaning given in the preamble above. 
 1.26 “Encumbrance” means any charge, claim, community or other marital property interest, condition, equitable interest, lien, option,
pledge, security interest, mortgage, right of way, easement, encroachment, servitude, right of first option, right of first refusal or similar restriction, including any restriction on use, voting (in the case of any security or equity interest),
transfer, receipt of income or exercise of any other attribute of ownership. 
 1.27 “Environment” means soil, land surface
or subsurface strata, surface waters (including navigable waters and ocean waters), groundwater, drinking water supply, stream sediments, ambient air (including indoor air), plant and animal life and any other environmental medium or natural
resource. 
 1.28 “Environmental Cure Notice Deadline” shall have the meaning given in Section 7.7(b). 
 1.29 “Environmental Cure Response Notice” shall have the meaning given in Section 7.7(b). 
 1.30 “Environmental Governmental Authorizations” shall mean the permits described in Attachment 1.30. 
 1.31 “Environmental Inspections” shall have the meaning given in Section 7.5. 
 1.32 “Environmental Laws” means any Legal Requirement that requires or relates to: 
 (a) advising appropriate authorities, employees or the public of intended or actual Releases of pollutants or hazardous substances or
materials, violations of discharge limits or other prohibitions and the commencement of activities, such as resource extraction or construction, that could have significant impact on the Environment; 
 (b) preventing or reducing to acceptable levels the Release of pollutants or hazardous substances or materials into the Environment;

 (c) reducing the quantities, preventing the Release or minimizing the hazardous characteristics of wastes that are
generated; 
 (d) assuring that products are designed, formulated, packaged and used so that they do not present unreasonable
risks to human health or the Environment when used or disposed of; 
 (e) protecting resources, species or ecological
amenities; 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 3 

 (f) reducing to acceptable levels the risks inherent in the transportation of hazardous
substances, pollutants, oil or other potentially harmful substances; 
 (g) cleaning up pollutants that have been Released,
preventing the Threat of Release or paying the costs of such clean up or prevention; or 
 (h) making responsible parties pay
private parties, or groups of them, for damages done to their health or the Environment or permitting self-appointed representatives of the public interest to recover for injuries done to public assets; 
 Environmental Laws include, but are not limited to, the Comprehensive Environmental Response, Compensation, and Liability Act, the Resource Conservation and Recovery
Act, the Clean Water Act, the Clean Air Act, the Toxic Substances and Control Act, and the Federal Insecticide, Fungicide, and Rodenticide Act. 
 1.33 “Environmental Remediation” shall mean the cure or correction of an Environmental Remediation Obligation to the levels required by Environmental Laws applicable to the Real Property. 
 1.34 “Environmental Remediation Obligation” shall have the meaning given in Section 7.7(b). 
 1.35 “Environmental Remediation Obligation Notice” shall have the meaning given in Section 7.7(b). 
 1.36 “Excluded Assets” shall have the meaning given in Section 2.2. 
 1.37 “Excluded Liabilities” shall have the meaning given in Section 2.4. 
 1.38 “Facilities” shall mean the Real Property, the Leased Properties and the biologic manufacturing facilities thereon. 
 1.39 “Governmental Authorization” means any Consent, license, registration or permit issued, granted, given or otherwise made available
by or under the authority of any Governmental Entity or pursuant to any Legal Requirement. 
 1.40 “Governmental Entity”
shall mean any court, tribunal, arbitrator, authority, agency, commission, department, bureau, board, including any board of fire underwriters, fire insurance rating organization, regulatory body, official or other instrumentality of the government
of the United States or of any foreign or multinational body, any state or any political subdivision of any such government or body (whether state, provincial, county, city, municipal or otherwise) or any other governmental, public or quasi-public
authority. 
 1.41 “Hazardous Substances” shall mean any material, waste, chemical, compound, substance, mixture, or
byproduct that is identified, defined, designated, listed, restricted or otherwise regulated under Environmental laws as a “hazardous constituent,” “hazardous substance,” “hazardous material,” “extremely hazardous
material,” “restricted hazardous waste,” “hazardous waste,” “acutely hazardous waste,” “hazardous waste constituent,” “infectious 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 4 

 
waste,” “medical waste,” “biohazardous waste,” “extremely hazardous waste,” pollutant,” “toxic pollutant,”
“toxic waste”, “toxic substance” or “contaminant,” or any other names intended to identify substances by reason of properties that are deleterious to the Environment, natural resources or public health or safety
including by reason of, without limitation, ignitability, corrosiveness, reactivity, carcinogenicity, toxicity, and reproductive toxicity. The term Hazardous Substance shall include, without limitation, the following: (i) a “Hazardous
Substance,” “Hazardous Material,” “Hazardous Waste,” or “Toxic Substance” under the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. Section 9601, et seq., the Hazardous
Materials Transportation Act, 49 U.S.C. Section 5101, et seq. or the Solid Waste Disposal Act, 42 U.S.C. Section 6901, et seq., including any regulations promulgated thereunder, as any of the foregoing may be amended;
(ii) “Oil” or a “Hazardous Substance” under Section 311 of the Federal Water Pollution Control Act, 33 U.S.C. Section 1321, as may be amended; as well as petroleum and any other hydrocarbonic substance, fraction,
distillate or by-product; (iii) mold; (iv) asbestos and any asbestos containing material, urea formaldehyde and polychlorinated biphenyls; and/or (v) a substance that, due to its characteristics or interaction with one or more other
materials, wastes, chemicals, compounds, substances, mixtures, or byproducts, damages or threatens to damage the Environment, natural resources or public health or safety, or is required by any law or public entity to be remediated, including
remediation which such law or public entity requires in order for property to be put to any lawful purpose. 
 1.42 “HSR”
shall mean the United States Hart-Scott-Rodino Antitrust Improvements Act of l976, as amended, and rules thereunder. 
 1.43 “HSR
Filings” shall have the meaning given in Section 7.1. 
 1.44 “Identified Employee” shall have the meaning
given in Section 7.8(a). 
 1.45 “Indemnified Party” shall have the meaning given in Section 12.4. 
 1.46 “Indemnifying Party” shall have the meaning given in Section 12.4. 
 1.47 “Inspection Notice Deadline” shall have the meaning given in Section 7.7(a). 
 1.48 “Inspection Response Notice” shall have the meaning given in Section 7.7(a). 
 1.49 “Intellectual Property Assets” shall have the meaning given in Section 5.12(a). 
 1.50 “JAMS” shall have the meaning given in Section 13.2. 
 1.51 “JAMS Rules” shall have the meaning given in Section 13.2 
 1.52 “Knowledge” shall mean, whenever any representation or warranty is made hereunder “to the Knowledge of” a party or to a
party’s Knowledge, (i) with respect to Seller, the actual knowledge of (A) any officer of Seller or any employee of Seller listed on Attachment 1.52 or (B) with respect to Buyer, the officers of Buyer and (ii) the
knowledge that any such person referenced in clause (i) hereof, as a prudent business person, would have obtained in the usual course of the performance of his or her professional responsibilities to such party. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 5 

 1.53 “Lease Assignment Agreement” shall have the meaning given in
Section 4.2(a)(v). 
 1.54 “Leased Properties” shall mean the facilities subject to the Leases. 
 1.55 “Leases” means, collectively, the 3750 Lease and the 3850 Lease. 
 1.56 “Legal Requirement” means any requirement imposed by any constitution, law, ordinance, principle of common law, code, regulation,
statute, treaty or order, injunction, judgment, decree, ruling, assessment or arbitration award of any Governmental Entity or arbitrator. 
 1.57 “Liability” or “Liabilities” shall mean liabilities or obligations of any kind or nature, primary or secondary, direct or indirect, absolute or contingent, known or unknown, disputed or undisputed,
liquidated or unliquidated, including but not limited to any liabilities for claims of product liability, personal injury or death, liability in tort or contract (including unripened liabilities due to past actions, failures to act or sales),
indebtedness, and any U.S. Food and Drug Administration or other Governmental Entity action or notification, and all costs and expenses (including reasonable attorneys’ fees), incurred in connection with the defense of any such claims.

 1.58 “Limited Warranty Deed” shall have the meaning given in Section 4.2(a)(ii). 
 1.59 “Material Adverse Effect” with respect to any Person shall mean any event or situation that has a material adverse change or
effect, respectively, on: [****]*. 
 1.60 “Minimum Assessment Agreement” shall have the meaning given in
Section 2.1(e). 
 1.61 “Note” shall mean the Tax Increment Revenue Note Series 2007 made by The Brooklyn Park Economic
Development Authority, dated August 1, 2007. 
 1.62 “Note Assignment” shall have the meaning given in
Section 4.2(a)(v). 
 1.63 “Operations” shall mean the biologic manufacturing operations conducted by Seller at the
Facilities. 
 1.64 “Operations Employee” shall have the meaning given in Section 5.19. 
 1.65 “Order” shall mean any order, injunction, judgment, decree, ruling, assessment or arbitration award of any Governmental Entity or
arbitrator. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 6 

 1.66 “Ordinary Course of Business” shall mean an action taken by a Person will be deemed
to have been taken in the Ordinary Course of Business only if that action: 
 (a) is recurring and consistent in nature, scope
and magnitude with the past practices of such Person and occurs in the normal day to day operations of such Person; and 
 (b)
does not require authorization by the board of directors or shareholders of such Person (or by any Person or group of Persons exercising similar authority) and does not require any other separate or special authorization of any nature. 

1.67 “Permitted Encumbrances” shall mean the Encumbrances set forth on Schedule 5.8(d)(ii) and as defined in Section 7.6
herein. 
 1.68 “Person” shall mean an individual, limited or general partnership, corporation (including any non-profit
corporation), business trust, limited liability company, limited liability partnership, joint stock company, trust, unincorporated association, joint venture, estate, organization, labor union or other entity or a Governmental Entity. 
 1.69 “Proceeding” shall mean any action, arbitration, audit, hearing, investigation, litigation or suit (whether civil, criminal,
administrative, judicial or investigative, whether formal or informal, whether public or private) commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Entity, private judge, tribunal or arbitrator(s).

 1.70 “Product-Related Inventory” shall mean the resin, media, master cell banks, working cell bank, stability pools and
retains and clinical supplies, including work in progress and finished goods used in the production of the “Products” (as such term is defined in the Clinical Drug Substance Supply Agreement). 
 1.71 “Property Condition” shall have the meaning given in Section 6.9. 
 1.72 “Purchase Price” shall have the meaning given in Section 3.1. 
 1.73 “Real Property” shall mean the parcel of land located in the City of Brooklyn Park, Minnesota and described in Schedule
5.8(d), together with all buildings, structures, improvements and fixtures situated thereon, all right, title and interest of Seller, if any, in and to the land lying in the bed of any street or highway in front of or adjoining said parcel of
land to the center line thereof and to any unpaid award for any taking by condemnation or any damage to said parcel of land by reason of a change of grade of any street or highway, and all privileges, rights, easements, rights of way, appurtenances
thereon and thereto, including mineral, air and development rights appurtenant thereon and thereto. 
 1.74 “Real Property
Inspection” shall have the meaning given in Section 7.5. 
 1.75 “Release” means any release, spill, emission,
leaking, pumping, pouring, dumping, emptying, injection, deposit, disposal, discharge, dispersal, leaching or migration on or into the Environment or into or out of any property. 
 1.76 “Response Notice” shall have the meaning given in Section 7.6. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 7 

 1.77 “Retained Lease” shall have the meaning given in Section 7.3. 
 1.78 “SEC” shall mean the United States Securities and Exchange Commission. 
 1.79 “Seller Contract” shall mean any Contract (a) under which Seller has or may acquire any rights or benefits; (b) under
which Seller has or may become subject to any obligation or liability; or (c) by which Seller or any of the Assets is or may become bound. 
 1.80 “Seller Indemnitees” shall have the meaning given in Section 12.2. 
 1.81 “Seller’s
Records” shall mean those certain agreements, plans, documentation and information concerning the Facilities, including all environmental reports, compliance audits, notices of violations and responses thereto, as well as all agency
correspondence pertaining to compliance with Environmental Laws or an Environmental Remediation Obligation on the Real Property, in Seller’s possession or control but excluding Environmental Governmental Authorizations. 
 1.82 “Settlement Statement” shall have the meaning given in Section 4.3(h). 
 1.83 “Software” means the software or firmware, if any, embedded in any Tangible Personal Property and documentation related thereto or
associated therewith, except for any software licensed to Seller installed on any computer (including servers and other information technology hardware) or electronic communication devices (e.g., Blackberries) included in the Tangible Personal
Property. 
 1.84 “Supplies” shall mean, collectively, (i) all inventory of Seller of raw materials, repair stock,
parts, pallets and supplies wherever located or in transit for use or consumption in the Operations but excluding Product-Related Inventory; (ii) all assignable warranties and licenses issued to Seller in connection with the Supplies; and
(iii) any assignable claims, credits and rights of recovery with respect to the Supplies. 
 1.85 “Tangible Personal
Property” means all machinery, equipment, tools, furniture, office equipment, computer hardware, supplies, materials, vehicles and other items of tangible personal property (other than Product-Related Inventory) of every kind owned or
leased by Seller (whether or not carried on Seller’s books) used in the Operations and located at the Facilities and all maintenance records and other documents relating thereto. 
 1.86 “Third Party Acquisition” shall have the meaning given in Section 7.4. 
 1.87 “Third Party Consents” shall have the meaning given in Section 5.4(b). 
 1.88 “Threat of Release” means a reasonable likelihood of a Release that may require action in order to prevent or mitigate damage to
the Environment that may result from such Release. 
 1.89 “Threshold Amount” shall have the meaning given in
Section 12.6(a). 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 8 

 1.90 “Title Commitment” shall have the meaning given in Section 7.6. 
 1.91 “Title Company” shall mean First American Title Insurance Company or such other reputable title insurance company authorized to
transact business in the State of Minnesota as may be selected by Buyer. 
 1.92 “Title Exceptions” shall have the meaning
given in Section 7.6. 
 1.93 “Title Objections” shall have the meaning given in Section 7.6. 
 1.94 “Trade Secrets” shall have the meaning given in Section 2.1(i). 
 1.95 “Transition Services Agreement” shall mean the agreement entered into by Buyer and Seller as of the Closing Date, whereby
(i) Buyer shall, for fees specified therein, provide certain services to Seller, including, continued development of ongoing life cycle management projects and continued assistance and support of a Seller-sponsored clinical trial, and
information technology and administrative services, to the extent and for the periods of time and at the costs as specified therein, and (ii) Seller shall, for fees specified therein, provide certain services to Buyer, including information
technology and administrative services, to the extent and for the periods of time and at the costs as specified therein. 
 1.96
“Unsatisfactory Condition” shall have the meaning given in Section 7.7(a). 
 1.97 “Unsatisfactory Inspection
Notice” shall have the meaning given in Section 7.7(a). 
 1.98 “WARN” shall have the meaning given in
Section 7.8(c). 
 ARTICLE 2 
 TRANSFER OF ASSETS; LICENSE AND SUBLICENSE 
 2.1 Purchase and Sale of Assets. Subject to the terms and conditions of
this Agreement, Seller shall sell, transfer, assign, convey, or deliver, as specified below, to Buyer, and Buyer shall acquire all of Seller’s right, title and interest in and to the property and assets of Seller identified in this
Section 2.1 (collectively, the “Assets”): 
 (a) Real Property. Seller’s fee ownership
interest in the Real Property. 
 (b) Leased Real Property. Seller’s leasehold or other non-fee ownership interest
in the Leased Properties, including any security deposit(s) being held for benefit of Seller by any lessor. 
 (c)
Governmental Authorizations. Seller’s interest in all transferable Governmental Authorizations owned by Seller or used in or necessary for the operation of the Assets. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 9 

 (d) Equipment. The Tangible Personal Property, including, without limitation, the
items of equipment each having a book value in excess of [****]* listed in Attachment 2.1(d). 
 (e) Assumed
Contracts. All rights and benefits of Seller in existence as of the Closing Date arising after the Closing Date under the contracts listed in Attachment 2.1(e) (the “Assumed Contracts”), including but not limited to that
certain Contract for Private Development by and between the Brooklyn Park Economic Development Authority and Seller, dated October 31, 2002 (the “Development Agreement”) and that certain Assessment Agreement and Assessor’s
Certificate by and between Brooklyn Park Development Authority and Seller, dated February 8, 2005 (the “Minimum Assessment Agreement”), all transferable statutory, express or implied construction warranties applicable to the
improvements on the Real Property and all transferable express or implied warranties from manufacturers, sellers or lessors of any item or component part of any Tangible Personal Property. 
 (f) Supplies. The Supplies. 
 (g) Note. All of Seller’s interest as “Owner” under the Note, in accordance with Section 7 of the Note pertaining to Registration and transfer. 
 (h) Books and Records. Any documentation related to operation of the Facilities (excluding documentation relating solely to the
manufacture of any specific product), including standard operating procedures, equipment manuals, historical supply cost data, maintenance records, vendor supply lists and current inventories of supplies. 
 (i) Trade Secrets. Know-how, trade secrets, confidential or proprietary information, Software, technical information, data, process
technology, plans, designs, drawings and blue prints that are related to the Operations (excluding any of same relating to the manufacture of any specific product) (collectively, “Trade Secrets”). 
 2.2 Excluded Assets. Buyer hereby acknowledges that Seller is not selling, transferring, assigning, conveying or delivering under this Agreement
any assets, rights or interests of Seller (collectively, the “Excluded Assets”) not listed or described in Section 2.1, including any assets or rights used in the research, development, manufacture, control, packaging or
release, marketing or sale of Seller’s products, and the Product-Related Inventory. 
 2.3 Assumed Liabilities. Buyer shall
assume and agree to honor, pay and discharge when due the following Liabilities of Seller (the “Assumed Liabilities”): 
 (a) all Liabilities of Seller under the Assumed Contracts, but only to the extent such Liabilities arise from any event, circumstance or condition occurring after the Closing Date; and 
 (b) all Liabilities of Seller for the Leased Properties (including all costs of preparing the Leased Real Properties for return to the
landlord upon the expiration or termination of the lease, which shall be deemed to arise after the Closing Date), but only to the extent such Liabilities arise from any event, circumstances or condition occurring after the Closing Date; and

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 10 

 (c) all Liabilities of Seller under contracts with third parties providing utility
services to the Facilities. 
 2.4 Excluded Liabilities. Seller hereby acknowledges that Buyer is not assuming hereunder any
Liabilities (collectively, the “Excluded Liabilities”) not specifically set forth in Section 2.3, including, without limitation, those Liabilities expressly set forth below: 
 (a) any Liability or obligation of Seller of any nature owed to, or on behalf or for the benefit of, any employees, directors, former
employees, agents or independent contractors, whether or not employed by Buyer after the Closing, that arises out of or relates to (A) the employment or service provider relationship between Seller and any such Person(s) (including, but not
limited to, claims for compensation, discrimination, harassment, or retaliation, or rights or other interest in any health, welfare, retirement or other benefit plan); or (B) events or conditions occurring on or before the Closing Date
(including the transactions contemplated by this Agreement); 
 (b) Liabilities arising out of any injury to individuals or
property as a result of the ownership, possession or use of the Assets or the Operations, including without limitation the manufacture, administration or other use of any “Product” (as such term is defined in the Clinical Drug Substance
Supply Agreement), prior to the Closing Date or the administration or other use after the Closing Date of any Product manufactured prior to the Closing Date, except to the extent attributable to the gross negligence or willful misconduct of Buyer;

 (c) all accounts payable of Seller arising prior to the Closing Date; and 
 (d) Liabilities of Seller relating to or arising under this Agreement. 
 2.5 Risk of Loss. All risk of loss with respect to the Assets (whether or not covered by insurance) shall be on Seller up to the time of Closing,
whereupon such risk of loss shall pass to Buyer. 
 ARTICLE 3 
 CONSIDERATION 
 3.1 Purchase Price. On the Closing Date, in consideration of Seller’s
sale of the Assets to Buyer, Buyer will assume the Assumed Liabilities and pay to Seller an aggregate purchase price in the amount equal to Two Hundred Forty Million United States Dollars ($240,000,000) (the “Purchase Price”).

 3.2 Method of Payment. The payment to be made by Buyer pursuant to Section 3.1, as adjusted by the closing prorations and
other cost allocations for both Buyer and Seller set forth in this Agreement, as shown on the Settlement Statement, shall be made by wire transfer in immediately available funds to the proper account of the Title Company (as identified by the Title
Company) on the Closing Date. Buyer and Seller shall coordinate with each other and the Title Company to agree to wiring deadlines such that Buyer will initiate the wire to the Title 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 11 

 
Company at an early enough time for the Title Company to wire the funds into an account identified by the Seller in time for Seller to earn overnight
interest on such funds as of the Closing Date (i.e., so that the funds do not remain un-invested overnight immediately following Closing). Provided Buyer has met any previously agreed to wiring deadline (as evidenced by a Fed Wire Reference Number
with the appropriate time stamp), Buyer shall have no liability for any delays in the transmittal of the wire from the Title Company to the Seller or the receipt or investment of the funds by the Seller’s designated depository account
representative (except to the extent such delay is caused by Buyer’s action). 
 3.3 Allocation of Purchase Price. Prior to
Closing, Buyer and Seller will make reasonable efforts to agree on an allocation of the Purchase Price among the Assets in a manner that is consistent with the principles of Section 1060 of the Internal Revenue Code of 1986, as amended (or any
successor provision of any future tax law, or any comparable provision of state, local or foreign tax law). Buyer and Seller will (i) act in accordance with the allocation in the preparation of financial statements and the preparation and
filing of all tax returns (including the preparation and filing of IRS Form 8594) and (ii) take no position inconsistent with the allocation for all tax purposes. In the event that such allocation is disputed by any taxing authority, the party
receiving notice of the dispute shall promptly notify the other party hereto and shall forward to such other party copies of all correspondence with such taxing authority in respect of such disputed allocation. 
 ARTICLE 4 
 CLOSING 
 4.1 Closing. The Closing of the sale of the Assets and the consummation of the other transactions contemplated by this Agreement shall be held at
the offices of Seller at the Real Property (the “Closing”) as promptly as practicable, but no later than the date five (5) business days after all conditions (other than the respective delivery obligations of the parties)
hereto have been satisfied or waived, or at such other place, time or date as may be agreed to by the parties to this Agreement (the “Closing Date”). 
 4.2 Actions at Closing. At the Closing, transfer of the Assets to Buyer will be effected by Seller pursuant to such good and sufficient instruments of conveyance, transfer and assignment as shall be necessary
to transfer to Buyer good and valid title to the Assets. 
 (a) Deliveries by Seller at Closing. The purchase of the
Assets by Buyer in accordance with the terms of this Agreement are subject to Seller’s delivery to Buyer at the Closing of the following instruments, documents, agreements and certificates: 
 (i) the General Assignment and Bill of Sale substantially in the form attached hereto as Exhibit A, duly executed by Seller;

 (ii) the limited warranty deed for the Real Property substantially in the form attached hereto as Exhibit B (the
“Limited Warranty Deed”), duly executed by Seller; 
 (iii) the Assignment and Assumption Agreement
substantially in the form attached hereto as Exhibit C (the “Assignment and Assumption Agreement”), duly executed by Seller; 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 12 

 (iv) a Lease Assignment and Assumption Agreement for each of the Leased Properties
substantially in the form attached hereto as Exhibit D (the “Lease Assignment and Assumption Agreement”), duly executed by Seller; 
 (v) the Note Assignment Agreement substantially in the form attached hereto as Exhibit E (the “Note Assignment”), duly executed by Seller; 
 (vi) the Transition Services Agreement substantially in the form attached hereto as Exhibit G, duly executed by Seller; 

(vii) all of the Third Party Consents in substantially the form attached hereto as Exhibit H signed by the parties set forth in
Attachment 4.2(a), including the consent of the landlord under the Leases to the assignment thereof to Buyer; 
 (viii)
a FIRPTA Certificate containing such information as is required by I.R.C. § 1445(b)(2) and its regulations; 
 (ix) an
Affidavit of Title or such affidavits as the Title Company shall reasonably require indicating that on the Closing Date there are no outstanding, unsatisfied judgments, tax liens or bankruptcies against or involving Seller or the Real Property; that
there has been no skill, labor or material furnished to the Real Property for which payment has not been made or for which mechanics’ liens could be filed; and that there are no other unrecorded interests in the Real Property; 
 (x) a Well Certificate if required by Minnesota Statutes, Chapter 1031; 
 (xi) a Sewer System Certificate if required by Minnesota Statutes, §115.55; 
 (xii) a Certificate of Occupancy for the Real Property; 
 (xiii) an Amendment to the Confidentiality Agreement, duly executed by Seller; 
 (xiv) a certificate executed by a duly authorized officer of Seller certifying that (i) each of the representations and warranties of
Seller set forth in Article 5 was true and correct in all material respects as of the Effective Date and as of the Closing Date, and (ii) all of the terms, covenants and conditions of this Agreement to be complied with and performed by Seller,
at or prior to the Closing have been duly complied with and performed in all material respects; and 
 (xv) a certificate of
the Secretary of Seller, in form and substance reasonably satisfactory to Buyer, as to the authenticity and effectiveness of the actions of the board of directors of Seller authorizing this Agreement and the transactions contemplated in this
Agreement; and identifying the name and title and bearing the signatures of the Persons authorized by Seller to execute and deliver this Agreement and the other Agreements and instruments contemplated hereby; 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 13 

 (xvi) a certificate of good standing of Seller, also attesting to payment of all
applicable taxes by Seller, issued by the Secretaries of State of the States of Delaware and Minnesota, dated within [****]* of the Closing; 
 (xvii) possession of the Facilities in the condition required by this Agreement, and the keys and/or electronic access cards and security codes therefor; and 
 (xviii) any other documents required by this Agreement to be delivered by Seller or as may be deemed necessary by Buyer’s counsel or
the Title Company to effect the transactions contemplated by this Agreement. 
 (b) Deliveries by Buyer at Closing. The
sale of the Assets by Seller in accordance with the terms of this Agreement are subject to Buyer’s delivery to Seller (unless noted otherwise) at the Closing of the following instruments, agreements and certificates: 
 (i) the Purchase Price, as adjusted for prorations as provided herein. 
 (ii) the Lease Assignment and Assumption Agreement, duly executed by Buyer; 
 (iii) the Assignment and Assumption Agreement, duly executed by Buyer; 
 (iv) the Transition Services Agreement, duly executed by Buyer; 
 (v) an Amendment to the Confidentiality Agreement, duly executed by Buyer; 
 (vi) a Certificate of Real Estate Value as required by MSA §272.115 executed by Buyer; 
 (vii) a certificate executed by a duly authorized officer of Buyer certifying that (i) each of the representations and warranties of
Buyer set forth in Article 6 was true and correct in all material respects as of the Effective Date and as of the Closing Date, and (ii) all of the terms, covenants and conditions of this Agreement to be complied with and performed by Buyer, at
or prior to the Closing have been duly complied with and performed in all material respects; 
 (viii) a certificate of the
Secretary of Buyer, in form and substance reasonably satisfactory to Seller, as to the authenticity and effectiveness of the actions of the board of directors (and shareholders, if applicable) of Buyer authorizing this Agreement and the transactions
contemplated in this Agreement; and identifying the name and title and bearing the signatures of the Persons authorized by Buyer to execute and deliver this Agreement and the other Agreements and instruments contemplated hereby; 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 14 

 (ix) any funds required by the Settlement Statement which are not appropriately an
adjustment to the Purchase Price; and 
 (x) any other document required by this Agreement to be delivered by Buyer or as may
be deemed necessary by Seller’s counsel or the Title Company to effect the transactions contemplated by this Agreement. 
 4.3
Prorations. The following are to be apportioned as of the Closing Date: 
 (a) Utility Charges. Buyer shall set
up new utility accounts (telephone, steam, electricity, gas) and arrange for existing utilities to be switched over to such accounts as of the Closing Date. Seller shall pay all charges for utilities used through the date prior to the Closing Date.
Upon confirmation from each utility that such deposits are assignable to Buyer, Buyer will pay to Seller at Closing the amount of any utility deposit(s) made by Seller, and Seller will assign to Buyer all of its right, title and interest in and to
the applicable deposit(s) relating thereto. Buyer will be responsible for the cost of all utilities used on or after the Closing Date. 
 (b) Lease Payments and Security Deposits. Amounts for all rents due or paid under the Leases shall be apportioned as of the Closing Date. Upon the confirmation from each Lessor under the Leases that it is
holding a security deposit, Buyer will pay to Seller at Closing the amount of any such security deposit(s) made by Seller, and Seller will assign to Buyer all of its right, title and interest in an to any such security deposit(s). 
 (c) Other Apportionments. Amounts payable under the Assumed Contracts, payments actually made to Seller under the Note, annual or
periodic permit and/or inspection fees with respect to Governmental Authorizations that are assignable and, in fact, assigned to Buyer at the Closing, fuel oil, if any, at the most recent cost thereof on the basis of a reading performed by the
supplier thereof on the day preceding the Closing and amounts for Property operation and maintenance expenses and other recurring costs to be assumed by Buyer and prepaid by Seller will be apportioned as of the Closing Date. 
 (d) Title Insurance. Buyer shall pay the premium for title insurance and the Title Company charges for the examination of title to
the Real Property and direct administrative closing costs. 
 (e) Survey. [****]* shall pay the cost up to a [****]* of
obtaining the Current Survey, which shall be certified to [****]* and the Title Company. 
 (f) Recording; Other.
[****]* shall pay the costs of recording the Limited Warranty Deed and all applicable real estate transfer taxes imposed by any Governmental Entity, including without limitation, the state deed tax. Payment of all other costs incurred in connection
with the transfer of the Real Property contemplated by this Agreement shall be [****]* in accordance with the custom of commercial real estate transactions consummated in Hennepin County, as reasonably determined by the Title Company. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 15 

 (g) Real Estate Taxes and Special Assessments. General real estate taxes and
personal property taxes which were or should have been due and payable in all calendar years ending prior to the Closing Date will be paid by Seller and shall remain the responsibility of Seller. General real estate taxes and personal property taxes
due and payable in the calendar year in which the Closing Date occurs will be prorated by Seller and Buyer on a calendar year basis as of the Closing Date, with the Seller being responsible for the period up to and including the Closing Date.
General real estate taxes and personal property taxes due and payable in all calendar years commencing after the Closing Date will be paid by Buyer. All special assessments levied or constituting a lien against the Real Property as of the Closing
Date will be paid [****]*. Buyer shall assume the obligation to pay any special assessments levied subsequent to the Closing Date. 
 (h) Settlement Statement. Title Company shall prepare a preliminary Closing settlement statement and shall deliver such statement to Buyer and Seller for approval no less than [****]* prior to the Closing Date (as approved, the
“Settlement Statement”). Upon Closing, the Title Company shall disburse funds in accordance with the approved Settlement Statement. 
 (i) Post-Closing Reconciliation. Seller and Buyer hereby agree that if the Closing shall occur before a new real estate tax rate is fixed or for any other reason any of the foregoing prorations cannot be
calculated accurately as of the Closing Date, then the same shall be estimated (based on current information then known, such as the most recent tax rate applied to the latest assessed valuation) for the purposes of Closing and within [****]* after
the Closing Date, or as soon as sufficient information is available to permit the parties to effectively calculate such prorations, either party owing the other party a sum of money based on such subsequent calculations shall pay such sum to the
other party within [****]* after such calculations. 
 (j) Survival. The provisions of this Section 4.3 shall
survive [****]*. 
 ARTICLE 5 
 REPRESENTATIONS AND WARRANTIES OF SELLER 
 Subject to the exceptions and disclosures listed in the Schedules attached to this Agreement
(which modify, vary and qualify certain of the representations and warranties contained in this Article 5), Seller represents and warrants to Buyer as of the Effective Date as follows: 
 5.1 Organization and Authority. Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of
Delaware with full corporate power and authority to execute and consummate this Agreement, and such other instruments, agreements and transactions as may be contemplated hereunder and thereunder. Seller has all requisite corporate power and
authority and all authorizations, licenses, permits and certifications necessary to carry on the Operations as now being conducted and to own, lease and operate the Assets. Seller is qualified as a foreign corporation to do business in every
jurisdiction in which the nature of its business or its ownership of property requires it to be qualified and in which the failure to be so qualified would have a Material Adverse Effect. All corporate acts and other proceedings required to be taken
by or on the part of Seller to authorize Seller to execute, deliver 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 16 

 and perform this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder or to
consummate the Contemplated Transactions, have been duly and properly taken. Seller is not required to obtain stockholder consent (i) to authorize Seller to execute, deliver and perform this Agreement and such other instruments, agreements and
transactions as may be contemplated hereunder or (ii) to consummate the Contemplated Transactions. This Agreement has been duly executed and delivered by Seller and constitutes legal, valid and binding obligations of Seller enforceable in
accordance with its terms, except as such enforceability may be subject to or limited by (i) applicable bankruptcy, reorganization, insolvency, moratorium and similar laws affecting the enforcement of creditors’ rights generally and
(ii) the rules governing the availability of specific performance, injunctive relief or other equitable remedies and general principles of equity, regardless of whether considered in a proceeding in law or equity. 
 5.2 No Violation or Conflict. The execution and delivery by Seller of this Agreement and such other instruments, agreements and transactions as
may be contemplated hereunder, and the consummation by Seller of the Contemplated Transactions will not (i) violate any judgment, order, writ, injunction or decree of any Governmental Entity or, to Seller’s Knowledge, law, statute, rule or
regulation or applicable to Seller, or (ii) conflict with, result in any breach of, or constitute a default (or an event which with notice or lapse of time or both would become a default) under the Certificate of Incorporation or bylaws of
Seller or any agreement to which Seller is a party, except for such violations, conflicts, breaches or defaults which individually or in the aggregate have not had and would not reasonably be expected to have a Material Adverse Effect on Seller.

 5.3 Consents and Approvals. Except as set forth in Schedule 5.3, no notice to, declaration, filing or registration with, or
authorization, consent or approval of, or permit from, any Governmental Entity, or any other Person, is required to be made or obtained by Seller in connection with the execution, delivery and performance of this Agreement and the consummation of
the Contemplated Transactions, except with respect to the HSR Filing and any declarations, filings, registrations, authorizations, consents, approvals or permits which if not obtained or made have not had and would not reasonably be expected to have
individually or in the aggregate a Material Adverse Effect on Seller or materially interfere with Buyer’s performance of its obligations under the Clinical Drug Substance Supply Agreement or the Transition Services Agreement. 
 5.4 Assumed Contracts. 
 (a) Seller has made available to Buyer true, complete and correct copies of all contracts material to the Operations and the Assets (excluding contracts related solely to the manufacture of specific products of Seller), including, without
limitation, the Assumed Contracts. Except as set forth in Schedule 5.4(a), all the Assumed Contracts are in full force and effect and are valid, binding and enforceable in accordance with their terms by and against Seller, except as such
enforceability may be subject to or limited by (i) applicable bankruptcy, reorganization, insolvency, moratorium and similar laws affecting the enforcement of creditors’ rights generally; and (ii) the rules governing the availability
of specific performance, injunctive relief or other equitable remedies and general principles of equity, regardless of whether considered in a proceeding in law or equity. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 17 

 (b) Schedule 5.4(b) sets forth a list of the Leases and all Assumed Contracts
which require the consent or waiver of any party to the assignment of such Assumed Contract as a result of the Contemplated Transactions (the “Third Party Consents”) and, except as set forth in Schedule 5.4(b), all the
Assumed Contracts are fully assignable by Seller and will be assigned to Buyer at the Closing. 
 (c) Except as set forth in
Schedule 5.4(c): 
 (i) Seller is, and at all times since January 1, 2004, has been, in compliance with all
applicable terms and requirements of each Lease, the Development Agreement and the Minimum Assessment Agreement; 
 (ii) each
other Person that has or had any obligation or Liability under any Lease, the Development Agreement or the Minimum Assessment Agreement, is, and at all times since January 1, 2004, has been, in full compliance with all applicable terms and
requirements of such Lease, the Development Agreement and the Minimum Assessment Agreement; 
 (iii) no event has occurred or
circumstance exists that (with or without notice or lapse of time) may contravene, conflict with or result in a breach of, or give Seller or other Person the right to declare a default or exercise any remedy under, or to accelerate the maturity or
performance of, or payment under, or to cancel, terminate or modify, any Lease; 
 (iv) no event has occurred or circumstance
exists under or by virtue of any Seller Contract that (with or without notice or lapse of time) would cause the creation of any Encumbrance affecting any of the Assets; and 
 (v) Seller has not given to or received from any other Person, at any time since January 1, 2004, any notice or other communication
(whether oral or written) regarding any actual, alleged, possible or potential violation or breach of, or default under, any Lease, the Development Agreement and the Minimum Assessment Agreement. 
 (d) Seller is in material compliance with all applicable terms and requirements of each Assumed Contract and no event has occurred or
circumstance exists that (with or without notice or lapse of time) may contravene, conflict with or result in a breach of, or give Seller or other Person the right to declare a default or exercise any remedy under, or to accelerate the maturity or
performance of, or payment under, or to cancel, terminate or modify any of the Assumed Contracts. There are no renegotiations of, attempts to renegotiate or outstanding rights to renegotiate any material amounts paid or payable by Seller under
current or completed Assumed Contracts with any Person having the contractual or statutory right to demand or require such renegotiation and no such Person has made written demand for such renegotiation. 
 5.5 Compliance with Legal Requirements; Governmental Authorizations. 
 (a) Except as set forth in Schedule 5.5(a): 
 (i) Seller is, and at all times since January 1, 2002, has been, in material compliance with each Legal Requirement (other than Legal
Requirements with respect to Environmental Laws) that is or was applicable to the Operations or the ownership or use of any of the Assets; 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 18 

 (ii) no event has occurred or circumstance exists that (with or without notice or lapse
of time) (A) may constitute or result in a violation by Seller of, or a failure on the part of Seller to comply with, any Legal Requirement with respect to the Assets or the Operations (other than Legal Requirements with respect to
Environmental Laws) or (B) may give rise to any obligation on the part of Seller to undertake, or to bear all or any portion of the cost of, any remedial action of any nature with respect to the Assets or the Operations (other than any
Governmental Remediation Obligation); and 
 (iii) Seller has not received, at any time since January 1, 2002, any notice
or other communication (whether oral or written) from any Governmental Entity or any other Person regarding (A) any actual, alleged, possible or potential violation of, or failure to comply with, any Legal Requirement with respect to the Assets
or the Operations (other than Legal Requirements with respect to Environmental Laws) or (B) any actual, alleged, possible or potential obligation on the part of Seller to undertake, or to bear all or any portion of the cost of, any remedial
action of any nature with respect to the Assets or the Operations (other than any Governmental Remediation Obligation). 
 (b)
Schedule 5.5(b) contains a complete and accurate list of each Governmental Authorization that is held by Seller or relating to the Operations or the Assets. Each Governmental Authorization listed or required to be listed in Schedule
5.5(b) is valid and in full force and effect. Except as set forth in Schedule 5.5(b): 
 (i) Each such Governmental
Authorization is transferable to Buyer and Seller is, and at all times since January 1, 2002, has been, in material compliance with all of the terms and requirements of each Governmental Authorization identified or required to be identified in
Schedule 5.5(b); 
 (ii) no event has occurred or circumstance exists that may (with or without notice or lapse of
time) (A) constitute or result directly or indirectly in a violation of or a failure to comply with any term or requirement of any Governmental Authorization listed or required to be listed in Schedule 5.5(b) or (B) result directly
or indirectly in the revocation, withdrawal, suspension, cancellation or termination of, or any modification to, any Governmental Authorization listed or required to be listed in Schedule 5.5(b); 
 (iii) Seller has not received, at any time since January 1, 2002, any notice or other communication (whether oral or written) from
any Governmental Entity or any other Person regarding (A) any actual, alleged, possible or potential violation of or failure to comply with any term or requirement of any Governmental Authorization listed or required to be listed in Schedule
5.5(b) or (B) any actual, proposed, possible or potential revocation, withdrawal, suspension, cancellation, termination of or modification to any Governmental Authorization listed or required to be listed in Schedule 5.5(b); and

  

 CONFIDENTIAL TREATMENT REQUESTED 
 19 

 (iv) all applications required to have been filed for the renewal of the Governmental
Authorizations listed or required to be listed in Schedule 5.5(b) have been duly filed on a timely basis with the appropriate Governmental Entities, and all other filings required to have been made with respect to such Governmental Authorizations
have been duly made on a timely basis with the appropriate Governmental Entities. 
 To Seller’s Knowledge, the Governmental Authorizations listed in
Schedule 5.5(b) collectively constitute all of the Governmental Authorizations necessary to permit Seller to lawfully conduct the Operations in the manner in which it currently conducts such Operations and to permit Seller to own and use the
Assets in the manner in which it currently owns and uses the Assets and to permit Buyer to perform its obligations under the Clinical Drug Substance Supply Agreement and the Transition Services Agreement. 
 5.6 Legal Proceedings; Orders. 
 (a) Except as set forth in Schedule 5.6(a), there is no pending or, to Seller’s Knowledge, threatened Proceeding: 
 (i) by or against Seller or that otherwise relates to or may affect the Operations of, or any of the Assets owned or used by, Seller; or

 (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with,
any of the Contemplated Transactions. 
 To Seller’s Knowledge, no event has occurred or circumstance exists that could reasonably be likely to give
rise to or serve as a basis for the commencement of any such Proceeding. Seller has delivered to Buyer copies of all pleadings, correspondence and other documents relating to each Proceeding listed in Schedule 5.6(a). 
 (b) Except as set forth in Schedule 5.6(b): 
 (i) there is no Order, nor in the past has there been any Order, to which Seller, the Operations or any of the Assets is subject; and

 (ii) no manager, officer, director, agent or employee of Seller is subject to any Order that prohibits such manager,
officer, director, agent or employee from engaging in or continuing any conduct, activity or practice relating to the Operations of Seller. 
 5.7 Environmental Matters. Except as described in Schedule 5.7: 
 (a) To Seller’s Knowledge,
Seller is, and at all times has been, in full compliance with, and has not been and is not in violation of or liable under, any Environmental Law. Seller has no basis to expect, nor has any other Person for whose conduct it is or may be held to be
responsible received, any actual or threatened Order, notice or other communication from (i) any Governmental Entity or private citizen acting in the public interest or (ii) any prior owner or operator of any Facilities, of any actual or
potential violation or failure to comply with any Environmental Law or of any actual or threatened obligation to undertake or bear the cost of any Environmental Remediation Obligation with respect to the Facilities or other property or asset at or
to which Hazardous Substances were transported, treated, stored, handled, transferred, disposed, recycled or received. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 20 

 (b) There are no pending or, to Seller’s Knowledge, threatened claims, Encumbrances,
or other restrictions of any nature arising under or pursuant to any Environmental Law with respect to the Facilities. 
 (c)
Seller does not have any Knowledge of or any basis to expect, nor has Seller received, any citation, directive, inquiry, notice, Order, summons, warning or other communication that relates to Hazardous Substances or any alleged, actual, or potential
violation or failure to comply with any Environmental Law or of any alleged, actual, or potential obligation to undertake or bear the cost of any Liabilities with respect to the Facilities or any other property to which Hazardous Substances were
transported, treated, stored, handled, transferred, disposed, recycled or received. 
 (d) Seller is not responsible for any
Environmental Remediation Obligation with respect to any property geologically or hydrologically adjoining the Facilities. 
 (e) To Seller’s Knowledge, there are no Hazardous Substances present on or in the Environment at the Facilities or any property geologically or hydrologically adjoining the Facilities which have not been remediated except for any
residual contamination related to remediation approved by the Minnesota Pollution Control Agency. 
 5.8 Title to Assets; Real Property,
Equipment and Supplies. 
 (a) Schedule 5.8(a) sets forth a description of all Tangible Personal Property. Except
as set forth on Schedule 5.8(a), Seller has good, valid and marketable title to all the Assets other than the Real Property free and clear of all Encumbrances and Seller warrants that, at the Closing, all the Assets other than the Real
Property shall be free and clear of all Encumbrances, and Seller shall sell, assign, transfer, convey and deliver good, valid and marketable title to the Assets other than the Real Property at Closing, free and clear of any and all, Encumbrances.
Except as set forth in Schedule 5.8(a), Seller beneficially owns all of the right, title or other interests to be transferred to Buyer hereunder with respect to all the Assets, and none of the Assets other than Leased Properties is leased,
rented, licensed, or otherwise not owned by Seller. 
 (b) Seller has not received any written notice that remains uncured
from any Governmental Entity alleging that any part of the Real Property is in violation of any zoning, building, health, fire, environmental or other similar statute, ordinance, regulation or code. Seller has not received any written notice of any
pending or threatened (and, to Seller’s Knowledge, there are no threatened) eminent domain, condemnation or other governmental taking of the Real Property or any part thereof. Seller has not received written notice from its insurance carriers,
lenders, any board of fire underwriters or any Governmental Entity that any repairs, replacements or alterations are required to be made to the Real Property which have not been made. 
 (c) Other than this Agreement, Seller has not entered into any purchase contracts, options or any other agreements of any kind, written or
oral, formal or informal, choate or inchoate, recorded or unrecorded, whereby any Person other than Buyer has acquired, or has any basis to assert, any right to purchase or acquire an interest in, lease, sublease, license or otherwise use or occupy
the Real Property or any of the Facilities. There are no parties in possession of any portion of the Real Property or any of the Facilities other than Seller. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 21 

 (d) Schedule 5.8(d)(i) contains a legal description of the Real Property. Except
as set forth in Schedule 5.8(d)(ii), Seller represents, but does not warrant, to Seller’s Knowledge that (i) Seller has good, valid and marketable title to all the Real Property free and clear of all Encumbrances other than
Encumbrances shown on the Title Report; and (ii) no part of any improvement or structure located on the Real Property encroaches on any real property not included in the Real Property, and there are no buildings, structures, fixtures or other
improvements situated on adjoining property which encroach on any part of the Real Property. True copies of any current surveys, abstract, title commitments and title opinions in Seller’s possession and all policies of title insurance currently
in force and in the possession of Seller with respect to the Real Property have been made available to Buyer. 
 (e) Other
than the Leases, there are no other material real property leases under which Seller is a lessee or lessor and that relate to the Assets. The Leases are in full force and effect and have not been modified or amended. All rents and sums payable by
Seller under the Leases are currently paid and shall be current at Closing, and Seller has no notice of any default or threatened default by Seller or any lessor under the Leases. There is no action or proceeding instituted against Seller by any
lessor presently pending in any court, no security deposits other than those set forth in the Leases, and to Seller’s Knowledge, no leasing commissions are due or owing with respect to the Leases. 
 (f) Seller has delivered to Buyer true, correct and complete copies of Seller’s Records and the Environmental Governmental
Authorizations. To Seller’s Knowledge, no Proceeding has been commenced regarding the Facilities since January 1, 2002. 
 5.9
Sufficiency of Assets. Except as set forth in Schedule 5.9, the Assets (a) constitute all of the assets, tangible and intangible, of any nature whatsoever, necessary to conduct the Operations in the manner presently conducted by
Seller other than information technology assets located in and operated out of Seller’s Redwood City, California offices and (b) include all of the operating assets of Seller (i) used to conduct the Operations and located at the
Facilities other than the Excluded Assets and (ii) necessary to permit Buyer to perform its obligations under the Clinical Drug Substance Supply Agreement and the Transition Services Agreement. 
 5.10 Condition of Tangible Personal Property. Each item of Tangible Personal Property is in good repair and good operating condition, ordinary
wear and tear excepted, is suitable for immediate use in the Ordinary Course of Business. No item of Tangible Personal Property is in need of repair or replacement other than as part of routine maintenance in the Ordinary Course of Business. Except
as disclosed in Schedule 5.10, all Tangible Personal Property used in the Operations is owned by and in the possession of Seller. 
 5.11 Supplies. All items included in the Supplies consist of a quality and quantity usable in the Ordinary Course of Business of Seller. Supplies now on hand were purchased in the Ordinary Course of Business of Seller. The quantities
of each item of Supplies (whether raw materials, supplies or work-in-process) are not excessive but are reasonable in the present circumstances of Seller and the Operations. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 22 

 5.12 Trade Secrets. Seller is the owner or licensee of all right, title and interest in and to
each of the Trade Secrets, free and clear of all Encumbrances, and has the right to use without payment to a third party all of the Trade Secrets and to assign them to Buyer at the Closing. Except as set forth in Schedule 5.12, all former and
current employees of Seller employed with respect to the Operations have executed written Contracts with Seller that assign to Seller all rights to any inventions, improvements, discoveries or information relating to the Operations. Seller has taken
all reasonable precautions to protect the secrecy, confidentiality and value of all Trade Secrets (including the enforcement by Seller of a policy requiring each Employee or contractor to execute proprietary information and confidentiality
agreements substantially in Seller’s standard form, and all current and former Employees and contractors of Seller have executed such an agreement). No Trade Secrets were developed, in whole or in part, with full- or partial-funding from a
Governmental Entity, including, without limitation, to the United States Government, or any agency thereof or in efforts with other entities receiving full or partial-funding from a Governmental Entity or any agency thereof. 
 5.13 Brokers and Finders. Except as set forth in Schedule 5.13, Seller has not employed any broker or finder or incurred any Liability for
any brokerage fee, commission, finder’s fee or other compensation in connection with the transactions contemplated by this Agreement. 
 5.14 No Implied Warranty. THE REPRESENTATIONS AND WARRANTIES GIVEN HEREIN BY SELLER ARE IN LIEU OF ANY IMPLIED WARRANTIES WHICH MAY OTHERWISE BE APPLICABLE BECAUSE OF THE PROVISIONS OF THE UNIFORM COMMERCIAL CODE OR ANY OTHER
STATUTE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. EXCEPT FOR THOSE COVENANTS, REPRESENTATIONS AND WARRANTIES THAT ARE EXPRESSLY SET FORTH IN THIS AGREEMENT OR IN ANY DOCUMENT EXECUTED AND
DELIVERED BY SELLER IN CONNECTION WITH THE CLOSING, SELLER MAKES, AND HAS MADE, NO (AND BUYER ACKNOWLEDGES THAT NO ONE ACTING OR PURPORTING TO ACT ON SELLER’S BEHALF, INCLUDING, WITHOUT LIMITATION, BROKER, HAS MADE, OR MAKES, ANY) COVENANT,
REPRESENTATION OR WARRANTY (EXPRESS OR IMPLIED) AS TO ANY ASPECT WHATSOEVER OF OR RELATING TO THE FACILITIES OR SELLER’S RECORDS, INCLUDING, WITHOUT LIMITATION, AS TO THE SUITABILITY OF THE FACILITIES OR AS TO THE PHYSICAL CONDITION THEREOF FOR
ANY PURPOSE WHATSOEVER. 
 5.15 Condition of Facilities. 
 (a) To Seller’s Knowledge, use of the Facilities for the various purposes for which it is presently being used is permitted as of
right under all applicable zoning legal requirements and is not subject to “permitted nonconforming” use or structure classifications. To Seller’s Knowledge, the Facilities located on the Real Property are in compliance with all
applicable Legal Requirements, including those pertaining to zoning, building and the disabled, 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 23 

 
are in good repair and in good condition, ordinary wear and tear excepted. The Facilities located on the Real Property have direct vehicular access to a
public road or has access to a public road via a permanent, irrevocable, appurtenant easement benefiting the Real Property, are supplied with public or quasi-public utilities and other services appropriate for the operation of the Facilities located
thereon and are not located within any flood plain or area subject to wetlands regulation or any similar restriction. To Seller’s Knowledge, there is no existing or proposed plan to modify or realign any street or highway or any existing or
proposed eminent domain or other condemnation proceeding that would result in the taking of all or any part of any Facilities or that would prevent or hinder the continued use of any of the Facilities as heretofore used in the conduct of the
Operations or the performance of Buyer’s obligations under the Clinical Drug Substance Supply Agreement or the Transition Services Agreement. 
 (b) Seller has not received written notice that Seller’s use or occupancy of the Facilities violates any Legal Requirement, covenant, condition or restriction that encumbers any of the Facilities, or that any of
the Facilities is subject to any restriction for which any authorization or certification of any Governmental Entity necessary to the current use thereof have not been obtained. 
 5.16 Disclosure. No representation or warranty or other statement made by Seller in this Agreement or otherwise in connection with the
Contemplated Transactions contains any untrue statement of a material fact or omits to state a material fact necessary to make any of them, in light of the circumstances in which it was made, not misleading. 
 5.17 Product Liability. Seller does not have any Liability (and, to Seller’s Knowledge, there is no basis for any present or future
Proceeding against it giving rise to any Liability) arising out of any injury to individuals or property as a result of the ownership, possession or use of the Assets or the Operations. 
 5.18 Suppliers. Except as disclosed in Schedule 5.18, Seller is not or has not been engaged in any material dispute with any of its
Suppliers. Seller has not received any actual notice or has any reason to believe that any of its Suppliers will not sell to Buyer services, products, equipment or goods after the Closing Date on terms and conditions substantially similar to those
currently in effect, subject only to general and customary price increases. Seller has adequate sources of supply for its business as now and proposed to be conducted. Except as disclosed in Schedule 5.18, Seller is not dependent on a
supplier that is the sole supplier of any goods and services it requires to operate the Assets. 
 5.19 Employees. Schedule
5.19 contains a complete and accurate list of the names, titles, current annual base salary and target annual bonus of each of Seller’s employees at the Facilities employed as of the Effective Date (each, an “Operations
Employee”), including a complete and accurate list of all employment agreements, letters or other agreements (including noncompetition agreements) with respect to the Operations Employees. Each Operations Employee is currently employed by,
and has not entered into any severance or termination agreement with, Seller. No Operations Employee has accepted an agreement (whether or not in writing) with Seller to continue or to commence employment with Seller following the Closing. No
Operations Employee is currently engaged in negotiations intended or likely to result in employment with Seller to continue or to commence employment with Seller following Closing. To Seller’s Knowledge, the Operations Employees are not
debarred or suspended under 21 U.S.C. §335a(a) or (b). 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 24 

 5.20 Insurance. Seller has not been refused any fire, liability, product liability, workmen’s
compensation, health or other forms of insurance, including performance bonds with respect to any aspect of the Operations or the ownership or use of the Assets or, since January 1, 2002, has had any claims denied by its insurers. There are no
pending claims against Seller with respect to any aspect of the Operations or the ownership or use of the Assets as to which insurers are defending under a reservation of rights or have denied liability and, to Seller’s Knowledge, no condition
exists or events have occurred since January 1, 2002 which could reasonably be expected to result in any such claim. 
 ARTICLE 6

 REPRESENTATIONS AND WARRANTIES OF BUYER 
 6.1 Organization and Authority. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. Buyer has full corporate power and authority to execute and
deliver this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, and to perform its obligations hereunder and thereunder. All corporate acts and other proceedings required to be taken by or on the part
of Buyer to authorize Buyer to execute, deliver and perform this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, have been duly and properly taken. This Agreement has been duly executed and
delivered by Buyer and constitutes the legal, valid and binding obligation of Buyer enforceable in accordance with its terms, except as such enforceability may be subject to or limited by (i) applicable bankruptcy, reorganization, insolvency,
moratorium and similar laws affecting the enforcement of creditors’ rights generally and (ii) the rules governing the availability of specific performance, injunctive relief or other equitable remedies and general principles of equity,
regardless of whether considered in a proceeding in law or equity, regardless of whether considered in a proceeding in law or equity. 
 6.2
No Conflict or Violation. The execution and delivery by Buyer of this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder and the consummation by Buyer of the Contemplated Transactions will not
(i) to Buyer’s Knowledge, violate any law, statute, rule or regulation or judgment, order, writ, injunction or decree of any Governmental Entity, or (ii) conflict with, result in any breach of, or constitute a default (or an event
which with notice or lapse of time or both would become a default) under the Certificate of Incorporation or bylaws of Buyer or, to Buyer’s Knowledge, any agreement to which Buyer is a party, except for such violations, conflicts, breaches or
defaults which individually or in the aggregate have not had and would not reasonably be expected to have a Material Adverse Effect on Buyer. 
 6.3 Consents and Approvals. No notice to, declaration, filing or registration with, or authorization, consent or approval of, or permit from, any Governmental Entity, or any other Person, is required to be made or obtained by Buyer
in connection with the execution, delivery and performance of this Agreement and the consummation of the Contemplated Transactions, except with respect to the HSR Filing and the Environmental Governmental Authorizations listed in Schedule
6.3, except for declarations, filings, registrations, authorizations, consents, approvals or permits which if not obtained or made have not had and would not reasonably be expected to have individually or in the aggregate a Material Adverse
Effect on Buyer. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 25 

 6.4 Cash Resources. Buyer has cash and/or readily available financing in an amount sufficient to
pay the Purchase Price at the Closing and any and all fees and expenses relating to the transactions contemplated under this Agreement and specifically acknowledges Seller has entered into this Agreement in reliance upon this representation. Buyer
acknowledges that obtaining financing shall not be a condition to Closing. 
 6.5 Seller’s Records. Buyer acknowledges that
Seller has heretofore delivered to Buyer (or has made available to Buyer for review and copying) copies of Seller’s Records. 
 6.6
Environmental Governmental Authorizations. Buyer acknowledges that Seller has previously delivered, or made available, to Buyer copies of certain Environmental Governmental Authorizations. 
 6.7 Litigation. There are no actions, suits, proceedings or claims pending or, to the Knowledge of Buyer, threatened in writing concerning Buyer
or any of its Affiliates with respect to the transactions contemplated in this Agreement. 
 6.8 Brokers and Finders. Except as set
forth in Schedule 6.8, Buyer has not employed any broker or finder or incurred any Liability for any brokerage fee, commission or finder’s fee in connection with the transactions contemplated by this Agreement. 
 6.9 Buyer Due Diligence. Buyer is experienced, and/or has engaged expert advisors experienced in the evaluation and purchase of property and
assets such as the Assets contemplated hereunder. Buyer acknowledges that prior to Closing it will have had the opportunity, pursuant to Section 7.5, to inspect the Facilities and observe the physical characteristics and condition of the
Facilities and any and all other matters, as to, concerning or with respect to any matter whatsoever relating to the Facilities or this Agreement or of concern to Buyer (“Property Condition”), including: title; the environmental
condition of the Facilities (including the presence or absence of Hazardous Substances in, on or about the Facilities, notwithstanding the issuance of letters of closure, no further action or liability assurance by the various federal, state or
local agencies and offices); water, soil, pest and geological conditions of the Facilities the financial condition of the Facilities; the suitability of the Facilities or any and all activities and/or uses which may be conducted thereon; the
compliance of or by the Facilities with any and all laws, rules, ordinances or regulations of any applicable governmental authority or body (including environmental, building codes, and the status of any development or use rights respecting the
Facilities); the habitability, merchantability, marketability, profitability or fitness for a particular purpose of the Facilities; or the physical condition of the improvements, including construction defects, deferred maintenance or other adverse
physical conditions or defects. Buyer further acknowledges and agrees that except for any representations, warranties or agreement made by Seller herein, neither Seller nor any Person acting or purporting to act on Seller’s behalf has made any
representation, warranty or agreement, express or implied, by or on behalf of Seller as to any matters concerning a Property Condition. Buyer hereby acknowledges, agrees and represents that, except as otherwise provided in this Agreement, the
Facilities are to 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 26 

 
be purchased, conveyed and accepted by Buyer at the Closing in their present condition, “AS IS”, “WHERE IS” AND WITH ALL FAULTS, and that
no patent or latent defect or deficiency in a Property Condition, whether or not known or discovered (other than the fraud of Seller), shall affect the rights of either Seller or Buyer hereunder, nor shall the Purchase Price be reduced as a
consequence thereof. Upon Closing, except as otherwise provided in this Agreement, Buyer will acquire the Facilities solely on the basis of its own physical and financial examinations, review and inspections and the title insurance protection
afforded by the owner’s title policy. Upon Closing, Buyer shall assume the risk that Property Conditions may not have been revealed by Buyer’s investigations. 
 ARTICLE 7 
 PRE-CLOSING COVENANTS 
 7.1 Governmental Filings. Buyer and Seller shall cooperate in promptly undertaking all filings required to be filed with any Governmental Entity
in connection with the transfer of Assets and other rights under this Agreement and to cooperate with one another as reasonably necessary to accomplish the foregoing, including, but not limited to, the filings required of both parties pursuant to
the HSR (such filings sometimes being referred to in this Agreement as the “HSR Filings”), and the filing of any additional information as required with respect to such HSR Filings as soon as practicable after receipt of request
therefor from the United States Federal Trade Commission. The filing fees associated with all HSR Filings shall be [****]*. 
 7.2 Conduct
of Operations. During the period on and from the Effective Date through and including the Closing Date, Seller shall maintain the Facilities in substantially the same condition as exist as of the Effective Date, maintain the same insurance
coverages on the Facilities currently in effect and operate the Assets in a manner reasonably determined in Seller’s discretion as prudent to prevent damage to, or deterioration of, the Facilities and to comply in all material respects with
applicable legal requirements and all applicable permits and approvals. 
 7.3 Obtaining Necessary Consents and Lease Extensions.
Seller shall use its commercially reasonable efforts to obtain any and all consents necessary for the effective assignment to and assumption by Buyer of the Assumed Contracts and Assumed Liabilities, including the Third Party Consents and the
consents set forth on Schedule 5.3. Further, Seller agrees not to (i) terminate the employment or reduce the salary on other benefits of any Operations Employee or remove any Tangible Personal Property included in the Assets from
any of the Facilities prior to the Closing without the prior written consent of Buyer except for immaterial quantities of supplies in the ordinary course of Business, except as otherwise required pursuant to Section 7.8(c), or (ii) to
modify or amend any Assumed Contracts or enter into any new contracts unless the same is terminable without penalty by Seller and by Buyer upon not more than thirty (30) days’ notice. Buyer shall cooperate with Seller to obtain Third Party
Consents for the assignment and assumption of the Leased Properties. In addition, Buyer and Seller shall use commercially reasonable efforts to cause St. Paul Properties, Inc., as landlord under the 3750 Lease and the 3850 Lease, to [****]*. Buyer
and Seller shall use commercially reasonable efforts to amend each Lease and that certain Lease Agreement between St. Paul 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 27 

 Properties, Inc., as landlord, and Seller, as tenant, dated February 10, 1992, as amended (the “Retained
Lease”), to [****]*. All such consents shall be in writing and executed counterparts thereof shall be delivered promptly to Buyer. To the extent (x) Buyer wishes to pursue a transfer of any of the Environmental Governmental
Authorizations, and (y) such Environmental Governmental Authorizations are transferable, then Seller shall reasonably cooperate with, and assist Buyer in effectuating such transfer, including the filing of any forms with the relevant
Governmental Entity that may be necessary to secure approval of such transfer by such Governmental Entity. 
 7.4 No Solicitation.
Seller will not (and it will cause its officers, directors, employees, agents and Affiliates not to) (a) take any action to solicit, initiate, seek, or affirmatively support any inquiry, proposal or offer from, any corporation, partnership,
Person or group (other than Buyer) relating to any acquisition of the Assets, (any such proposed transaction being a “Third Party Acquisition”); or (b) participate in any discussions or negotiations with, or provide any
non-public information to, any corporation, partnership, Person or group (other than Buyer) relating to any proposed Third Party Acquisition. In no event will Seller accept or enter into an agreement concerning any such Third Party Acquisition prior
to the termination of this Agreement pursuant to Article 11. Notwithstanding this provision, nothing herein shall be deemed to in any way restrict or limit the right of Seller to engage in discussions, negotiations, furnishing of information or any
other activities relating to or in support of transactions involving the acquisition or sale of Seller and/or any other product lines or businesses of Seller other than the Assets, so long as this Agreement shall remain in full force and effect and
shall remain binding on the parties hereto. 
 7.5 Access. During the period from the Effective Date and continuing until the Closing,
upon reasonable advance notice received from Buyer and at Buyer’s expense, Seller shall (i) afford Buyer and its representatives reasonable access to the Facilities, during regular business hours, for the purposes of making, at
Buyer’s expense, (A) engineering, architectural, title, zoning, survey, and other similar studies that Buyer reasonably deems necessary or desirable in connection with the transaction contemplated hereby (the “Real Property
Inspections”) and (B) environmental investigations, assessments or studies of the Real Property and all related reports and correspondence (the “Environmental Inspections”), and (ii) otherwise cooperate and assist
with Buyer’s investigation of the Assets as Buyer may reasonably request. Buyer shall coordinate with Seller to minimize any interference with the operations of Seller that may be caused by any Real Property Inspection and Environmental
Inspection. Buyer will obtain (or ensure that its agents, consultants and contractors, as applicable, will obtain) public liability and property damage insurance insuring against any liability arising out of any entry, tests or investigations of the
Property pursuant to the provisions hereof. Buyer will provide to Seller, upon request, a certificate of insurance evidencing Buyer’s or Buyer’s agents’, consultants’ and/or contractors’, as applicable, procurement of a
commercial general liability insurance policy as required herein prior to or simultaneous with their conducting any physical inspection of the Facilities. Such insurance shall be in the amount of [****]* combined single limit for injury to or death
of one or more persons in an occurrence, and for damage to tangible property (including loss of use) in an occurrence. The aforementioned insurance coverage may 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 28 

 be obtained under a blanket policy carried by Buyer or its agents, consultants or contractors, as the case may be. In
conducting any inspections, investigations or tests of the Property, Buyer and its agents and representatives shall: (i) not unreasonably interfere with the operation and maintenance of the Property; (ii) not perform any invasive or
destructive testing or sampling and not otherwise damage any part of the Property or any personal property; (iii) not injure Seller or its agents, guests, invitees, contractors or employees; (iv) comply with all applicable laws;
(v) promptly pay when due the costs of all tests, investigations, and examinations done with regard to the Property; (vi) not permit any liens to attach to the Property by reason of the exercise of its rights hereunder; (vii) repair
any damage to the Property resulting directly or indirectly from any such inspection or tests; (viii) not reveal or disclose prior to Closing any information obtained by Buyer prior to Closing concerning the Property or documents related
thereto, except as may be otherwise required by law, and (ix) not cause the Release of any Hazardous Substance discovered through any such inspection nor exacerbate any existing Release of Hazardous Substance discovered through such inspection.
Buyer shall afford Seller the opportunity to have a representative of Seller present to accompany the parties undertaking such evaluations, inspections, tests and other investigations of the physical condition of the Property. If this Agreement is
terminated, Buyer shall restore the Property to the condition in which it was found by Buyer. Buyer’s obligation to restore the Property shall survive any termination of this Agreement. 
 7.6 Title Insurance. Schedule 5.8(d)(i) sets forth a description of the Real Property. Buyer has ordered from the Title Company a title
insurance search and commitment for a title insurance policy (the “Title Commitment”), setting forth the status of title to the Real Property and any defects in or exceptions or objections to title (“Title
Exceptions”). No later than ten (10) business days after Buyer’s receipt of the Survey and Title Commitment, Buyer shall notify Seller of any Title Exceptions disclosed by the Title Commitment (or the Current Survey) which are not
Permitted Encumbrances and are objectionable to Buyer (“Title Objections”). Each Title Exception not objected to shall be deemed a Permitted Encumbrance. Upon receipt of a Title Objection, Seller may notify Buyer by written notice
(the “Response Notice”), not later than five (5) business days after receipt of the Title Objection (the “Cure Notice Deadline”) that either (i) Seller agrees to cure, at Seller’s expense, all Title
Objections prior to Closing, or (ii) Seller does not intend to cure such Title Objections. A title defect shall be deemed cured if Title Company deletes reference to the item constituting the title defect as an encumbrance and exception to the
Title Company’s insurance coverages without additional or special premium. If Seller declines to cure the Title Objections prior to Closing, Buyer may terminate this Agreement by written notice delivered to Seller within five (5) business
days after receipt of the Response Notice and Seller shall reimburse Buyer for all of its costs and expenses incurred in connection with the due diligence, the negotiation of the letter of intent between Seller and Buyer dated January 24, 2008
and this Agreement (including the negotiation of all associated agreements and all actions performed as part of this Agreement). Such termination shall be Buyer’s sole remedy. If Buyer does not terminate this Agreement, such Title Objections
shall be deemed Permitted Encumbrances; provided, however, that if such a Title Objection can be cured by the payment of money only, Buyer’s shall have the option at the Closing to deduct from the Purchase Price the amount of money necessary,
in the opinion of the Title Company, to cure the Title Objection, which amount may include such other sums as may be deemed necessary of desirable by the Title Company. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 29 

 7.7 Inspections. 
 (a) Promptly after receipt of any report pertaining to any Real Property Inspection which identifies (i) any failure of the
Facilities to comply with any Legal Requirement or (ii) any defect in the physical condition of the Facilities, including construction defects or deferred maintenance, where the cost to correct or cure such defective physical condition could,
in the opinion of Buyer’s engineering consultants, exceed [****]* (in either case, an “Unsatisfactory Condition”), then, Buyer promptly shall deliver a copy of such report and written notice to Seller (the
“Unsatisfactory Inspection Notice”) setting forth in reasonable detail conditions and, if available, a good faith estimate of the likely costs to remedy the Unsatisfactory Condition. Upon receipt of an Unsatisfactory Inspection
Notice, Seller may notify Buyer by written notice (the “Inspection Response Notice”), not later than five (5) business days after receipt of the Unsatisfactory Inspection Notice (the “Inspection Notice
Deadline”) that either (i) Seller agrees to cure such conditions prior to the Closing or (ii) Seller does not intend to cure such conditions prior to the Closing. If Seller does not provide an Inspection Response Notice to Buyer
by the Inspection Notice Deadline, Seller shall be deemed to have agreed to cure such conditions prior to the Closing. If Seller provides an Inspection Response Notice that Seller does not intend to cure such conditions prior to the Closing, Buyer
may notify Seller by written notice, not later than five (5) business days after the Inspection Notice Deadline (the “Buyer Notice Deadline”) that Buyer is terminating this Agreement, whereupon Seller shall reimburse Buyer for
its costs and expenses incurred in connection with the due diligence, the negotiation of the letter of intent between Seller and Buyer dated January 24, 2008 and this Agreement (including the negotiation of all associated agreements and all
actions performed as part of this Agreement). If Buyer does not terminate this Agreement by Buyer Notice Deadline or fails to respond by Buyer Notice Deadline, Buyer shall be deemed to have accepted Seller’s response (or deemed response) in the
Inspection Response Notice. Effective as of Closing, provided that Seller has effected the cure of all conditions Seller agreed to cure in the Inspection Response Notice, Buyer shall be deemed to have accepted the Real Property “as-is” as
of the Closing Date and to have waived and released any claims against Seller with respect thereto except as otherwise provided in this Agreement. Notwithstanding the foregoing, a circumstance or condition which constitutes an Environmental
Remediation Obligation under Section 7.7(b) shall not constitute an Unsatisfactory Condition. 
 (b) Buyer shall use
commercially reasonable efforts to obtain a Phase I Environmental Site Assessment of the Facilities promptly, and in all events, prior to the Closing Date. Promptly after receipt of any report pertaining to any Environmental Inspection which
identifies any Hazardous Substance that is or is suspected of being located at, on, under or migrating to or from the Real Property that requires or may require remediation under any applicable Environmental Laws (an “Environmental
Remediation Obligation”), then, Buyer promptly shall deliver a copy of such report and written notice to Seller (the “Environmental Remediation Obligation Notice”) setting forth in reasonable detail the basis for and any
evidence of an actual or suspected Environmental Remediation Obligation, and, if available, a good faith estimate of the likely costs associated with such Environmental Remediation (as defined herein) or with any further Environmental Inspections,
such as a Phase II Environmental Site 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 30 

 Assessment, needed to investigate further any suspected Environmental Remediation Obligation(s). Upon
receipt of an Environmental Remediation Obligation Notice, Seller may notify Buyer by written notice (the “Environmental Cure Response Notice”), not later than five (5) business days after receipt of the Environmental
Remediation Obligation Notice (the “Environmental Cure Notice Deadline”) that either (i) Seller agrees to conduct an Environmental Remediation of such Environmental Remediation Obligation and conduct such further Environmental
Inspections as may be necessary to determine whether or not each suspected Environmental Remediation Obligation is, in fact, an Environmental Remediation Obligation and, upon the determination of the environmental consultant reasonably acceptable to
Buyer performing such further Environmental Inspections that one or more additional Environmental Remediation Obligations exist that Seller agrees to conduct an Environmental Remediation of such additional Environmental Remediation Obligations, or
(ii) Seller does not intend to conduct an Environmental Remediation of such Environmental Remediation Obligation or any further Environmental Inspections. If Seller does not provide an Environmental Cure Response Notice to Buyer by the
Environmental Cure Notice Deadline, Seller shall be deemed to have agreed to conduct an Environmental Remediation of such Remediation Obligation and to conduct such further Environmental Inspections and, upon the determination of said environmental
consultant reasonably that one or more additional Environmental Remediation Obligations exist, to conduct an Environmental Remediation of such additional Environmental Remediation Obligations. If Seller provides an Environmental Cure Response Notice
that Seller does not intend to conduct an Environmental Remediation of such Remediation Obligation, Buyer may notify Seller by written notice, not later than five (5) business days after the Environmental Cure Notice Deadline (the
“Buyer Termination Deadline”) that Buyer is terminating this Agreement, whereupon Seller shall reimburse Buyer for its costs and expenses incurred in connection with the due diligence, the negotiation of the letter in intent between
Seller and Buyer dated January 24, 2008 and this Agreement (including the negotiation of all associated agreements and all actions performed as part of the Agreement). If Buyer does not terminate this Agreement by Buyer Termination Deadline or
fails to respond by Buyer Termination Deadline, Buyer shall be deemed to have accepted Seller’ response (or deemed response) in the Environmental Cure Response Notice. If Seller provides an Environmental Cure Response Notice that Seller intends
to conduct an Environmental Remediation of such Remediation Obligation and to conduct such further Environmental Inspections and, upon the determination of said environmental consultant reasonably that one or more additional Environmental
Remediation Obligations exist, to conduct an Environmental Remediation of such additional Environmental Remediation Obligations, then Seller and Buyer on or before the Closing Date shall negotiate and enter into a remediation agreement to accomplish
the requirements of this Section 7.7(b). Effective as of Closing, Buyer shall be deemed to have accepted all matters requiring Environmental Remediation expressly disclosed in the Environmental Inspection and Seller’s Reports, and to have
waived and released any claims against Seller with respect thereto except as provided for in this Agreement and the remediation agreement. 
 7.8 Employees. 
 (a) Buyer shall have the right prior to Closing to contact and to discuss possible terms of
employment with all of the Operations Employees, except the Seller’s Retained Employees listed on Schedule 7.8(a). Buyer anticipates offering all or substantially all the Operations Employees the opportunity to become employees of Buyer
in positions comparable to 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 31 

 
those they currently hold with Seller, effective immediately after the Closing. Buyer shall deliver to Seller a list of the Operations Employees to whom
Buyer has or intends to make offers of employment (each, an “Identified Employee”) at least fifteen (15) days prior to the date of the Closing. 
 (b) Other than those Seller’s Retained Employees listed on Schedule 7.8(a), Seller shall terminate the employment of all
Operations Employees who are offered employment by Buyer, effective immediately prior to the Closing. Seller shall take all action necessary to give any notification required by the Worker Adjustment and Retraining Notification Act
(“WARN”), United States Code, title 29, Section 2101 and Section 116L.976 of the Minnesota Statutes Annotated, comply with any requirements of the Consolidated Omnibus Budget Reconciliation Act of 1985 and pay any and all
severance, vacation, paid time off, unpaid wages, unpaid bonuses, unpaid commissions or other sums that may be due to Operations Employees in connection with their termination of employment with Seller, if any, or otherwise pursuant to the terms of
any of Seller’s employee benefit plan. Buyer shall provide to Seller in a timely manner any information reasonably necessary to determine whether an Identified Employee has been offered employment in a comparable position and such other
information as is reasonably necessary for Seller to comply with its obligations, if any, under WARN or any similar state law, rule or regulation with respect to Seller’s termination of the employment of any Operations Employees. Seller will
not exercise any right it may have under any agreement between Seller and any Operations Employee to prevent any such Operations Employee from accepting an offer of employment from Buyer or providing services to Buyer, and Seller will not otherwise
enforce any restrictive covenants that would adversely effect the employment of or services provided by such Operations Employees on behalf of Buyer. Seller shall not for a period of [****]* after the Closing Date (i) induce, persuade or
attempt to induce or persuade any employee, consultant or other personnel of Buyer at the Facilities or any former employee of Seller at the Facilities to reduce, terminate, restrict or otherwise alter his or employment relationship with Buyer;
or (ii) solicit, hire, offer to hire, entice away or engage the services of any employee, consultant or other personnel of Buyer at the Facilities or any former employee of Seller at the Facilities. 
 7.9 Bulk Transfer Laws. Seller shall comply with the provisions of any applicable so-called “bulk transfer law” of any jurisdiction in
connection with the sale of the Assets to Buyer. 
 7.10 Brokers and Finders. Seller agrees to pay to each Person named on Schedule
5.13 a commission pursuant to separate agreement and Buyer agrees to pay to each Person named on Schedule 6.8 a commission pursuant to separate agreement. The provisions of this Section 7.10 shall survive the Closing or other
termination of this Agreement. 
 ARTICLE 8 
 CONDITIONS TO CLOSING 
 8.1 Conditions to Obligations of Buyer. All obligations of Buyer
hereunder are, at the option of Buyer, subject to the conditions precedent (all or any of which may be waived by Buyer, in whole or in part) that, at the Closing: 
 (a) The waiting period or periods required under the HSR, if applicable, shall have expired or shall have been terminated. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 32 

 (b) Seller shall have furnished to Buyer all deliverables set forth in
Section 4.2(a), including the Lease Assignment and Assumption Agreement. 
 (c) The representations and warranties of
Seller set forth in Article 5 hereof shall be true and correct in all material respects at and as of the Closing Date as though then made, except that any such representation or warranty made as of a specified date (other than the date hereof) shall
only need to have been true on and as of such date. 
 (d) The [****]*. 
 (e) The Environmental Governmental Authorizations, if any, necessary in order for Buyer to perform its obligations under the Clinical Drug
Substance Supply Agreement and the Transition Services Agreement [and identified as conditions to Closing on Schedule 6.3] shall have been issued in the name of Buyer by the respective Governmental Entity Issuers thereof. 
 (f) All of the covenants and obligations that Seller is required to perform or to comply with pursuant to this Agreement at or prior to
the Closing (considered collectively), and each of these covenants and obligations (considered individually), shall have been duly performed and complied with in all material respects. 
 (g) Buyer shall have obtained the Phase I Environmental Site Assessment in accordance with Section 7.7(b) herein. 
 (h) Buyer shall have obtained a fully enforceable policy of title insurance insuring Buyer’s title to the Real Property in accordance
with Section 7.6 herein. 
 8.2 Conditions to Obligations of Seller. All obligations of Seller hereunder are, at the option of
Seller, subject to the conditions precedent (all or any of which may be waived by Seller, in whole or in part) that, at the Closing: 
 (a) The waiting periods required under the HSR, if applicable, shall have expired or shall have been terminated. 
 (b) Buyer shall have furnished to Seller all deliverables set forth on Section 4.2(b). 
 (c) The
representations and warranties of Buyer set forth in Article 6 hereof shall be true and correct in all material respects at and as of the Closing Date as though then made, except that any such representation or warranty made as of a specified date
(other than the date hereof) shall only need to have been true on and as of such date. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 33 

 ARTICLE 9 
 POST-CLOSING COVENANTS 
 9.1 Further Assurances. The parties agree to execute, acknowledge and
deliver such further instruments, and to do all such other reasonable acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement, including those acts necessary or useful to satisfy the Closing
conditions specified in Sections 8.1 and 8.2. Each party shall bear its own costs and expenses associated with fulfilling its obligations as set forth in this Article 9, except for such fees as provided for in the Transition Services Agreement.

 ARTICLE 10 
 CONFIDENTIALITY

 10.1 Confidentiality. Each party has disclosed, and may hereafter from time to time in the course of the performance of this
Agreement disclose, Confidential Information to the other party. Each party shall hold in confidence all Confidential Information of the other party and shall take all reasonable steps to prevent disclosure to, or use of the Confidential Information
of the other party by, any third party, except as permitted under this Agreement or as necessary to carry out the activities contemplated hereby. Further, neither party shall, without the prior written consent of the other party, use the
Confidential Information of the other party for any purpose other than performing its obligations or exercising its rights under this Agreement or in connection with the Contemplated Transactions. Each party shall disclose the Confidential
Information of the other party only to its directors, employees, consultants, vendors and clinicians under written agreements of confidentiality at least as restrictive as those set forth in this Agreement or comparable assurances of
confidentiality, who have a need to know such information in connection with such party performing its obligations or exercising its rights under this Agreement or in connection with the Contemplated Transactions. No provision of this Agreement
shall be construed so as to preclude such disclosure of Confidential Information as may be inherent in or reasonably necessary to the securing from any Governmental Entity of any necessary approval or license related to the Assets. Upon the
termination of this Agreement, and upon the written request of the other party, each party shall promptly return to the other party all copies and embodiments of the Confidential Information of such other party, subject to the retention by each
party’s legal department of one complete copy for archival purposes and except, with respect to Buyer, to the extent that Buyer has acquired such Confidential Information at Closing pursuant to Section 2.1(i) hereof; which Confidential
Information shall, effective as of the Closing, become the Confidential Information of Buyer for all purposes of this Agreement and the Confidentiality Agreement. 
 10.2 Publicity. No party to this Agreement shall originate any publicity, news release or other public announcement, written or oral, whether relating to this Agreement or the existence of any arrangement
between the parties, without the prior written consent of the other party whether named in such publicity, news release or other public announcement or not, except where such publicity, news release or other public announcement is required by law or
by the rules or regulations of any stock exchange on which any security of Seller or Buyer is listed for trading (“Stock Exchange”); provided that in such event, the party issuing same shall still be required to consult with
the other party whether named in such publicity, news release or public announcement or not, a reasonable time prior to its release to allow the other party to comment 

  

 CONFIDENTIAL TREATMENT REQUESTED 
 34 

 
thereon and, after its release, shall provide the other party with a copy thereof. Each party shall use commercially reasonable efforts to provide reasonable
advance notice of and to respond to and cooperate with the other party in connection with any such publicity. If the party whose comments are solicited fails to comment within [****]* days from the initial consultation with respect to any pending
disclosure (or such shorter period of time as may be necessary for the party proposing to issue such publicity or its Affiliates to avoid a violation of any applicable Legal Requirement or any rule or regulation of any Stock Exchange). The other
party shall be free to issue its publicity, news release or other public announcement. If either party, based on the advice of its counsel, determines that this Agreement, or any of the other documents executed in connection herewith, must be filed
with the SEC or any Stock Exchange, then such party, prior to making any such filing, shall provide the other party and its counsel with a redacted version of this Agreement (or any other related documents) which it intends to file, and will give
due consideration to any comments provided by the other party or its counsel and use reasonable efforts to ensure the confidential treatment by the SEC or any applicable Stock Exchange of those sections specified by the other party or its counsel.

 ARTICLE 11 
 TERM AND
TERMINATION 
 11.1 Termination. This Agreement may be terminated prior to the Closing: 
 (a) By Buyer, upon written notice (i) at any time prior to Closing, if Seller shall have failed to comply in any material respect
with any of its obligations in this Agreement, and such failure shall be continuing, or pursuant to any other termination right of Buyer set forth specifically in this Agreement, or if any one or more of the representations or warranties of Seller
contained in this Agreement shall prove to have been inaccurate in any material respect when made; provided, however, Buyer shall give Seller thirty (30) days to cure any such failure to so comply or to remedy any such inaccuracy
under this Agreement; or (ii) at Closing, if any of the conditions precedent to the performance of Buyer’s obligations at the Closing under Article 7 or Article 8 shall not have been fulfilled (unless the failure results primarily from
Buyer’s breach of any representation, warranty, covenant or agreement contained this Agreement); provided, however, that in the event that Buyer shall desire to terminate this Agreement as a result of the failure of the accuracy
in any material respect of a representation or warranty at the Closing, Buyer shall be required to give Seller prior notice that it intends to terminate this Agreement as a result of such inaccuracy and Seller shall have a reasonable period of time,
not to exceed thirty (30) days, to cure such inaccuracies. 
 (b) By Seller, upon written notice (i) at any time
prior to Closing, if Buyer shall have failed to comply in any material respect with any of its covenants or agreements contained in this Agreement and such failure shall be continuing, or pursuant to any other termination right or Seller
specifically set forth in this Agreement, or if any one or more of the representations or warranties of Buyer contained in this Agreement shall prove to have been inaccurate in any material respect when made; provided, however, Seller
shall give Buyer thirty (30) days to cure any such failure to so comply or any such inaccuracy under this Agreement; or 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 35 

 (ii) at the Closing, if any of the conditions precedent to the performance of its obligations at the
Closing under Article 7 or Article 8 shall not have been fulfilled (unless the failure results from Seller’s breach of any representation, warranty, covenant or agreement contained this Agreement); provided, however, that in the
event that Seller shall desire to terminate this Agreement as a result of the failure of the accuracy in any material respect of a representation or warranty at the Closing, Seller shall be required to give Buyer prior notice that it intends to
terminate this Agreement as a result of such inaccuracy and Buyer shall have a reasonable period of time, not to exceed thirty (30) days, to cure such inaccuracies. 
 (c) By either party if the Closing shall not have occurred on or before April 30, 2008, provided that such date shall be extended to
the extent necessary under the circumstances in the event the waiting period under the HSR is extended, restarted or renewed beyond the initial 30-day period, or the Title Commitment and Current Survey have not been received by Buyer and Seller or a
dispute exists in connection with any matter described in Section 7.7 hereof, unless such failure to close is primarily the result of the breach of any representations, warranties, covenants or agreements contained in this Agreement by the
party seeking to terminate. 
 11.2 [****]*. 
 11.3 Consequences of Termination. In the event of termination of this Agreement prior to the Closing in accordance with its terms (rather than for willful breach of this Agreement): (i) each party will
redeliver all documents, work papers and other material of any other party relating to the Contemplated Transactions, whether so obtained before or after the Effective Date, to the party furnishing the same; (ii) the provisions of Article 10
shall continue in full force and effect; and (iii) no party hereto shall have any Liability or further obligation to any other party to this Agreement; provided that if this Agreement is terminated pursuant to Section 11.1(a)(i) hereof,
Seller shall reimburse Buyer for all of its costs and expenses incurred in connection with the due diligence, the negotiation of the letter of intent between Seller and Buyer dated January 24, 2008 and this Agreement (including the negotiation
of all associated agreements and all actions performed as part of this Agreement); provided further that if this Agreement is terminated pursuant to Section 11.1(b)(i) hereof, Buyer shall reimburse Seller for all of its costs and expenses
incurred in connection with the due diligence, the negotiation of the letter of intent between Seller and Buyer dated January 24, 2008 and this Agreement (including the negotiation of all associated agreements and all actions performed as part
of this Agreement). 
 11.4 Effectiveness. Termination under this Article 11 shall not become effective so long as the alleged grounds
for termination are in dispute and the matter(s) at issue have been submitted for resolution pursuant to this Agreement. 
 ARTICLE 12

 INDEMNIFICATION 
 12.1
Survivability of Representations and Warranties. The representations and warranties made in Articles 5 and 6 or any instrument delivered pursuant to this Agreement survive the Closing Date and the consummation of the Contemplated Transactions
for a period of [****]*; provided, however, that: 
 (a) Seller’s representations and warranties set forth
in Sections [****]* shall survive [****]*; 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 36 

 (b) Seller’s representations and warranties set forth in Sections [****]*, and
Buyer’s representations and warranties set forth in Sections [****]* shall survive [****]*; 
 (c) Sellers’
representations and warranties set forth in Section [****]* will survive the Closing Date for a period [****]*, including Governmental Entities, with respect to matters addressed in such Section; and 
 (d) Seller’s representations and warranties set forth in [****]*. 
 12.2 Indemnification by Buyer. Buyer
indemnifies and holds harmless Seller, and any of its directors, officers, employees, Affiliates, controlling persons, agents and representatives (the “Seller Indemnitees”) from and against any Liabilities (a) to the extent
such Liabilities relate to the Assumed Liabilities, (b) arising from Buyer’s breach of this Agreement or any instrument delivered pursuant to this Agreement, (c) arising from the arising from the breach of any representation or
warranty made by Buyer in this Agreement, or (d) third party Claims arising from the conduct of Buyer’s business at the Facilities after the Closing Date (other than third party Claims arising under the Clinical Drug Substance Supply
Agreement). 
 12.3 Indemnification by Seller. Seller indemnifies and holds harmless Buyer, and any of its directors, officers,
employees, Affiliates, controlling persons, agents and representatives (the “Buyer Indemnitees”) from and against any Liabilities (a) to the extent such Liabilities constitute Excluded Liabilities, (b) arising from
Seller’s breach of this Agreement or any instrument delivered pursuant to this Agreement, (c) arising from the breach of any representation or warranty made by Seller in this Agreement, or (d) third party Claims arising from the
conduct of the Operations prior to the Closing Date. 
 12.4 Claims. Any Buyer Indemnitee or Seller Indemnitee claiming that it may be
entitled to indemnification under this Article 12 (the “Indemnified Party”) shall give prompt notice to the other party (the “Indemnifying Party”) of each matter, action, cause of action, claim, demand, fact or
other circumstances upon which a claim for indemnification (a “Claim”) under this Article 12 may be based. Such notice shall contain, with respect to each Claim, such facts and information as are then reasonably available, the
specific basis for indemnification hereunder, together with the amount or, if not then reasonably ascertainable, the estimated amount, determined in good faith. Failure to give prompt notice of a Claim hereunder shall not affect the Indemnifying
Party’s obligations under this Article, except to the extent the Indemnifying Party is prejudiced by such failure. If a Claim relates to a Proceeding brought against an Indemnified Party by a third party, the Indemnifying Party shall
immediately upon receipt of notice of such claim, assume the defense of such claim with counsel reasonably by acceptable to the Indemnified Party. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 37 

 12.5 Assertion of Claims. No claim shall be brought under Sections 12.2 or 12.3 unless Buyer
Indemnitees, or any of them, or Seller Indemnitees, or any of them, as the case may be, at any time prior to the expiration of the applicable representation or warranty (as provided in Section 12.1), provide Buyer or Seller, as the case may be,
with written notice of the existence of any such claim, specifying the nature and basis of such claim and the amount thereof, to the extent known; provided, that, the failure so to provide such notice to Buyer or Seller, as the case may be, will not
relieve Buyer or Seller, as the case may be, from any Liability which they may have to Buyer Indemnitees or Seller Indemnitees, as the case may be, under this Agreement or otherwise, except to the extent that Buyer or Seller, as the case may be,
reasonably demonstrates that such failure results in the loss or compromise of any rights or defenses of Buyer or Seller, as the case may be, and that Buyer or Seller, as the case may be, was not otherwise aware of such action or claim. Upon the
giving of such written notice as aforesaid, Buyer Indemnitees, or any of them, or Seller Indemnitees, or any of them, as the case may be, shall have the right to commence legal proceedings prior or subsequent to the applicable survival date for the
enforcement of their rights under Sections 12.2 or 12.3, as the case may be. 
 12.6 Payment of Claims; Limitation on Indemnification.

 (a) Notwithstanding anything to the contrary in Sections 12.2 or 12.3, any Liability under Section 12.2(c) and
Section 12.3(c), respectively, shall be limited as follows: [****]*. 
 (b) The aggregate maximum Liability of Seller or
Buyer to the other party under [****]*. 
 12.7 Limitation; Exclusivity. No Claim shall be made or have any validity unless the
Indemnified Party shall have given written notice of such Claim to the Indemnifying Party. If full recovery under any such Claim is not had within [****]* of such written notice, arbitration, pursuant to Section 13.2, must be commenced within
thirty (30) days following the end of such [****]* period or such Claim shall be invalidated. This Article 12 provides the exclusive means by which a party may assert Claims against the other party, other than Claims based on fraud or willful
misconduct, and Section 13.2 provides the exclusive means by which a party may bring actions against the other party with respect to any breach by the other party of its obligations under this Agreement. 
 ARTICLE 13 
 MISCELLANEOUS 

13.1 No Third Party Beneficiaries. Nothing in this Agreement, express or implied, is intended to or shall (i) confer on any Person other
than the parties hereto (and Buyer Indemnitees and Seller Indemnitees referred to in) and their respective successors or assigns any rights (including third party beneficiary rights), remedies, obligations or liabilities under or by reason

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT REQUESTED 
 38 

 of this Agreement, or (ii) constitute the parties hereto as partners or as participants in a joint venture. This
Agreement shall not provide third parties with any remedy, claim, liability, reimbursement, cause of action or other right in excess of those existing without reference to the terms of this Agreement. No third party shall have any right, independent
of any right which may exist irrespective of this Agreement, under or granted by this Agreement, to bring any suit at law or equity for any matter governed by or subject to the provisions of this Agreement. 
 13.2 Governing Law; Jurisdiction; Dispute Resolution and Arbitration. This Agreement shall be deemed to have been made in the State of Minnesota
and its form, execution, validity, construction and effect shall be determined in accordance with the laws of the state of Minnesota, without giving effect to the principles of conflicts of law thereof. Disputes arising out of, relating to or in
connection with this Agreement, or in relations between the parties with respect to the subject matter hereof, for any reason or under any circumstances, will be finally settled by a single arbitrator in a binding arbitration in accordance with the
Judicial Arbitration and Mediation Services (“JAMS”) Comprehensive Arbitration Rules and Procedures (the “JAMS Rules”). Upon receipt of written notice of the existence of a dispute by one party hereto to the other,
the parties shall, within thirty (30) days conduct a meeting of one or more senior executives of each party, with full settlement authority, in an attempt to resolve the dispute. Each party shall make available appropriate personnel to meet and
confer with the other party reasonably within the 30-day period. Upon the expiration of the 30-day period, or upon the termination of discussions between the senior executives, either party may elect arbitration of any dispute by written notice to
the other (the “Arbitration Notice”). The arbitration shall be held in Minneapolis, Minnesota before one (1) arbitrator from JAMS having substantial experience as a jurist and mediator with significant disputes in the
biotechnology and/or pharmaceuticals industry selected by the mutual agreement of Buyer and Seller; provided, however, that if such parties cannot agree on an arbitrator within thirty (30) days of the Arbitration Notice, either
party may request JAMS select the arbitrator, and JAMS shall select an arbitrator pursuant to the procedure set out by the JAMS Rules, provided, however, that the arbitrator selected be a former judge with at least fifteen (15) years experience
addressing as a jurist and/or mediator significant disputes in the biotechnology and or pharmaceutical industry. The arbitration shall be administered by JAMS pursuant to its AAA Rules. Judgment on the arbitration award may be entered in any court
having jurisdiction. The arbitrator may, in the arbitration award, allocate for payment by the non-prevailing party all or part of the costs of the arbitration, including fees of the arbitrator and the reasonable attorneys’ fees and costs
incurred by the prevailing party. This Section shall not preclude the parties from seeking provisional remedies in aid of arbitration from a court of appropriate jurisdiction. In respect of any actions for injunctive or other equitable relief
hereunder, any action or proceeding may be brought against any party in the state and federal courts located in the city of Minneapolis, Minnesota and each of the parties consents to the jurisdiction of such courts in any such action or proceeding
and waives any objection to venue laid therein. 
 13.3 Severability. If any provision of this Agreement is held by a court of
competent jurisdiction to be invalid or unenforceable, it shall be modified, if possible, to the minimum extent necessary to make it valid and enforceable or, if such modification is not possible, such provision shall be stricken and the remaining
provisions shall remain in full force and effect. If any of the terms or provisions of this Agreement is in conflict with any applicable statute or rule of law in any jurisdiction, then such term or provision shall be deemed inoperative in such
jurisdiction to the extent of such conflict and the parties will renegotiate the affected terms and conditions of this Agreement to resolve any inequities. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 39 

 13.4 Entire Agreement. This Agreement and the ancillary transaction documents to be executed and
delivered pursuant to this Agreement are intended to define the full extent of the legally enforceable undertakings and representations of the parties hereto, and no promise or representation, written or oral, which is not set forth explicitly in
this Agreements or such ancillary transaction documents is intended by either party to be legally binding; provided, however, in the event this Agreement terminates, the Confidentiality Agreement shall continue in full force and effect
pursuant to its terms. Each party acknowledges that in deciding to enter into this Agreement and to consummate the transaction contemplated hereby it has not relied upon any statements or representations, written or oral, other than those explicitly
set forth in this Agreement. 
 13.5 Amendment. This Agreement may not be amended, supplemented or otherwise modified except by an
instrument in writing signed by both parties that specifically refers to this Agreement. 
 13.6 Notices. All notices and other
communications given or made pursuant hereto shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile, (iii) five (5) days after
having been sent by registered or certified mail, return receipt requested, postage prepaid or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of
receipt. All communications shall be sent to the respective parties at the addresses set forth below (or at such other addresses as shall be specified by notice given in accordance with this Section): 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 40 

			
	 If to Seller:
  
 PDL BioPharma, Inc.
 Attention: General Counsel
 1400 Seaport Boulevard
 Redwood City, CA 94063
 Facsimile: 650-454-1468
 E-mail: Francis.Sarena@pdl.com
  
 with a copy to: (not to constitute notice)
  
 DLA Piper US LLP
 Attention: Howard Clowes
 153 Townsend Street, Suite 800
 San Francisco, CA 94107-1957
 Facsimile:415-659-7410
 E-mail: howard.clowes@dlapiper.com
	  	 If to Buyer:
  
 GMN, Inc.
 Attention: President
 c/o Genmab, Inc.
 457 North Harrison Street
 Princeton,
NJ 08540
 Facsimile: +1 609-430-2482
 E-mail:
TLH@Genmab.com
  
 with a copy to: (not to constitute notice)
  
 Lisa Drakeman, President
 Genmab A/S
 c/o Genmab, Inc.
 457
North Harrison Street
 Princeton, NJ 08540
 Facsimile: +1
609-430-2482

 13.7 Assignment. This Agreement and the rights and obligations hereunder shall be binding
upon and inure to the benefit of the parties hereto, their respective successors and assigns, but this Agreement shall not be assignable by either party hereto without the express written consent of the other party hereto which will not be
unreasonably withheld. 
 13.8 No Agency. It is understood and agreed that each party shall have the status of an independent
contractor under this Agreement and that nothing in this Agreement shall be construed as authorization for either party to act as agent for the other. Neither party shall incur any Liability for any act or failure to act by employees of the other
party. 
 13.9 Construction. 
 (a) This Agreement has been prepared jointly and shall not be strictly construed against either party. 
 (b) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender
shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. 
 (c)
Except as otherwise indicated, all references in this Agreement to “Articles,” “Sections,” “Exhibits,” “Schedules” and “Attachments” are intended to refer to Articles and Sections of and Exhibits,
Schedules and Attachments to this Agreement. 
 (d) The table of contents and headings contained in this Agreement are for
reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 41 

 13.10 Payment of Expenses. Except as otherwise set forth in this Agreement, all costs and expenses
associated with this Agreement and the Contemplated Transactions, including the fees of counsel and accountants, shall be borne by the party incurring such expenses. 
 13.11 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but which together shall constitute one and the same instrument. Any executed
counterpart delivered by facsimile or other means of electronic transmission shall be deemed an original for all purposes. 
 [Remainder of
page intentionally left blank; signature page follows] 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 42 

 IN WITNESS WHEREOF, the parties, through their authorized officers, have duly executed this as of the
date first written above. 
  

									
	PDL BioPharma, Inc.,	 		 	GMN, Inc.,
	a Delaware corporation	 		 	a Delaware corporation
					
	By:	 	/s/ L. Patrick Gage	 		 	By:	 	/s/ Torben Lund-Hansen
	Name:	 	L. Patrick Gage	 		 	Name:	 	Torben Lund-Hansen
	Title:	 	Chief Executive Officer	 		 	Title:	 	President
					
	By:	 	/s/ Andrew Guggenhime	 		 		 	
	Name:	 	Andrew Guggenhime	 		 		 	
	Title:	 	Senior Vice President and Chief Financial Officer	 		 		 	

 SIGNATURE PAGE 
 ASSET PURCHASE AGREEMENT 
  

 CONFIDENTIAL TREATMENT REQUESTED 
 43 

 EXHIBIT A 
 GENERAL ASSIGNMENT AND BILL OF SALE 
 THIS GENERAL ASSIGNMENT AND BILL OF SALE (this “Bill of
Sale”) is made and delivered as of [                    ], 2008 (the “Effective Date”) by PDL BioPharma, Inc., a
Delaware corporation (“Seller”) for the benefit of GMN Inc., a Delaware corporation (“Buyer”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement (as
defined below). 
 RECITALS 
 WHEREAS, Seller and Buyer have entered into that certain Asset Purchase Agreement (the “Purchase Agreement”), dated as of February [            ], 2008,
pursuant to which, among other things, Seller has agreed to sell, convey, transfer, assign and deliver to Buyer all of Seller’s right, title and interest in and to the Assets. 
 NOW, THEREFORE, in consideration of the agreements and covenants contained in the Purchase Agreement, and for other good and valuable consideration, the
receipt, adequacy and sufficiency of which are hereby acknowledged, and subject to the terms and conditions of the Purchase Agreement: 
 1.
Transfer of Assets. Seller hereby sells, conveys, transfers, assigns and delivers unto Buyer, and its successors and assigns, forever, effective immediately upon consummation of the Closing, all of Seller’s right, title and interest in
and to the Assets, including, without limitation, the Assets set forth on Schedule A hereto. 
 2. Further Actions. Seller covenants
and agrees to warrant and defend the sale, transfer, assignment, conveyance, grant and delivery of the Assets hereby made against all persons whomsoever, to take all steps reasonably necessary to establish the record of Buyer’s title to the
Assets and, at the request of Buyer, to execute and deliver further instruments of transfer and assignment and take such other action as Buyer may reasonably request to more effectively transfer and assign to and vest in Buyer each of the Assets,
all at the sole cost and expense of Seller. 
 3. Terms of the Purchase Agreement. The terms of the Purchase Agreement, including but
not limited to Seller’s representations, warranties, covenants, agreements and indemnities relating to the Assets, are incorporated herein by this reference. Seller acknowledges and agrees that the representations, warranties, covenants,
agreements and indemnities contained in the Purchase Agreement shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the
Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern. 
 4. Binding Effect. This Bill of Sale
shall inure to the benefit of Buyer and its successors and assigns. 
 5. Governing Law. This Bill of Sale shall be governed by and
construed under the laws of the State of Minnesota without regard to conflicts of laws principles. 
 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, Seller has executed this Bill of Sale as of the date first above written. 

 

			
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

 GENERAL ASSIGNMENT AND BILL OF SALE 
 SIGNATURE PAGE 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT B 
 (Top 3 inches reserved for recording data) 
  
  

			
	LIMITED WARRANTY DEED	  	Minnesota Uniform Conveyancing Blanks
	Business Entity to Business Entity	  	Form 10.2.9 (2006)

  

							
	DEED TAX DUE: $
                            	 		  	DATE:
                                
		 		 		  	              (month/day/year)

  

			
	FOR VALUABLE CONSIDERATION,	  	 
	(insert name of Grantor)
	
	 

  

							
	a                                       
              	  	under the laws of	  	 	  	(“Grantor”),

  

			
	hereby conveys and quitclaims to 	  	 
		  	(insert name of Grantee)

  
  

							
	a                                       
              	  	under the laws of 	  	 	 	, (“Grantee”),

 real property in
                         County, Minnesota, legally described as follows: 
 Check here if all or part of the described real property is Registered (Torrens)    ̈ 
 together with all hereditaments and appurtenances. 
 This Deed conveys
after-acquired title. Grantor warrants that Grantor has not done or suffered anything to encumber the property, EXCEPT: 
  

											
	 Check applicable box:
	 		 	Grantor
				
	  ̈        
	 	The Seller certifies that the Seller does not know of any wells on the described property.	 		 	 
				
	  ̈        
	 	A well disclosure certificate accompanies this document.	 		 	(name of Grantor)
						
	  ̈        
	 	I am familiar with the property described in this instrument and I certify that the status and number of wells on the described real property have not changed since the last
previously filed well disclosure certificate.	 		 	By: 	 	 	 	 
	 	 		 		 	(signature) 
	 	 		 		 	
		 	 		 		 	
		 	 		 		 	Its: 	 	 
		 		 		 		 		 	 (type of authority)

		 		 		 	By: 	 	 
		 		 		 		 	(signature) 
						
		 		 		 		 	Its: 	 	 
		 		 		 		 		 	 (type of authority)

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

			
	Page 2 of 2	  	Minnesota Uniform Conveyancing Blanks    Form 10.2.9

  

									
	State of                                     
                ,	  	County of 	  	 	  		  	

									
				
	This instrument was acknowledged before me on 	  	 	  	by 	  	 
		  		  	(month/day/year)	  		  	(name of authorized signer)
	 	  	as 	  	 
		  		  	(type of authority)

									
		
	and by 	  	 
		  	(name of authorized signer)

									
	as 	  	 	  	of 	  	 
	(type of authority)	  		  	(name of Grantor)

  

					
	(Seal, if any)	  	 
		  	(signature of notarial officer)
			
		  	Title (and Rank):	 	 
			
		  	My commission expires:	 	 
		  		 	(month/day/year)
		
	 THIS INSTRUMENT WAS DRAFTED BY:
 (insert name and
address)
	  	 TAX STATEMENTS FOR THE REAL PROPERTY
DESCRIBED IN THIS INSTRUMENT SHOULD BE SENT
TO:
 (insert name and address of Grantee to whom tax statements should be sent)

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT C 
 ASSIGNMENT AND ASSUMPTION AGREEMENT 
 THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this
“Agreement”) is made and entered into as of [                    ], 2008 (the “Effective Date”) by and among
PDL BioPharma, Inc., a Delaware corporation (“Seller”) and Genmab MN, Inc., a Delaware corporation (formerly known as GMN, Inc., a Delaware corporation, a wholly owned subsidiary of Genmab A/S, a corporation existing under the laws
of Denmark) (“Buyer”). Buyer and Seller are referred to hereinafter as the “Parties”. 
 RECITALS

 WHEREAS, the Parties have entered into that certain Asset Purchase Agreement (the “Purchase Agreement”), dated as of
February [    ], 2008, pursuant to which, among other things, Seller has agreed to assign, and Buyer has agreed to assume, the Assumed Contracts and the Assumed Liabilities. 
 NOW, THEREFORE, in consideration of the agreements and covenants contained in the Purchase Agreement, and the premises and mutual covenants hereinafter
set forth, and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 
 1. Capitalized Terms. Capitalized terms used but not defined herein (including in the recitals above) shall have the meanings ascribed to them in
the Purchase Agreement. 
 2. Assignment. In accordance with and subject to the terms of the Purchase Agreement, Seller hereby sells,
assigns, transfers, conveys and delivers to Buyer all of Seller’s right, title and interest, legal and equitable, in, to and under (i) the Assumed Contracts and (ii) the Assumed Liabilities (the “Assignment”).

 3. Assumption. In accordance with and subject to the terms of the Purchase Agreement, Buyer hereby (a) accepts the Assignment
and (b) assumes and agrees to honor, pay and discharge when due all of (i) the executory obligations of Seller to be performed from and after the date hereof under the Assumed Contracts and (ii) the Assumed Liabilities. For the
avoidance of doubt, Buyer assumes no Liability of Seller other than as specifically stated above, and, specifically, does not assume the Excluded Liabilities, and the Parties agree that all Liabilities that have not been assigned herein shall remain
the sole responsibility of Seller. Furthermore, nothing contained herein shall prevent Buyer from having the ability to contest, in good faith, any claim of Liability asserted by any person or entity other than Seller and its Affiliates. 

4. Terms of the Purchase Agreement. The terms of the Purchase Agreement, including but not limited to Seller’s representations,
warranties, covenants, agreements and indemnities relating to the Assumed Contracts and Assumed Liabilities, are incorporated herein by this reference. Each of the Parties hereby acknowledges and agrees that the representations, warranties,
covenants, agreements and indemnities contained in the Purchase Agreement shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms
of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 5. Further Assurances. Seller, for itself and its successors and assigns, hereby covenants and
agrees that, at any time and from time to time after delivery of this instrument, at Buyer’s request, but without further consideration, it will do, execute, acknowledge or deliver, or will cause to be done, executed, acknowledged or delivered,
all such further acknowledgments, deeds, conveyances, transfers, and similar instruments of assignment as may be reasonable and necessary for the conveying, assigning, transferring, confirming or vesting in Buyer, and the assumption by Buyer of, any
of the Assumed Contracts or Assumed Liabilities or to more effectively consummate the assignments and assumptions contemplated by this Agreement. 
 6. Governing Law. This Agreement will be governed by and construed under the laws of the State of Minnesota without regard to conflicts of laws principles. 
 7. Binding Effect. This Agreement shall inure to the benefit of, and shall be binding upon, the Parties hereto and their respective successors and
assigns. This Agreement shall not provide third parties with any remedy, claim, liability, reimbursement, cause of action or other right in excess of those existing without reference to the terms of this Agreement. No third party shall have any
right, independent of any right which may exist irrespective of this Agreement, under or granted by this Agreement, to bring any suit at law or equity for any matter governed by or subject to the provisions of this Agreement. 
 8. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but which together shall
constitute one and the same instrument. Any executed counterpart delivered by facsimile or other means of electronic transmission shall be deemed an original for all purposes. 
 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. 
  

			
	SELLER:
	
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
	
	BUYER:
	
	Genmab MN, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

 ASSIGNMENT & ASSUMPTION AGREEMENT 
 SIGNATURE PAGE 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT D 
 LEASE ASSIGNMENT AND ASSUMPTION 
 THIS LEASE ASSIGNMENT AND ASSUMPTION AGREEMENT (this
“Agreement”) is made as of [                    ], 2008 (“Effective Date”), by and among PDL BioPharma,
Inc., a Delaware corporation (“Seller”) and Genmab MN, Inc., a Delaware corporation (formerly known as GMN, Inc., a Delaware corporation, a wholly owned subsidiary of Genmab A/S, a corporation existing under the laws of Denmark)
(“Buyer”). Buyer and Seller are referred to hereinafter as the “Parties.” 
 RECITALS 
 WHEREAS, Buyer and Seller have entered into that certain Asset Purchase Agreement, dated as of February [    ], 2008 (the
“Purchase Agreement”), pursuant to which Buyer has agreed, among other things, to assume all of Seller’s right, title and interest in and to, and obligations under, the leases listed on Exhibit A attached hereto (each a
“Lease” and collectively, the “Leases”), from and after the Effective Date. 
 WHEREAS, pursuant to the
Purchase Agreement, Seller desires and has the ability to assign the Leases listed on Exhibit A to Buyer and Buyer desires to assume Seller’s rights, title and interest in and to, and obligations under, the Lease listed on Exhibit
A, from and after the Effective Date. 
 NOW, THEREFORE, for and in consideration of the mutual agreements and covenants contained herein
and in the Purchase Agreement, and for other good and valuable consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged, effective as of the Effective Date, the Parties agree as follows: 
 1. Capitalized Terms. Capitalized terms used but not defined herein (including in the recitals above) shall have the meanings ascribed to such
terms in the Purchase Agreement. 
 2. Assignment and Assumption. 
 (a) Seller hereby sells, assigns, transfers, conveys and delivers to Buyer, forever, all right, title and interest of Seller in and to
each Lease set forth on Exhibit A attached hereto, together with the interest of Seller in security deposits collected and held by landlord to secure the performance of the duties and obligations of tenants under the Lease
(“Assignment”). Seller is delivering possession of the Demised Premises (as defined in each Lease) to Buyer simultaneously with the execution and delivery of this Agreement. 
 (b) Buyer hereby accepts the Assignment and assumes and agrees to be bound by each Lease, and assumes and agrees to pay, perform and
discharge when due any and all Liabilities arising under each Lease from and after the date of this Agreement. For the avoidance of doubt, Buyer assumes no Excluded Liabilities, and the parties hereto agree that all such Excluded Liabilities shall
remain the sole responsibility of Seller. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 3. Purchase Agreement. The terms of the Purchase Agreement, including but not limited to
Seller’s representations, warranties, covenants, agreements and indemnities relating to each Lease, are incorporated herein by this reference. Seller acknowledges and agrees that the representations, warranties, covenants, agreements and
indemnities contained in the Purchase Agreement shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Purchase Agreement
and the terms hereof, the terms of the Purchase Agreement shall govern. 
 4. Seller Representation. Seller hereby covenants,
represents and warrants to Buyer and to Landlord that there are no filed mechanics liens for work performed within the Demised Premises at the request of or for the benefit of Seller, or materials supplied on account of such work, and Seller has no
reason to believe that any mechanics lien may be filed on account of such work. 
 5. Further Actions. Each of the Parties hereto
covenants and agrees, at its own expense, to execute and deliver, at the request of the other party hereto, such further instruments of transfer and assignment and to take such other action as such other Party may reasonably request to more
effectively consummate the assignments and assumptions contemplated by this Agreement. 
 6. Successors and Assigns. This Agreement
shall be binding upon and shall inure to the benefit of Seller and Buyer and their respective successors and permitted assigns. 
 7.
Governing Law. This Agreement shall be governed by, and construed under the laws of the State of Minnesota, without regard to conflicts of laws principles. 
 8. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument. Copies
of executed counterparts transmitted by telecopy, telefax or other electronic transmission service shall be considered original executed counterparts for purposes of this Section 7. 
 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the day and year first above written.

  

			
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
	
	BUYER:
	
	Genmab MN, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT E 
 NOTE ASSIGNMENT 
 THIS NOTE ASSIGNMENT (this “Note Assignment”) is made and
delivered as of [                    ], 2008 (the “Effective Date”) by PDL BioPharma, Inc., a Delaware corporation, formerly
known as Protein Design Labs, Inc. (“Seller”) for the benefit of Genmab MN, Inc., a Delaware corporation (formerly known as GMN, Inc., a Delaware corporation, a wholly owned subsidiary of Genmab A/S, a corporation existing under the
laws of Denmark) (“Buyer”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement (as defined below). 
 RECITALS 
 WHEREAS, Seller and Buyer have entered into that certain Asset Purchase
Agreement (the “Purchase Agreement”), dated as of February [    ], 2008, pursuant to which, among other things, Seller has agreed to sell, convey, transfer, assign and deliver to Buyer all of Seller’s
right, title and interest in and to the Note (as defined in the Purchase Agreement). 
 NOW, THEREFORE, in consideration of the agreements
and covenants contained in the Purchase Agreement, and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, and subject to the terms and conditions of the Purchase Agreement: 

1. Transfer of Note. Seller hereby sells, conveys, transfers, assigns and delivers unto Buyer, and its successors and assigns, forever,
effective immediately upon consummation of the Closing, all of Seller’s right, title and interest in and to the Note. 
 2. Further
Actions. Seller covenants and agrees to warrant and defend the sale, transfer, assignment, conveyance, grant and delivery of the Note hereby made against all persons whomsoever, to take all steps reasonably necessary to establish the record of
Buyer’s title to the Note and, at the request of Buyer, to execute and deliver further instruments of transfer and assignment and take such other action as Buyer may reasonably request to more effectively transfer and assign to and vest in
Buyer the Note, all at the sole cost and expense of Seller. 
 3. Registration Process. This Note Assignment is subject to the
registration and transfer requirements of Section 7 of the Note. Seller shall reimburse Buyer any transfer fees or charges imposed by Authority upon the transfer of the ownership of the Note to Buyer. 
 4. Terms of the Purchase Agreement. The terms of the Purchase Agreement, including but not limited to Seller’s representations, warranties,
covenants, agreements and indemnities relating to the Note, are incorporated herein by this reference. Seller acknowledges and agrees that the representations, warranties, covenants, agreements and indemnities contained in the Purchase Agreement
shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase
Agreement shall govern. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 5. Binding Effect. This Note Assignment shall inure to the benefit of Buyer and its successors and
assigns. 
 6. Governing Law. This Note Assignment shall be governed by and construed under the laws of the State of Minnesota without
regard to conflicts of laws principles. 
 [SIGNATURE PAGE FOLLOWS] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, Seller has executed this Note Assignment as of the date first above written.

  

			
	PDL BioPharma, Inc.,
	a Delaware corporation
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT F 
  
  
 CLINICAL DRUG
SUBSTANCE SUPPLY AGREEMENT 
 by and between 
 GMN, INC. 
 and 
 PDL BIOPHARMA, INC. 
  
  
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 TABLE OF CONTENTS 
  

					
	1.	  	DEFINITIONS	  	1
			
	2.	  	SUPPLY	  	6
			
	3.	  	PURCHASE AND DELIVERY	  	7
			
	4.	  	STANDARD OF PERFORMANCE, TECHNICAL INFORMATION, SPECIFICATIONS	  	9
			
	5.	  	QUALITY CONTROL, ACCEPTANCE AND REJECTION, FAILURE TO SUPPLY	  	9
			
	6.	  	FACILITIES AND INSPECTIONS	  	12
			
	7.	  	PRICING	  	12
			
	8.	  	SAFETY, ADVERSE EVENT REPORTING, RECALLS AND REGULATORY MATTERS	  	14
			
	9.	  	INTELLECTUAL PROPERTY	  	15
			
	10.	  	REPRESENTATIONS, WARRANTIES AND OTHER MATTERS	  	15
			
	11.	  	CONFIDENTIAL INFORMATION	  	16
			
	12.	  	INDEMNIFICATION	  	18
			
	13.	  	TERM AND TERMINATION	  	19
			
	14.	  	LIMITATION OF LIABILITY	  	20
			
	15.	  	DISPUTE RESOLUTION	  	21
			
	16.	  	MISCELLANEOUS	  	21

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 CLINICAL DRUG SUBSTANCE SUPPLY AGREEMENT 
 THIS CLINICAL DRUG SUBSTANCE SUPPLY AGREEMENT (this
“Agreement”) is effective as of the Effective Date (as defined below) and is by and between GMN, Inc., a Delaware corporation and a wholly owned subsidiary of Genmab A/S, a corporation organized under the laws of Denmark, having its
principal place of business at 9450 Winnetka Avenue N, Brooklyn Park, MN (“GMN”) and PDL BioPharma, Inc., a corporation organized under the laws of Delaware, having its principal place of business at 1400 Seaport Boulevard, Redwood
City, CA 94063 (“PDL”). 
 RECITALS 
 WHEREAS, the parties have entered into that certain Asset Purchase Agreement dated as of February 21, 2008 (the “Purchase Agreement”) relating to the purchase by GMN of PDL’s
manufacturing assets and facilities in Minnesota, including the Facilities (as defined herein); and 
 WHEREAS, the Purchase
Agreement contemplates that the parties shall enter into this Agreement to provide, among other things, for the supply of the Products (as defined below) by GMN to PDL for the purposes of the conduct of clinical trials by PDL. 
 AGREEMENT 
 NOW,
THEREFORE, for and in consideration of the above-described recitals, the mutual promises and covenants of the parties hereinafter contained and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged by the parties, the parties hereto (the “Parties”), intending to be legally bound, enter into the agreements contained herein. 
 1. DEFINITIONS 
 For purposes of this Agreement, the following terms shall have the meanings set forth below: 
 “Act” shall mean the United States Food, Drug and Cosmetic Act and applicable regulations promulgated thereunder, as they may be amended
or supplemented from time to time, or an equivalent application under any successor laws or regulations. 
 “Adverse Event”
shall mean any untoward medical occurrence in a patient or clinical investigation subject temporally associated with the use of a Product whether or not considered related to the Product. 
 “Affiliate” shall mean, with respect to either Party, any person or entity which, directly or indirectly, controls, is controlled by, or
is under common control with, the specified Party. For the purposes of this definition, the term “control”, as applied to any person or entity, means the ownership or control, directly or indirectly, of more than the lesser of
(a) fifty percent (50%) or (b) the maximum percentage allowed by law in the country of the controlled person or entity, of all of the voting power of the shares (or other securities or rights) entitled to vote for the election of
directors or other governing authority giving the Party the power to direct or cause the direction of the management and policies of the person or other entity or the power to elect or appoint fifty percent (50%) or more of the members of the
governing body of the person or other entity; provided that such person or entity shall be considered an “Affiliate” only during the time that such “control” exists. 
 “Agreement” shall have the meaning set forth in the Preamble. 
  

					
		  	1	  	CONFIDENTIAL TREATMENT REQUESTED

 “Batch Records” shall mean the documentation of all steps related to the manufacture of
a Product. The documentation includes but is not limited to records of the dispensing, weighing, mixing, and processing of a Product, the release documents of the Raw Materials used in the manufacture of a Product and the Product release testing
documentation. 
 “Claim” shall mean any charge, allegation, notice, civil, criminal or administrative claim, demand,
complaint, cause of action, suit, proceeding, arbitration, hearing or investigation. 
 “Commercially Reasonable Efforts”
shall mean that level of effort as is customary in the specialty biotechnology pharmaceutical industry for carrying out a particular task or obligation in relation to the manufacture of antibody products for clinical trials in accordance with GMP.

 “Dispute” shall have the meaning set forth in Section 15.1. 
 “Drug Master File” or “DMF” shall mean the drug master file for a Product and the drug master file(s) for any
excipients for that Product held by a Raw Materials manufacturer filed with the FDA (if any) as of the Effective Date in accordance with 21 CFR (chapter 314.420), and as subsequently supplemented from time to time. 
 “Engineering Runs” shall have the meaning set forth in Section 2.9. 
 “Effective Date” shall mean the date upon which the Closing (as that term is defined in the Purchase Agreement) of the transactions
contemplated by the Purchase Agreement shall have been consummated. 
 “EMEA” shall mean the European Medicines Agency and any
successor agencies. 
 “Facility” shall mean the Brooklyn Park biologic manufacturing facility located at 9450 Winnetka
Avenue N, Brooklyn Park, MN acquired by GMN from PDL pursuant to the Purchase Agreement. 
 “FDA” shall mean the U.S. Food
and Drug Administration of the U.S. Department of Health and Human Services and any successor agencies. 
 “Force Majeure
Event” shall mean any cause or contingency beyond a Party’s reasonable control, including, riots, quarantines, communicable disease outbreaks, wars, acts of terrorism, fires, floods or storms. 
 “Fully Burdened Cost” shall mean: in connection with the manufacture, testing and storage of any Product, or in connection with the
performance or provision of a service hereunder, all costs (full cost) incurred by GMN, including, without limitation, labor, material costs, allocable amortization and depreciation, product quality assurance/control costs, allocable facilities
costs (e.g. sewer, water, property taxes), insurance and other support costs borne by GMN. In order to minimize large swings in the overhead allocation based on production volume, overhead allocations shall be made on the basis of a practical plant
capacity of [****]* for the Transition Product, the Initial Purchase Order, the Second Purchase Order and the Third Purchase Order, respectively, and [****]* for the Engineering Runs, 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	2	  	CONFIDENTIAL TREATMENT REQUESTED

 adjusted for changeovers in production. All allocable costs shall be allocated on a percentage of effort basis. Direct
costs (e.g. materials and production labor) will be based on actual costs incurred for each production run and will include any variances from the production standard. Such Fully Burdened Cost calculations shall be evidenced by reasonably detailed
supporting documentation and shall be prepared consistently from period to period. 
 “GMP” shall mean
(a) “current Good Manufacturing Practices” or “cGMP” as specified at 21 Code of Federal Regulations (CFR) (chapters 210 and 211) as amended from time-to-time, and (b) “Good Manufacturing Practices” or “EU
GMP” as specified in the EU Guidelines to Good Manufacturing Practice: Medicinal Products for Human or Veterinary Use, as amended from time-to-time. 
 “GMN Indemnitee” shall have the meaning set forth in Section 12.2. 
 “Indemnifying Party” shall have the meaning set forth in Section 12.3. 
 “Indemnitee” shall
have the meaning set forth in Section 12.3. 
 “Initial Term” shall mean the twenty-four (24) months immediately
following the Effective Date. 
 “Initial Purchase Order” shall have the meaning set forth in Section 3.1.1.

 “Intellectual Property Rights” shall mean patents, trade marks, service marks, rights (registered or unregistered) in any
designs, applications for any of the foregoing, trade or business names, copyright (including rights in computer software) and topography rights, know-how, secret formulae and processes, and other proprietary knowledge and information; internet
domain names, rights protecting goodwill and reputation, database rights and all rights and forms of protection of a similar nature to any of the foregoing or having equivalent effect anywhere in the world and all rights under licences and consents
in respect of any of the rights and forms of protection mentioned in this definition. 
 “Law” shall mean any federal, state
or local law, statute or ordinance, or any rule, regulation, or published guidelines promulgated by any governmental authority, including a Regulatory Authority, as in effect on the Effective Date or adopted thereafter which are applicable to a
Party’s activities hereunder, including the Act. 
 “Out of Freeze
Date” shall mean the date on which [****]*. 
 “Party” shall have the meaning set forth in the Preamble. 
 “PDL
Indemnitee” shall have the meaning set forth in Section 12.1. 
 “PDL-Provided Material” shall have the
meaning set forth in Section 2.6. 
 “Preliminary Purchase Price” shall mean the estimated purchase price for a batch
of Product. The Preliminary Purchase Price for the Initial Purchase Order, the Second Purchase Order and the Third Purchase Order is set forth in Annex E hereto. After the Initial Term and for any purchase order during 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	3	  	CONFIDENTIAL TREATMENT REQUESTED

 the Initial Term other than the Initial Purchase Order, the Second
Purchase Order and the Third Purchase Order, the Preliminary Purchase Price shall be renegotiated by the parties in good faith on an annual basis during the Term hereof. The parties shall agree on, and shall enter into a written amendment to this
Agreement setting forth, the new Preliminary Purchase Price no later than [****]* prior to the end of each year. 
 “Products” shall mean the humanized antibody products set forth on Annex A hereto each as drug substance and each in the same
form as manufactured immediately before the Effective Date by PDL at the Facility, and each as intended to be used by PDL in clinical trials investigating the safety or efficacy of the aforementioned humanized antibody products, as Annex A
may be amended from time to time by the prior written agreement of the Parties in accordance with Section 2.4. 
 “Raw
Materials” shall mean, either individually or collectively as the context requires under this Agreement, all raw materials, including media, resins, stability pools and retains, excipients, components, work in progress, supplies and packing
as indicated in the Specifications, which are utilized in the manufacture or filling of the Products, as applicable, other than the master cell banks and working cell banks for the Products. PDL shall provide the master cell banks and/or working
cell banks to GMN as described in Section 2.5. 
 “Recall” shall mean (i) a recall (as defined in 21 CFR (chapter
7)), field correction, clinical withdrawal, stock recovery, or other similar action with respect to a Product; and/or (ii) any decision by PDL not to sell or ship a Product to third parties which would have been subject to recall (as defined in
21 CFR (chapter 7)), field correction, clinical withdrawal, stock recovery, or other similar action if it had been sold or shipped, in each case taken in the good faith belief that such action was appropriate under the circumstances. 
 “Regulatory Approval” shall mean with respect to any Product, any approval required under the Act and any similar governmental approvals
of any Regulatory Authority required to Exploit such Product. For this purpose, “Exploit” shall mean to formulate, develop, seek Regulatory Approval for, make, have made, use, sell, have sold, offer for sale, market, promote,
import, export, display, distribute, out-license or otherwise commercialize or dispose of. 
 “Regulatory Authority” shall
mean the FDA, and any similar governmental authority, administrative agency or commission of any region, country, state, province, county, city or other political subdivision in the Territory, including, without limitation, the EMEA. 
 “Second Purchase Order” shall have the meaning set forth in Section 3.1.2. 
 “Seizure” shall mean any action by any Regulatory Authority or other government agency to detain or destroy a Product. 
 “Specifications” shall mean the specifications for each Product as set forth in Annex B, as such specifications may be changed
from time to time by written agreement of the Parties as set forth in Section 5 below. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	4	  	CONFIDENTIAL TREATMENT REQUESTED

 “Technical Agreement” shall mean a technical agreement regarding the quality and testing
of Product between the Parties in substantially the form given in Annex D. 
 “Technical Information” shall mean all
relevant information regarding the manufacture and testing of the Products (including the approved methods of manufacture and testing of the Products and information relating to Raw Materials), as applicable, provided by PDL to GMN and set out in
Annex B as updated from time to time. 
 “Term” shall have the meaning set forth in Section 13.1. 
 “Territory” shall mean the world. 
 “Third Party” shall mean any person or entity other than GMN, PDL, or their respective Affiliates. 
 “Third Party Losses” shall mean all liabilities, losses and damages finally awarded to a Third Party by a court, arbitration tribunal or other entity of competent jurisdiction that result from any Claim made or brought
against an Indemnitee by or on behalf of such Third Party. Third Party Losses shall include any reasonable direct out-of-pocket costs and expenses (including reasonable attorneys’ fees) incurred by that Indemnitee while investigating or
conducting the defense of such Third Party Claim, regardless whether such Claim is successful. 
 “Third Purchase Order”
shall have the meaning set forth in Section 3.1.3. 
 Unless the context of this Agreement otherwise requires: (a) words of any
gender include each other gender; (b) words using the singular or plural number also include the plural or singular number, respectively; (c) the terms “hereof,” “herein,” “hereby,” and derivative or similar
words refer to this entire Agreement; (d) the terms “Section” or “Annex” refer to the specified Section or Annex of this Agreement; (e) the term “or” has, except where otherwise indicated, the inclusive
meaning represented by the phrase, “and/or”; (f) the term “including” means “including, without limitation”; (g) “days” refers to calendar days; and (h) the term “not to unreasonably
withhold approval” and words of similar import includes not to unreasonably delay or condition such approval. All references to “$” amounts hereunder shall be deemed to be United States Dollars, and all payments due hereunder shall be
made in United States Dollars. 
 “[****]* Successful Batches” means, with respect to each Product, the manufacture at the
Facility of [****]* batches of such Product that conform to the Specifications, whether manufactured by PDL prior to the Effective Date or by GMN on or after the Effective Date. 
 “Transition Product” shall have the meaning set forth in Section 2.8. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	5	  	CONFIDENTIAL TREATMENT REQUESTED

 2. SUPPLY 
 2.1 Clinical Supply Initial Term. During the Initial Term of this Agreement GMN shall manufacture the Product at the Facility in accordance with this Agreement in order to supply PDL with Product to meet PDL’s requirements for
its clinical development programs as specified in the Initial Purchase Order, the Second Purchase Order and the Third Purchase Order. Furthermore, PDL shall be entitled to purchase and GMN shall be obligated to supply during the Initial Term the
number of batches of Product as set forth in Sections 3.1.1, 3.1.2 and 3.1.3. 
 2.2 Other Clinical Supply. Supply of Product with an
Out of Freeze Date outside the Initial Term or above the number of batches GMN has committed to during the Initial Term may be requested by PDL in accordance with the procedure in Section 3 during the Term of the Agreement. GMN shall use
Commercially Reasonable Efforts to accommodate such request taking into account the then current operation of the Facility and GMN’s plans, but shall have no obligation to provide such additional supply of Product. 
 2.3 Adequate Reserves. GMN shall maintain at all times during the Term an inventory of Raw Materials sufficient in GMN’s reasonable judgment
to maintain continuity of supply of Product to PDL, based on the accepted purchase orders, provided that GMN shall use up the PDL-Provided Materials listed in Annex G. All PDL-Provided Materials provided to GMN from PDL to perform
GMN’s obligations under the Agreement shall be licensed or otherwise provided to GMN cost-free. 
 2.4 Amendments to Products.
During the Term, PDL may request the addition or substitution of additional humanized antibodies products to Annex A by written notice to GMN. Upon receipt of such notice, GMN shall promptly consider such request in good faith and shall use
Commercially Reasonable Efforts to accommodate such request taking into account the then current operation of the Facility and GMN’s plans, but shall have no obligation to amend Annex A as requested by PDL. If the Parties agree to
PDL’s request, they shall promptly agree in writing on an amendment to this Agreement setting forth pricing and such other commercially reasonable terms as are equitably required for GMN to manufacture the additional products pursuant to this
Agreement. 
 2.5 Master Cell Banks/Working Cell Banks. PDL shall deliver the master cell banks and/or working cell banks for the
Products to GMN, [****]*, for use by GMN in manufacturing the Product pursuant to this Agreement. GMN shall maintain the master cell banks and working cell banks in accordance with written instructions provided by PDL, and shall return the master
cell banks and working cell banks to PDL promptly after the termination of this Agreement. The master cell banks and working cell banks shall remain the property of PDL at all times. 
 2.6 PDL-Provided Materials. PDL shall deliver to GMN, [****]*, the supplies of Raw Materials listed in Annex G hereto (the
“PDL-Provided Materials”) solely for use by GMN in manufacturing the Products pursuant to this Agreement. GMN shall return said PDL-Provided Materials to PDL promptly after the termination of this Agreement. Such PDL-Provided
Materials shall remain the property of PDL at all times. 
 2.7 Batch Adjustments. During the Initial Term, PDL shall have the right
on not less than [****]* prior written notice to GMN, to adjust the batch sizes and number of batches between and among the Products set forth in Annex A, provided that the total number of [****]* batches for the applicable period
remain unchanged. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	6	  	CONFIDENTIAL TREATMENT REQUESTED

 2.8 Transition Product. GMN acknowledges that prior to the Effective Date, PDL was in the process
of manufacturing up to [****]* batches of [****]* at the Facility (the “WIP”). Commencing on the Effective Date, GMN hereby agrees to complete the manufacture of the WIP at the Facility and deliver the completed Products (the
“Transition Product”) to PDL in accordance with this Agreement. Within [****]* after the Effective Date, the Parties shall conduct a mutual assessment of the manufacturing process completed by PDL as of the Effective Date as a
percentage of the total manufacturing process, in order to determine the remaining percentage of the manufacturing process required to be carried out by GMN in order to complete the manufacture of each batch of the Transition Product (the
“GMN Completion Percentage”). The GMN Completion Percentage shall be used in determining the Preliminary Purchase Price for each batch of the Transition Product as set forth in Section 7.1. Notwithstanding anything in this
Agreement to the contrary, GMN shall have no liability to PDL for any non-conformance of the Transition Product to the Specifications, unless such non-conformance is due to the gross negligence or willful misconduct of GMN. 
 2.9 Engineering Runs. PDL shall have the right to request that GMN manufacture at the Facility engineering runs of Product (“Engineering
Runs”). The Engineering Runs shall only be used for internal purposes. All requests for Engineering Runs shall be subject to acceptance by GMN pursuant to Section 3.1.4 and 3.2. GMN shall consider all such requests in good faith and
shall use Commercially Reasonable Efforts to accommodate all such requests. 
 3. PURCHASE AND DELIVERY 
 3.1 Purchase Orders 
 3.1.1
Initial Purchase Order. On the Effective Date PDL shall place and GMN shall accept an initial purchase order covering PDL’s requirement for Product covering the period from the Effective Date through [****]*, which initial purchase order
shall contain no fewer than [****]* batches of Product and no more than [****]* batches of Product (the “Initial Purchase Order”). 
 3.1.2 Second Purchase Order. No later than [****]*, PDL shall place and GMN shall accept a second purchase order covering the period of from [****]* through [****]*, which purchase order shall contain no fewer
than [****]* batches of Product and no more than [****]* batches of Product (the “Second Purchase Order”). 
 3.1.3 Third Purchase Order. No later than [****]*, PDL shall place and GMN shall accept a third purchase order covering the period of from [****]* through [****]*, which purchase order shall contain no fewer than [****]* batches of
Product and no more than [****]* batches of Product (the “Third Purchase Order”); provided that the Second Purchase Order and the Third Purchase Order shall contain an aggregate minimum order of no fewer than [****]* batches
of Product. 
 3.1.4 Other Purchase Orders. PDL and/or its Affiliates may place one or more further purchase orders
with GMN for Products for its clinical development programs. Such purchase order shall be sent to GMN no later than [****]* before the Out of Freeze Date. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	7	  	CONFIDENTIAL TREATMENT REQUESTED

 3.1.5 Contents of Purchase Orders. Each purchase order under this Agreement shall
as a minimum specify the number of batches and the estimated delivery dates for each Product ordered. All purchase orders shall be in substantially the form mutatis mutandis as set out in Annex C as provided on the Effective Date.

 3.2 Acceptance. Within [****]* of receipt of a purchase order (other than the Initial Purchase Order, the Second Purchase Order and the Third Purchase Order) by GMN, GMN shall notify PDL in writing whether it
intends to accept or reject such purchase order. 
 3.3 Terms of Agreement Govern. No modification or amendment to this Agreement
shall be effected by or result from the receipt, acceptance, signing or acknowledgement of a purchase order, quotations, invoices, shipping terms or other document submitted pursuant to this Agreement or any other document passing between the
Parties which contains terms or conditions in addition to or inconsistent with the terms of this Agreement. The terms of this Agreement shall control and prevail and such additional or inconsistent terms are hereby expressly rejected. 
 3.4 Delivery 
 3.4.1
GMN shall deliver to PDL each order of Product, packed for shipment in accordance with the applicable purchase order, EXW (Incoterms 2000) at the Facility or at another location as otherwise agreed in writing. Risk of loss and damage to each
shipment of Product shall pass to PDL when the Product [****]*. If PDL and/or its designee does not pick-up the Product on the delivery date GMN shall use Commercially Reasonable Efforts to ensure proper storage of such Product until such time as
the Product is finally loaded by PDL or its designated carrier and PDL shall reimburse GMN the cost of the storage in accordance with Section 7. For the avoidance of doubt, [****]*. Prior to shipment, all Products must be approved by GMN in
accordance with its internal QA release process and each shipment of Product must be accompanied by a Certificate of Conformance confirming the same. 
 3.4.2 GMN shall ensure that Product is delivered to PDL by the date for delivery, as specified in the accepted purchase order or as subsequently revised by the parties in writing. [****]*. 
 3.4.3 Title to any Product shall not pass to PDL until payment in full of the relevant invoice issued by GMN in respect of such Product.

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	8	  	CONFIDENTIAL TREATMENT REQUESTED

 4. STANDARD OF PERFORMANCE, TECHNICAL INFORMATION, SPECIFICATIONS 
 4.1 GMN Standard of Performance. During the Term GMN shall manufacture the Products at the
Facility in accordance with the Technical Information and supply the Product in accordance with the purchase orders accepted under the terms of this Agreement. GMN shall adhere to GMP and applicable Laws but, except for the obligation to test in
accordance with Section 5, GMN shall have no obligation and makes no warranty or representations with respect to the conformity with the Specifications of the Products and Raw Materials not provided by PDL, except to the extent that failure to
meet the Specifications is due to the gross negligence or willful misconduct of GMN or, GMN’s failure to follow the procedures set forth in the Technical Information after [****]* Successful Batches, other than non-material deviations from the Technical Information. [****]*. 
 4.2 Technical Information. PDL shall provide GMN with updates to Technical Information from time to time as they become available, and shall provide GMN with reasonable support with respect to such updates,
[****]*, if necessary. 
 4.3 Specifications. The Specification for each Product is set forth in Annex B based on PDL’s
manufacture of the Products at the Facility prior to the Effective Date. GMN makes no warranty or representations with respect to the Specifications or the Technical Information as received by GMN on the Effective Date. 
 4.4 Mandated Changes to Specifications. If: (i) any Regulatory Authority having jurisdiction requires either Party to implement any changes
to the Specifications; (ii) any changes to the Specifications are required in order to comply with changes to applicable Law; or (iii) any changes to the Specifications are required in order to obtain Regulatory Approval, the Parties shall
use their Commercially Reasonable Efforts to agree upon amended Specifications accordingly. GMN shall promptly advise PDL as to any lead-time changes or other terms that may result from a change to the Specifications, including price adjustments
necessary to enable GMN to recover costs it incurred for materials already purchased by GMN expressly for PDL and rendered unusable by PDL due to such a change. PDL shall bear the costs incurred to generate and implement modified Specifications
(including any modifications or changes to the equipment or processes involved in the manufacture of the Product). If GMN is not able, using Commercially Reasonable Efforts, to change the Specifications as requested by PDL, then such inability shall
be deemed to be a Force Majeure event affecting GMN. 
 5. QUALITY CONTROL, ACCEPTANCE AND REJECTION, FAILURE TO SUPPLY 
 5.1 Batch Records. GMN shall prepare and maintain Batch Records with respect to each production lot of Product, including information relating to
the manufacturing, quality control testing and analysis in accordance with applicable Laws. Such Batch Records and all other records relating to production hereunder shall be retained by GMN in accordance with the Technical Agreement. In addition,
GMN shall make available such Batch Records, as well as updates to the validation package for Product, to PDL during any audit or site visit in accordance with Section 6.2. 
 5.2 Quality Control and Testing. GMN shall conduct quality control testing of Product prior to release and delivery of the Product in accordance
with quality control testing procedures identified in the applicable Specifications and the Technical Agreement or as required in order to comply with any GMPs and applicable Law, [****]*. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	9	  	CONFIDENTIAL TREATMENT REQUESTED

 5.3 Stability Testing. In accordance with
Annex F, GMN shall conduct stability tests on the Products and on the other materials listed on Annex F (the “Additional Samples”). [****]* In the event that any lot of Products fails stability testing, GMN and PDL shall jointly investigate the causes of such failure. Upon request, GMN shall provide PDL any and all data and results in its possession relating to the stability
testing. GMN obligations under this paragraph shall survive any termination of this Agreement for a period of [****]* from [****]*. During such survival period and for the Additional Samples during the Term of the Agreement, [****]*. 
 5.4 Acceptance Testing; Rejection. PDL may inspect or cause to be inspected all shipments of Product supplied by GMN hereunder promptly after
delivery of such shipment. Within [****]* after delivery of such shipment, PDL may reject any shipment or part thereof which fails to conform with the Specifications, provided the non-conformity is caused by the gross negligence or willful
misconduct of GMN or, GMN’s failure to follow the procedures set forth in the Technical Information after [****]* Successful Batches, other than non-material deviations from the Technical Information. If tests show that Products fail to meet
Specifications and PDL believes this to be caused by the gross negligence or willful misconduct of GMN or, GMN’s failure to follow the procedures set forth in the Technical Information after [****]* Successful Batches, other than non-material
deviations from the Technical Information, PDL shall provide GMN with a notice of the shipment or batch numbers of the rejected Product, together with notification as to the basis for the rejection and a secured representative sample of the rejected
shipment. If PDL does not provide GMN with such notice of rejection, upon the expiry of the applicable [****]* period, PDL shall be deemed to have accepted the shipment of Product. 
 5.5 Confirmation. After its receipt of a notice of rejection and samples of the rejected shipment from PDL pursuant to Section 5.3 above, GMN
shall have [****]* within which to re-test the rejected samples against appropriate retained samples, and to notify PDL whether it accepts PDL’s basis for rejection. PDL shall cooperate with GMN in determining whether such rejection was
necessary or justified. Any Product that GMN agrees was defective or non-conforming at the time of delivery due to the gross negligence or willful misconduct of GMN or, GMN’s failure to follow the procedures set forth in the Technical
Information after [****]* Successful Batches, other than non-material deviations from the Technical Information, shall be returned or destroyed by PDL in accordance with Section 5.5 in return for a refund or replacement in respect of such
Product by GMN in accordance with Section 5.6. If the Parties are unable to agree as to whether a shipment of Product or part thereof fails to meet Specifications, such Product in question shall be submitted to an independent quality control
laboratory mutually agreed upon by the Parties. The findings of such independent laboratory shall be binding upon the Parties. The cost of the independent quality control laboratory shall be borne by the Party whose position is shown by such
laboratory to have been incorrect. If the laboratory agrees that the Product does not meet Specifications, the Product shall be returned or destroyed by PDL in accordance with Section 5.5 in return for a refund or replacement in respect of such
Product by GMN in accordance with Section 5.6. 
 5.6 Return or Destruction of Rejected Product. PDL shall not return or destroy
any batch of Product until GMN has accepted PDL’s basis for rejection as set forth in Section 5.4 above. Upon written authorization from GMN to do so, or if the independent lab described in 5.4 above agrees that the Product 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	10	  	CONFIDENTIAL TREATMENT REQUESTED

 does not meet Specifications, PDL shall promptly destroy the rejected batch of Product, at GMN’s expense, and
provide GMN with written certification of such destruction. Upon receipt of GMN’s request for return, PDL shall promptly return the rejected batch of Product to GMN or its designee, at GMN’s expense. 
 5.7 Refund or Replacement of Rejected Product. PDL shall be entitled, upon confirmation
that (a) such Product failed to meet the applicable Specification and (b) that the non-conformity was caused by the gross negligence or willful misconduct of GMN or, GMN’s failure to follow the procedures set forth in the Technical
Information after [****]* Successful Batches, other than non-material deviations from the Technical Information, to require GMN, at PDL’s
discretion, either to refund the part of the purchase price paid relating to the rejected Product or to replace such rejected Product at no additional cost to PDL. If PDL elects replacement GMN shall then use its Commercially Reasonable Efforts to
replace the rejected Product as soon as reasonably practicable after the rejection. For the avoidance of doubt, the foregoing shall represent PDL’s sole remedy in relation to the rejected Product, and GMN shall have no further obligations in
respect of the rejected Product and the replacement thereof. 
 5.8 Replacement of Non-Conforming Product. In the event that PDL
requests GMN to replace a non-conforming batch of Product which is not rejected pursuant to Section 5.7, GMN shall investigate in good faith whether such request can be accommodated taking into account the then current operation of the Facility
and GMN’s production plans, but shall have no obligation to provide such additional supply of Product. 
 5.8.1 In case
GMN agrees to provide such additional supply of Product it shall be at PDL’s cost on the same terms as the original purchase order for the Product. The price of the non-conforming batch of Product shall be borne by PDL based on [****]* of the
actual costs incurred until the point of identified failure plus [****]*, plus in addition thereto [****]*, less any amounts paid by PDL pursuant to Section 7 with respect to such non-conforming batch. 
 5.8.2 In case GMN does not agree to provide such additional supply of Product, the price of the non-conforming batch of Product shall be
borne by PDL based on [****]* plus [****]*, plus in addition thereto [****]*, less any amounts paid by PDL pursuant to Section 7 with respect to such non-conforming batch. 
 5.8.3 In case PDL does not request GMN to replace such Product, PDL shall pay to GMN [****]*. 
 5.9 Failure to Supply. PDL shall not be entitled to cancel any unfulfilled part of a purchase order or to refuse to accept the Product on grounds
of late performance, late delivery or failure to produce the estimated quantities (if any) of Product for delivery, provided, however, that the Parties shall negotiate in good faith in an attempt to resolve the issue in a commercially
reasonable way (e.g. by rescheduling the delivery or discounting the purchase price). 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	11	  	CONFIDENTIAL TREATMENT REQUESTED

 6. FACILITIES AND INSPECTIONS 
 6.1 Facilities and Inspections. 
 6.1.1 GMN shall permit PDL authorized representatives, during normal working hours and upon reasonable written notice to GMN to (a) inspect that portion of its facilities utilized and records maintained for the manufacture,
preparation, processing, storage or quality control of any Product and (b) be on-site at GMN during the manufacture of Product. PDL’s authorized representatives shall be accompanied by personnel of GMN at all times, shall be qualified to
conduct such manufacturing audits or be present during manufacturing, and shall comply with all applicable rules and regulations relating to facility security, health and safety. PDL shall ensure that such authorized representatives shall comply
with the confidentiality provisions of this Agreement and shall conduct each manufacturing audit and site visit in such a manner as to not interfere with the normal and ordinary operation of GMN. PDL acknowledges and agrees that it shall remain
fully liable to GMN in respect of any negligent acts or omissions of its authorized representatives during the conduct of such audits or site visits. PDL’s audit rights shall be limited as follows: (i) [****]* per year without cause, (ii) [****]* per batch of Products without cause, and (iii) [****]* audits per year for cause. 
 6.1.2 GMN shall make its facilities available for inspection by representatives of Regulatory Authorities in compliance with all
applicable Laws. GMN will, to the extent permitted by applicable Laws, promptly, and in any event within [****]*, notify PDL in writing of its receipt of any correspondence, notice or any other indication whatsoever of any FDA or other Regulatory
Authority inspection, investigation or other inquiry, or other notice or communication from any Regulatory Authority of any type, that could reasonably be expected to affect the continuity of supply of Product to PDL hereunder in a material way.
Such notice shall include a copy of any related correspondence. PDL shall have the right to be present at the inspection as permitted by applicable Law. PDL’s representative shall not interact with the Regulatory Authorities during such
inspection unless permitted by GMN. 
 7. PRICING 
 7.1 Pricing. The purchase price for Products (including Transition Products) shall equal [****]* of GMN’s Fully Burdened Costs therefor. The Preliminary Purchase Price for the Initial Purchase Order,
Second Purchase Order, Third Purchase Order and the Engineering Runs is set forth in Annex E. The Preliminary Purchase Price for each batch of Transition Product shall be equal to [****]*. By way of example, but not by limitation, if the GMN
Completion Percentage for a batch of Transition Product is [****]* percent [****]*, the Preliminary Purchase Price for that batch shall be US$[****]*. All other services rendered by GMN to PDL under this Agreement or costs to be reimbursed, refunded
or otherwise finally borne by PDL in accordance with this Agreement shall be paid by PDL at a price equal to [****]* of GMN’s Fully Burdened Costs therefore. 
 7.2 Invoicing; Payment. GMN shall be entitled to invoice PDL for Product as follows: 
  

	 	•	 	 [****]* of the Preliminary Purchase Price at acceptance of the relevant purchase order, provided that the Preliminary Purchase Price for the Transition
Product shall be paid within [****]* of the determination of the Completion Percentage pursuant to Section 2.8; and 

  

	 	•	 	 The balance of the Preliminary Purchase Price on acceptance of the Product covered by the relevant purchase order; 

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	12	  	CONFIDENTIAL TREATMENT REQUESTED

 provided, however, that [****]* of the purchase price related to Raw Materials (unless such Raw
Materials are provided by PDL [****]* ) may in any event be invoiced [****]* before the anticipated Out of Freeze Date set forth in the accepted purchase order. 
 Furthermore, if for any reason, other than GMN’s gross negligence or willful misconduct or, GMN’s failure to follow the procedures set forth in the Technical Information after [****]* Successful Batches,
other than non-material deviations from the Technical Information, PDL instructs GMN to cancel the manufacture of a batch under an accepted purchase order, GMN may invoice the full Preliminary Purchase Price at the date of such decision, which shall
be non-refundable. 
 GMN shall prepare a final statement of the actual purchase price and send to PDL a final invoice or credit note, as
applicable, with regard to the balance between the Preliminary Purchase Price and the final purchase price, provided that in no event shall the final purchase price exceed [****]* of GMN’s Fully Burdened Costs therefor. GMN shall use
Commercially Reasonable Efforts to send such final invoice or credit note to PDL within [****]*, but in no event later than [****]*, of PDL’s receipt of the final certificate of analysis for the applicable Product. Such final invoice or credit
note shall be accompanied by detailed supporting documentation setting forth the basis for the final invoice and reasonably acceptable to PDL. 
 With respect to other services to be rendered to PDL or costs to be reimbursed, refunded or otherwise finally borne by PDL, GMN shall be entitled to invoice PDL on [****]*. PDL shall pay, or cause to be paid, such invoice within [****]*
after receipt of the invoice. 
 All invoices shall be sent to the address specified in the applicable purchase order. PDL shall pay, or
cause to be paid, all invoices within [****]* after receipt. Subject to Section 7.5 all payment by PDL shall be made without deduction, deferment, set-off, lien or counterclaim of any nature. 
 7.3 Currency; Late Payments. All amounts due hereunder are stated in, and shall be paid in, U.S. dollars. The rate of interest applicable to late
payments is [****]*. Interest due for late payments shall be calculated [****]*. 
 7.4 Books and Records. GMN shall keep, and shall
cause its Affiliates to keep, complete and accurate books of accounts of record in connection with its manufacture and supply of Product to permit verification of payments made and the obligations owed hereunder. Such records shall be maintained for
a period of at least (i) [****]* from the date on which they were generated; or (ii) as otherwise required by applicable Law, which ever is later. 
 7.5 Audit Rights. PDL shall have the right to have an independent nationally-recognized accounting firm reasonably acceptable to GMN access the books and records of GMN and its Affiliates solely to the extent
necessary to verify GMN’s Fully Burdened Cost described in Section 7.1. Such audit shall be conducted upon at least [****]* advanced written notice to GMN and shall commence on a date reasonably acceptable to both Parties, not to be later
than [****]* after PDL’s notice. Such audit shall only be during GMN’s normal business hours. Such audit shall not be more frequent than [****]*, may occur only with respect to the immediately preceding [****]*, may not audit less than
[****]*, and may not be conducted more than [****]* with respect to any particular [****]*. The auditing party shall be 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	13	  	CONFIDENTIAL TREATMENT REQUESTED

 required to sign a confidentiality agreement for the benefit of, and in a form reasonably acceptable to, GMN and/or its
Affiliates. GMN shall be provided the opportunity to discuss any discrepancies found during such audit with the auditors prior to such auditor issuing its final report. The final report shall be shared with both of the Parties, after PDL has
reviewed and discussed the report with its accounting firm. If any audit discloses any underpayments by PDL to GMN, then unless contested by PDL within [****]* after receipt of the necessary documentation of the amount owed, any underpayment shall
be paid by PDL to GMN within [****]* of it being so disclosed. If any audit discloses any overpayments by PDL to GMN, then unless contested by GMN within [****]* after receipt of the necessary documentation of the amount owed, PDL shall have the
right to credit the amount of the overpayment together with any interest thereon calculated in accordance with Section 7.3, against subsequent payment due to GMN under this Agreement or have any such overpayment and interest refunded to it. If
any audit discloses any overcharges by GMN in excess of [****]*, GMN shall pay the costs of the accounting firm. 
 8. SAFETY, ADVERSE EVENT REPORTING,
RECALLS AND REGULATORY MATTERS 
 8.1 Drug Master Files. GMN shall grant PDL a right of reference to their applicable Drug Master
Files to the extent necessary to enable PDL to apply for, obtain and maintain Regulatory Approvals for any of the Products. Such Drug Master Files shall be maintained by GMN with the FDA and any other applicable Regulatory Authorities during the
Term consistent with applicable Law. 
 8.2 Material Safety; Facility Safety. It is agreed that PDL shall have the responsibility to
provide GMN with all information necessary for the manufacture of the Products, including all chemical or biological compositions thereof and the impact and interactions thereof on all other materials to be used in the manufacture of the Products as
well as information regarding handling precautions, toxicity and hazards with respect to any of the Products and to promptly update this information during the Term of the Agreement if changes occur. If the provision of such information requires, in
GMN’s reasonable opinion after good faith consultation with PDL, additional safety measures to be taken, including tests, PDL shall refund the GMN the reasonable cost hereof in accordance with Section 7. 
 8.3 Adverse Event Reporting. The Parties shall comply with the provisions of the Technical Agreement in relation to pharmacovigilance and
applicable Law as they relate to the reporting and investigation of any Adverse Event. 
 8.4 Product Recalls. 
 8.4.1 In the event that either Party believes it may be necessary to conduct a Recall of any Product, it shall notify the other Party
thereof as soon as reasonably practicable, and the Parties shall promptly consult with each other as to how best to proceed and use Commercially Reasonable Efforts in assisting one another; it being understood and agreed that the final decision as
to any Recall of any Product shall be made by PDL; provided that, neither Party shall be prohibited hereunder from taking any action that it is required to take by applicable Law. The Parties shall establish and maintain a system for
implementing any such Recall and managing all related communication and/or correspondence with the relevant Regulatory Authorities. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	14	  	CONFIDENTIAL TREATMENT REQUESTED

 8.4.2 To the extent any Recall or Seizure does not arise out of, or relate to, or occur
as a direct result of any breach of any representation, warranty or covenant of GMN herein, or a breach of this Agreement by GMN, or the gross negligence or willful misconduct of GMN or, GMN’s failure to follow the procedures set forth in the
Technical Information after [****]* Successful Batches, other than non-material deviations from the Technical Information, PDL shall reimburse GMN for its reasonable costs related thereto. To the extent any Recall or Seizure arises out of, or
relates to, or occurs as a direct result of any breach of any representation, warranty or covenant of GMN herein, or a breach of this Agreement by GMN, or the gross negligence or willful misconduct of GMN, or, GMN’s failure to follow the
procedures set forth in the Technical Information after [****]* Successful Batches, other than non-material deviations from the Technical Information, GMN shall reimburse PDL for its reasonable costs related thereto. 
 9. INTELLECTUAL PROPERTY 
 9.1 License to GMN.
PDL grants to GMN a [****]* license, [****]*, under any and all Intellectual Property Rights owned or controlled by PDL necessary for GMN to fulfill its obligations under this Agreement, and for use by GMN only for that purpose. 
 9.2 Improvements. GMN will disclose promptly to PDL any and all inventions, discoveries and improvements to PDL’s Intellectual Property
Rights related to the Products and the manufacture thereof, including the Technical Information, whether or not patentable, conceived, made or reduced to practice by GMN in connection with this Agreement (the “Improvements”). GMN shall be
the sole owner of such Improvement, provided that GMN hereby irrevocably grants to PDL, its successors and assigns, a non-exclusive, perpetual, worldwide, irrevocable, fully-paid, royalty-free, sublicensable and assignable right and license
to use and exploit the Improvements for any and all purposes. 
 10. REPRESENTATIONS, WARRANTIES AND OTHER MATTERS 
 10.1 Corporate Existence and Power. Each Party represents and warrants to the other that: (a) it is and as of the Effective Date will be a
corporation duly organized, validly existing and in good standing under the Laws of the state or jurisdiction in which it is incorporated or organized; and (b) it has and as of the Effective Date will have full power and authority and the legal
right to own or license and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement. 
 10.2 Authority. Each Party represents and warrants to the other that: (a) it has and as of the Effective Date will have the power and authority and the legal right to enter into this Agreement and perform
its obligations hereunder; (b) it has and as of the Effective Date will have taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;
(c) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms; (d) all necessary consents,
approvals and authorizations of all governmental authorities and other persons or entities required to be obtained by such Party in connection with entry into this Agreement have been or as of the Effective Date will have been obtained; provided,
however, that with respect to GMN it is understood and agreed that some of such consents, approvals and 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	15	  	CONFIDENTIAL TREATMENT REQUESTED

 authorizations cannot reasonably have been obtained prior to the Effective Date and that with respect to such consents,
GMN shall undertake Commercially Reasonable Efforts to obtain same; (e) the execution and delivery of this Agreement and the performance of such Party’s obligations hereunder (i) do not and as of the Effective Date will not conflict
with or violate any requirement of applicable Law or any provisions of such Party’s charter documents in any material way, and (ii) do not and as of the Effective Date will not conflict with, violate or breach or constitute a default or
require any consent under, any contractual obligation or court or administrative order by which such Party is bound. 
 10.3 PDL’s
Warranties. PDL represents and warrants to GMN that: 
 10.3.1 GMN’s production of the Products in accordance with
the Technical Information and the fulfillment of its other obligations as contemplated hereunder will not, to PDL’s knowledge, infringe the Intellectual Property Rights of any Third Party in the United States. 
 10.4 GMN’s Warranties. GMN represents and warrants to PDL that: 
 10.4.1. All Product sold to PDL hereunder shall be manufactured, tested, stored and handled in conformance with the Technical Information,
GMP, this Agreement and all applicable Laws, provided, however, that GMN may rely on that PDL’s written instructions, including the procedures set out in the Technical Information, the Technical Agreement and the Specifications do not
contravene GMP and applicable Law. 
 10.4.2 GMN represents and warrants that it is not, and that it shall not during the Term
hereof use the services of any person or entity debarred or suspended under 21 U.S.C. §335a(a) or (b) in any capacity associated with or related to the manufacture of Products or any other services provided to PDL hereunder. GMN further
represents and warrants that it shall not during the Term hereof hire or retain as an officer or employee any person who has been convicted of a felony under the laws of the United States for conduct relating to the regulation of any drug product
under the United States Food, Drug, and Cosmetic Act. If at any time any of the foregoing representations and warranties are no longer accurate, GMN shall immediately notify PDL of such fact. 
 10.5 Disclaimer. THE EXPRESS WARRANTIES IN THIS SECTION 10 ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, AND EXCEPT AS SET FORTH
HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR ARISING FROM A COURSE OF DEALING, USAGE
OR TRADE PRACTICES. 
 11. CONFIDENTIAL INFORMATION 
 11.1 Confidentiality. PDL agrees to maintain secret and confidential all confidential information that it may acquire or has acquired from GMN under this Agreement (“GMN Confidential Information”), to
use the same exclusively as permitted under this Agreement, and to disclose the same only and to the extent that such disclosure is reasonably necessary for the purposes of this Agreement. GMN agrees to maintain secret and confidential all
confidential information that it may acquire or has acquired from PDL under this Agreement (“PDL Confidential Information”) and to disclose the same only to the extent that such disclosure is reasonably necessary for the purposes of this
Agreement. The foregoing obligations of this Section 11.1 shall not apply to information which: 
 11.1.1 prior to
receipt thereof from one Party was in the rightful possession of the recipient Party and at its free disposal, as can be demonstrated by the recipient Party through written evidence; 
  

					
		  	16	  	CONFIDENTIAL TREATMENT REQUESTED

 11.1.2 is subsequently disclosed to the recipient Party without any obligations of
confidence by a third party who has not derived it directly or indirectly from the disclosing Party; 
 11.1.3 is or becomes
generally available to the public through no act or default of the recipient Party or its Affiliates, employees, contractors, agents, or sublicensees; 
 11.1.4 is independently developed by the receiving Party without the benefit of any disclosure hereunder, as demonstrated by documented evidence prepared contemporaneously with such independent development;

 11.1.5 is required to be disclosed by Law, regulation or action of any governmental agency or authority or to comply with
the requirements of any securities exchange or to any governmental or Regulatory Authority, provided that the recipient Party shall provide the other Party with prompt written notice of such requirement in order to allow the other Party to
limit or prevent disclosure to the extent permitted by applicable Law (and the recipient Party shall reasonably cooperate in such efforts), and provided further that any such information required to be disclosed shall continue to be
“Confidential Information” for all other purposes. 
 11.2 Publicity. No Party to this Agreement shall originate any
publicity, news release or other public announcement, written or oral, whether relating to this Agreement or the existence of any arrangement between the Parties, without the prior written consent of the other Party whether named in such publicity,
news release or other public announcement or not, except where such publicity, news release or other public announcement is required by law or by the rules or regulations of any stock exchange on which any security of Seller or Buyer is listed for
trading (“Stock Exchange”); provided that in such event, the Party issuing same shall still be required to consult with the other Party whether named in such publicity, news release or public announcement or not, a reasonable
time prior to its release to allow the other Party to comment thereon and, after its release, shall provide the other Party with a copy thereof. Each Party shall use Commercially Reasonable Efforts to provide reasonable advance notice of and to
respond to and cooperate with the other Party in connection with any such publicity. If the Party whose comments are solicited fails to comment within [****]* from the initial consultation with respect to any pending disclosure (or such shorter
period of time as may be necessary for the Party proposing to issue such publicity or its Affiliates to avoid a violation of any applicable Law or any rule or regulation of any Stock Exchange). The other Party shall be free to issue its publicity,
news release or other public announcement. If either Party, based on the advice of its counsel, determines that this Agreement, or any of the other documents executed in connection herewith, must be filed with the U.S. Securities and Exchange
Commission (the “SEC”) or any Stock Exchange, then such Party, prior to making any such filing, shall provide the other Party and its counsel with a redacted version of this Agreement (or any other related documents) which it
intends to file, and will give due consideration to any comments provided by the other Party or its counsel and use reasonable efforts to ensure the confidential treatment by the SEC or any applicable Stock Exchange of those sections specified by
the other Party or its counsel. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	17	  	CONFIDENTIAL TREATMENT REQUESTED

 12. INDEMNIFICATION 
 12.1 Indemnification by GMN. GMN shall indemnify and hold harmless PDL and each of its respective employees, officers, directors and agents (each a “PDL Indemnitee”) from and against any Third Party
Losses arising out of (a) the breach by GMN of this Agreement, including, without limitation, the breach of any representation, warranty or covenant contained herein; (b) GMN’s gross negligence or willful misconduct in connection with
this Agreement, or (c) any Claim that a Product or the production of any Product infringes the Intellectual Property Rights of such Third Party; provided, however, that such indemnification right shall not apply to any Claims or Third
Party Losses to the extent directly attributable to the gross negligence or willful misconduct of a PDL Indemnitee, or, for the avoidance of doubt, to the extent such Claims or Third Party Losses arises out of circumstances under which PDL would be
obliged to indemnify GMN in accordance with Section 12.2. 
 12.2 Indemnification by PDL. PDL shall indemnify and hold harmless
GMN, its Affiliates, and each of their respective employees, officers, directors and agents (each a “GMN Indemnitee”) from and against any Third Party Losses arising out of (a) the breach by PDL of this Agreement, including, without
limitation, any representation, warranty or covenant contained herein; (b) any Claim that a Product or the production of any Product infringes the Intellectual Property Rights of such Third Party; (c) any Claim related to [****]*;
(e) [****]*; (f) PDL’s gross negligence or willful misconduct in connection with this Agreement; provided, however, that such indemnification right shall not apply to any Claims or Third Party Losses to the extent directly
attributable to the gross negligence or willful misconduct of GMN or GMN’s failure, with respect to Product for which [****]* have been manufactured without failure, to follow the procedures set forth in the Technical Information, or, for the
avoidance of doubt, to the extent such Claims or Third Party Losses arises out of circumstances under which GMN would be obliged to indemnify PDL in accordance with Section 12.3. 
 12.3 Indemnification Procedures. Promptly after receipt by a Party seeking indemnification under this Section 12 (an “Indemnitee”)
of notice of any pending or threatened Claim against it, such Indemnitee shall give written notice thereof to the Party from whom the Indemnitee is entitled to seek indemnification pursuant to this Section 12 (the “Indemnifying
Party”); provided that the failure so to notify the Indemnifying Party shall not relieve it of any liability that it may have to any Indemnitee hereunder, except to the extent the Indemnifying Party demonstrates that it is materially prejudiced
thereby. The Indemnifying Party shall be entitled to participate in the defense of such Claim and, to the extent that it elects within [****]* of its receipt of notice of the Claim from the Indemnitee, to assume control of the defense of such Claim
(unless (i) the Indemnifying Party is also a party to such proceeding and the Indemnifying Party has asserted a cross claim against the Indemnified Party or a court has otherwise determined that such that joint representation would be
inappropriate, or (ii) the Indemnifying Party fails to provide reasonable assurance to the Indemnitee of its financial capacity to defend the Indemnitee in such Proceeding) with counsel reasonably satisfactory to the Indemnitee and, after
notice from the Indemnifying Party to the Indemnitee of its election to assume the defense of such Claim, the Indemnifying Party shall not, as long as it diligently conducts such defense, be liable to the Indemnitee for any out-of-pocket costs
subsequently incurred by the Indemnitee in investigating or defending such Claim. No compromise or settlement of any Claim which is to be indemnified may be effected by either Party without the other Party’s written consent, which consent shall
not be unreasonably withheld or delayed. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	18	  	CONFIDENTIAL TREATMENT REQUESTED

 12.4 Insurance. During and after the Term, each of GMN and PDL shall have and maintain such type
and amounts of liability insurance covering its activities under this Agreement as is normal and customary in the pharmaceutical industry generally for parties similarly situated. Each Party shall, upon request of the other Party, provide the
requesting Party with a Certificate of Insurance for the foregoing policies of insurance. [****]*. 
 13. TERM AND TERMINATION 
 13.1 Term. This Agreement shall become effective and the term of this Agreement shall begin upon the Effective Date (for the avoidance of doubt
the Parties expressly acknowledge that unless the Closing (as that term is defined in the Purchase Agreement) of the transactions contemplated by the Purchase Agreement shall have been consummated, this Agreement shall be void and without any force
or effect) and shall continue in full force and effect until termination as hereinafter provided in this Section 13 (the “Term”). In the event that the Purchase Agreement is terminated prior to the Effective Date, this Agreement shall
automatically terminate without any further action required by either Party. 
 13.2 Termination. Either Party may terminate this
Agreement upon not less than twelve (12) months’ prior written notice to the other Party, provided, however, that such termination shall not be effective prior to the expiration of the Initial Term. Termination in accordance with this
Section 13.2 shall not affect the Parties’ obligations in relation to purchase orders already accepted by GMN. 
 13.3
Termination for Cause 
 13.3.1 Either Party may terminate this Agreement upon sixty (60) days written notice to
the other if the other Party breaches any term of this Agreement and does not cure such breach within such sixty (60) day period following receipt of such notice, except in the case of a payment default as to which PDL shall have only a [****]*
notice and cure period. 
 13.3.2 Either Party may terminate this Agreement upon the occurrence of one or more of the
following immediately upon written notice to the other Party in the event that: 
 (a) the other Party initiates a voluntary
proceeding in bankruptcy or insolvency or for reorganization or arrangement under the bankruptcy laws of the United States or under any insolvency act of any state, or is dissolved, or makes an assignment for the benefit of creditors; or 

(b) becomes the subject of an involuntary proceeding under any bankruptcy law or insolvency act or for its dissolution, or a receiver
or trustee is appointed for all or substantially all of its property and such proceeding is not dismissed or the receivership or trusteeship is not vacated within ninety (90) days after institution or appointment. 
 13.4 Procedure upon Termination or Expiration of Agreement. 
 13.4.1 Termination shall not relieve either Party of any obligations (including payment obligations) which have accrued prior to the
effective date of such termination. In the case of any breach of the terms of this Agreement, a decision not to terminate does not reduce or eliminate any recourse otherwise available to either Party. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	19	  	CONFIDENTIAL TREATMENT REQUESTED

 13.4.2 Upon any termination of this Agreement, PDL shall reimburse GMN for the cost of
any inventory of Product, or Raw Materials or other supplies or services purchased or irrevocable committed to by GMN for producing the Product to the extent (i) GMN or its Affiliates reasonably acquired and held such inventory or purchased or
committed to such services consistent with accepted purchase orders, and (iii) with respect to inventory, GMN delivers (at PDL’s cost) such inventory to PDL. 
 13.4.3 At PDL’s request following the service of any notice of termination by PDL or GMN, GMN shall use its Commercially Reasonable
Efforts to provide such services as PDL may reasonably request in respect of the transfer of the manufacturing of the Products to PDL or its designee, but subject always to: 
 (a) payment of a transfer fee of $[****]* per Product for the transfer of which GMN’s services are required plus the reimbursement by
PDL of [****]* of GMN’s Fully Burdened Costs in providing such services in accordance with Section 7; and 
 (b)
nothing in this Section 13.4.3 shall require GMN to assign or to license to PDL any Intellectual Property Rights owned or controlled by GMN, except as required by Section 10.2. 
 13.5 Survival. Except as expressly provided herein, Sections [****]* and [****]*, and any other provisions hereof which by their nature are
intended to survive expiration or early termination shall survive the expiration of the Term or any termination of this Agreement, provided that [****]* shall survive for a period of [****]*. 
 14. LIMITATION OF LIABILITY. EXCEPT FOR GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, OR WITH RESPECT TO ANY INDEMNIFICATION OBLIGATION OWED WITH RESPECT TO A THIRD
PARTY LOSS (BUT NOT OTHER LOSS), NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY UNDER ANY CIRCUMSTANCES OR ANY LEGAL OR EQUITABLE THEORY, WHETHER IN CONTRACT, STRICT LIABILITY OR OTHERWISE, FOR ANY SPECIAL, CONSEQUENTIAL OR INDIRECT DAMAGES
ARISING OUT OF OR RELATED TO THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OR ANY LIMITED REMEDY. 
 NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, THE TOTAL LIABILITY OF GMN FOR ANY LOSS OR
DAMAGE SUFFERED BY PDL AS A RESULT OF ANY BREACH OF THIS AGREEMENT OR OF ANY OTHER LIABILITY OF GMN, AS APPLICABLE (INCLUDING WITH RESPECT TO ANY INDEMNIFICATION OBLIGATION OWED HEREUNDER) SHALL BE LIMITED TO THE SUM OF US$[****]*, EXCEPT THAT THE TOTAL 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	20	  	CONFIDENTIAL TREATMENT REQUESTED

 LIABILITY OF GMN SHALL BE LIMITED TO THE GREATER OF (A) US$[****]* OR (B) [****]* IN THE EVENT THAT SUCH
LIABILITY IS DUE TO THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF GMN; AND EXCEPT THAT THE TOTAL LIABILITY OF GMN SHALL BE LIMITED TO THE SUM OF US$[****]* TO THE EXTENT THAT SUCH LIABILITY IS DUE TO GMN’S FAILURE TO FOLLOW THE
PROCEDURES SET FORTH IN THE TECHNICAL INFORMATION AFTER [****]* SUCCESSFUL BATCHES, OTHER THAN NON-MATERIAL DEVIATIONS FROM THE TECHNICAL INFORMATION. 
 15. DISPUTE RESOLUTION 
 This Agreement shall be deemed to have been made in the State of New York and its form, execution,
validity, construction and effect shall be determined in accordance with the laws of the State of New York, without giving effect to the principles of conflicts of law thereof. Disputes arising out of, relating to or in connection with this
Agreement, or in relations between the parties with respect to the subject matter hereof, for any reason or under any circumstances, will be finally settled by a single arbitrator in a binding arbitration in accordance with the Judicial Arbitration
and Mediation Services (“JAMS”) Comprehensive Arbitration Rules and Procedures (the “JAMS Rules”). Upon receipt of written notice of the existence of a dispute by one Party hereto to the other, the Parties shall, within thirty
(30) days conduct a meeting of one or more senior executives of each Party, with full settlement authority, in an attempt to resolve the dispute. Each Party shall make available appropriate personnel to meet and confer with the other Party
reasonably within the 30-day period. Upon the expiration of the 30-day period, or upon the termination of discussions between the senior executives, either Party may elect arbitration of any dispute by written notice to the other (the
“Arbitration Notice”). The arbitration shall be held in Minneapolis, Minnesota before one (1) arbitrator from JAMS having substantial experience as a jurist and mediator with significant disputes in the biotechnology and/or
pharmaceuticals industry selected by the mutual agreement of GMN and PDL; provided, however, that if such Parties cannot agree on an arbitrator within thirty (30) days of the Arbitration Notice, either Party may request JAMS select the
arbitrator, and JAMS shall select an arbitrator pursuant to the procedure set out by the JAMS rules, provided, however, that the arbitrator selected be a former judge with at least fifteen (15) years experience addressing as a jurist and/or
mediator significant disputes in the biotechnology and or pharmaceutical industry. The arbitration shall be administered by JAMS pursuant to its AAA Rules. Judgment on the arbitration award may be entered in any court having jurisdiction. The
arbitrator may, in the arbitration award, allocate for payment by the non-prevailing Party all or part of the costs of the arbitration, including fees of the arbitrator and the reasonable attorneys’ fees and costs incurred by the prevailing
Party. This Section shall not preclude the Parties from seeking provisional remedies in aid of arbitration from a court of appropriate jurisdiction. In respect of any actions for injunctive or other equitable relief hereunder, any action or
proceeding may be brought against any Party in the state and federal courts located in the city of Minneapolis, Minnesota and each of the parties consents to the jurisdiction of such courts in any such action or proceeding and waives any objection
to venue laid therein. 
 16. MISCELLANEOUS 
 16.1 Unenforceability. Both Parties hereby expressly state that it is the intention of neither Party to violate any Law. If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable
provisions shall be replaced by valid and enforceable provisions which will achieve as far as possible the economic business intentions of the Parties. 
 16.2 No Waiver. The failure by either Party to take any action or assert any right hereunder shall in no way be construed to be a waiver of such right, nor in any way be deemed to affect the validity of this
Agreement or any part hereof, or the right of a Party to thereafter enforce each and every provision of this Agreement. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	21	  	CONFIDENTIAL TREATMENT REQUESTED

 16.3 Drafting. This Agreement shall not be construed more strictly against one Party than the
other because it may have been drafted by one of the Parties or its counsel, each Party having contributed through its counsel substantially and materially to the negotiation and drafting thereof. 
 16.4 Assignment. This Agreement and the Parties’ rights and obligations hereunder shall not be assignable except with the prior written
consent of the other Party, not to be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, (a) GMN may transfer to any Affiliate all or part of its obligations hereunder without the consent of PDL, and (b) PDL may
assign this Agreement to an Affiliate or to a Third Party that acquires all or substantially all of the assets of PDL related to this Agreement or one or more Products, whether by sale, merger, consolidation, acquisition, transfer, operation of Law
or otherwise, without the consent of GMN [****]*. 
 16.5 Relationship of the Parties. In making and performing this Agreement, the
Parties are acting, and intend to be treated, as independent contractors and nothing contained in this Agreement shall be construed or implied to create an agency, partnership, joint venture, or employer and employee relationship between or among
any of the Parties. Except as otherwise provided herein, no Party may make any representation, warranty or commitment, whether express or implied, on behalf of or incur any charges or expenses for or in the name of any other Party. No Party shall be
liable for the act of any other Party unless such act is expressly authorized in writing by such Party. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	22	  	CONFIDENTIAL TREATMENT REQUESTED

 16.6 Notices. All notices and other communications given or made pursuant hereto shall be in
writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile, (iii) five (5) days after having been sent by registered or certified mail, return
receipt requested, postage prepaid or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the respective
parties at the addresses set forth below (or at such other addresses as shall be specified by notice given in accordance with this Section), other than notices and communications related to technical and manufacturing matters, which shall be sent to
the responsible persons identified in the Technical Agreement: 
  

			
	 If to PDL:
  
 PDL BioPharma, Inc.
 Attention: General Counsel
 1400 Seaport Boulevard
 Redwood City, CA 94063
 Facsimile: 650-454-1468
 E-mail: francis.sarena@pdl.com
	  	 If to GMN:
  
 Prior to the Effective Date:
 GMN, Inc.
 Attention: President
 c/o Genmab, Inc.
 457 North
Harrison Street
 Princeton, NJ 08540
 Facsimile: +1 609-430-2482

		
	 with a copy to: (not to constitute notice)
  
	  	
	 DLA Piper US LLP
 Attention: Howard Clowes
 153 Townsend Street, Suite 800
 San Francisco, CA 94107-1957
 Facsimile: 415- 659-7410
 E-mail:
howard.clowes@dlapiper.com
	  	 After the Effective Date:
 GMN, Inc.
 Attention: President
 9450 Winnetka Avenue N
 Brooklyn Park, MN 554443

		
		  	 with copies at all times to: (not to constitute notice)
  
 Lisa Drakeman, President
 Genmab A/S
 c/o Genmab, Inc.
 457 North Harrison Street
 Princeton, NJ 08540
 Facsimile: +1 609-430-2482

 16.8 Entire Agreement; Amendments. This Agreement and its Annexes contain the entire
understanding between the Parties relating to the subject matter hereof and supersedes any and all prior agreements, understandings and arrangements, whether written or oral, between the Parties relating to such subject matter and to the extent
relating to Product. No amendments, changes, modifications, waivers or alterations of the terms and conditions of this Agreement shall be binding upon either Party hereto unless in writing and signed by both Parties. 
 16.9 Force Majeure. If and to the extent that either Party is prevented or delayed by a Force Majeure Event which is not reasonably preventable by
taking industry standard precautions (provided that such industry standard precautions shall not require GMN to have Product manufactured at other facilities or by a third party manufacturer) from performing any of its obligations under this
Agreement and promptly so notifies the other Party, specifying the matters constituting a Force Majeure Event together with such evidence in verification thereof as it can reasonably give and specifying the period for which it is estimated that the
prevention or delay will continue, then the Party so affected shall be relieved of liability to the other for failure to perform or for delay in performing such obligations (as the case may be), but shall nevertheless use its best endeavours to
resume full performance thereof, provided that if the Force Majeure Event continues for a period of [****]* days or more following notification, the Party not affected by the Force Majeure Event may terminate this Agreement by giving not less than
[****]* days prior notice to the other Party and the provisions of Section 13.4 shall then apply. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	23	  	CONFIDENTIAL TREATMENT REQUESTED

 16.10 Headings. The captions to the Sections hereof are not a part of this Agreement, but are
merely guides or labels to assist in locating and reading the several Sections hereof. 
 16.11 Counterparts. This Agreement may be
executed in counterparts and each such counterpart shall be deemed an original hereof. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	24	  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, the parties hereto
have executed this CLINICAL DRUG SUBSTANCE SUPPLY AGREEMENT with effect from the Effective Date. 
  

			
	GMN, INC.
		
	By:	 	/s/ Torben Lund-Hansen
	Name:	 	Torben Lund-Hansen
	Title:	 	President
	
	PDL BIOPHARMA, INC.
		
	By:	 	/s/ Andrew Guggenhime
	Name:	 	Andrew Guggenhime
	Title:	 	Senior Vice President and Chief Financial Officer

  

					
		  	25	  	CONFIDENTIAL TREATMENT REQUESTED

 ANNEX A 
 PRODUCTS 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	26	  	CONFIDENTIAL TREATMENT REQUESTED

 ANNEX B 
 PRODUCT SPECIFICATIONS AND TECHNICAL INFORMATION 
  

					
		  	27	  	CONFIDENTIAL TREATMENT REQUESTED

 [****]* Specifications 
  

	1.0	Formulated Drug Substance 

 1.1 Formulated Drug Substance
Profile 
 [****]* 
 1.1.1 [****]*

 1.1.2 Manufacturer and Location 
 [****]* 
 1.1.3 Formulation 
 [****]* 
 1.1.4 Container Closure System 
 [****]* 
 1.1.5 Storage Conditions 
 [****]* 
 1.1.6 Shelf Life / Retest Date

 [****]* 
 1.2 Shelf Life /
Retest Date 
 [****]* 
 Table 1:
Required Testing for Identity and for the Presence of Adventitious Agents 
 [****]* 
 1.3 Formulated Drug Substance Manufacture 
 [****]* 
 1.3.1 List of Raw Materials / Components 
 [****]* 
 1.3.2 Specifications Product 
 [****]* 
 Production and control related
documents 
 [****]* 
 1.3.3
Quality Control Requirements 
 [****]* 
 Table 2: [****]* Specification & Test 
 [****]* 
 Table 3: Drug Substance In-Process Controls 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	28	  	CONFIDENTIAL TREATMENT REQUESTED

 1.3.4 [****]* Storage Conditions 
 [****]* 
 1.3.5 Other Documentation 
 [****]*

  

	2.0	Finished Drug Product 

 2.1 Finished Drug Product Profile

 [****]* 
 2.1.1 Formulation

 [****]* 
 2.1.2 Container
Closure System 
 [****]* 
 2.1.3
Storage Conditions 
 [****]* 
 2.2 Storage Conditions 
 [****]* 
 Table 4: Raw Material/Component List and Procedures 
 [****]* 
 2.2.1 Product Specification 
 [****]*

 2.2.2 Quality Control 
 [****]*

 Table 5: [****]* Specification and Test Methods 
 [****]* 
 Table 6: [****]* Drug Product In-Process Controls 
 [****]* 
 2.2.3 Storage Conditions 

[****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	29	  	CONFIDENTIAL TREATMENT REQUESTED

 [****]* Specifications 
  

	1.0	Formulated Drug Substance 

 1.1 Formulated Drug Substance
Profile 
 [****]* 
 1.1.2
Manufacturer and Location 
 [****]* 
 1.1.3 Formulation 
 [****]* 
 1.1.4 Container Closure System 
 [****] 
 1.1.5 Storage Conditions 
 [****]* 
 1.1.6 Shelf Life / Retest Date 
 [****]*

 1.2 Cell Bank Manufacture 
 [****]* 
 Table 1: Required Testing for Identity and for the Presence of Adventitious Agents 
 [****]* 
  

	1.3	Formulated Drug Substance Manufacture 

 1.3.1 List of Raw
Materials / Components 
 [****]* 
 1.3.2 Product Specifications 
 [****]* 
 Quality Control Requirements 
 [****]* 
 Table 2: [****]* Specification & Test 
 [****]* 
 Table 3: [****]* Specification & Test 
 [****]* 
 Table 4: Drug Substance In-Process
Controls - [****]* 
 [****]* 
 Table 5: Drug Substance In-Process Controls - [****]* 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 1.3.3 Storage Conditions 
 [****]* 
 1.3.4 Other Documentation 
 [****]* 
  

	2.0	Finished Drug Product 

 2.1 Finished Drug Product Profile

 [****]* 
 2.1.2 Formulation

 [****]* 
 2.1.3 Container
Closure System 
 [****]* 
 2.1.4
Storage Conditions 
 [****]* 
 2.2 Drug Product Manufacture 
 [****]* 
 Table 6: Raw Material/Component List and Procedures, [****]* 
 [****]* 
 Table 7: [****]* Material/Com 
 [****]*

 2.2.2 Product Specification 
 [****]* 
 2.2.3 Quality Control 
 [****]* 
 Table 8: [****]* Specification and Test Methods 
 [****]* 
 Table 9: [****]* Specification and
Test Methods 
 [****]* 
 Table
10: [****]*, In-Process Controls 
 [****]* 
 Table 11: [****]*, In-Process Controls 
 2.2.4 Storage Conditions 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 [****]* Specifications 
  

	1.0	Formulated Drug Substance 

 1.1 Formulated Drug Substance
Profile 
 [****]* 
 1.1.2
Manufacturer and Location 
 [****]* 
 1.1.3 Formulation 
 [****]* 
 1.1.4 Container Closure System 
 [****]* 
 1.1.5 Storage Conditions 
 [****]* 
 1.1.6 ShelfLife/RetestDate 
 [****]*

 1.2 Cell Bank Manufacture 
 [****]* 
 Table 1: Required Testing for Identity and for the Presence of Adventitious Agents 
 [****]* 
 1.3 Formulated Drug Substance
Manufacture 
 1.3.1 List of Raw Materials / Components 
 [****]* 
 1.3.2 Product Specifications 
 [****]* 
 1.3.3 Quality Control Requirements

 [****]* 
 Table 2: [****]*
Specification & Test 
 [****]* 
 Table 3: Drug Substance In-Process Controls 
 [****]* 
 1.3.4 Storage Conditions 
 [****]* 
 1.3.5 Other Documentation 
 [****]*

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

	2.0	Finished Drug Product 

 2.1 Finished Drug Product Profile

 [****]* 
 2.1.2 Formulation

 [****]* 
 2.1.3 Container
Closure System 
 [****]* 
 2.1.4
Storage Conditions 
 [****]* 
 2.2 Drug Product Manufacture 
 [****]* 
 Table 4: Raw Material/Component List and Procedures 
 [****]* 
 2.2.2 Product Specification 
 [****]*

 2.2.3 Quality Control 
 [****]*

 Table 5: [****]* Specification and Test Methods 
 [****]* 
 Table 6: [****]* In-Process Controls 
 [****]* 
 2.2.4 Storage Conditions 

[****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 [****]* Specifications 
  

	1.0	Formulated Drug Substance 

 1.1 Formulated Drug Substance
Profile 
 [[****]* 
 1.1.2
Manufacturer and Location 
 [****]* 
 1.13 Formulation ([****]*) 
 [****]* 
 1.1.4 Container Closure System 
 [****]* 
 1.1.5 Storage Conditions 
 [****]* 

1.1.6 Shelf Life / Retest Date 
 [****]*

 1.2 Cell Bank Manufacture 
 [****]* 
 Table 1: Required Testing for Identity and for the Prescence of Adventitious Agents 
 [****]* 
  

	1.3	Formulation Drug Substance Manufacturer 

 1.3.1 List of Raw
Materials / Components 
 [****]* 
 1.3.2 Product Specifications 
 [****]* 
 1.3.3 Quality Control Requirements 
 [****]* 
 Table 2: [****]* Specification and Test Methods 
 [****]* 
 Table 3: [****]* Drug Substance In-Process Controls 
 [****]* 
 1.3.4 Storage Conditions 

[****]* 
 1.3.5 Other Documentation

 [****]* 
  

	2.0	Finished Drug Product 

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 2.1 Finished Drug Product Profile 
 [****]* 
 2.1.2 Formulation 
 [****]* 
 2.1.3 Container Closure System

 [****]* 
 2.1.4 Storage
Conditions 
 [****]* 
 Table 4:
[****]* Raw Material/Component List 
 [****]* 
 2.2.2 Product Specification 
 [****]* 
 2.2.3 Quality Control 
 [****]* 
 Table 5: [****]* Specification and Test Methods 
 [****]* 
 Table 6: [****]*In-Process Controls 
 [****]* 
 2.2.4 Storage Conditions 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ANNEX C 
 FORM OF PURCHASE ORDER 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 PURCHASE ORDER NO          
 PDL hereby places Purchase Order No. [        ] pursuant to Section 3.1 of the Clinical Drug Substance Supply
Agreement effective as of the Effective Date by and between Genmab MN, Inc. (formerly, GMN, Inc.) and PDL BioPharma, Inc. (the “Agreement”), as follows: 
 Product:                                  
 Number of batches:
                             
  

							
	 Batch #
	 	 Scale
	 	 Out of Freeze Date
	 	 Estimated delivery date

		 		 		 	
		 		 		 	
		 		 		 	
		 		 		 	

 This Purchase Order is subject to the terms and conditions of the Agreement. Capitalized terms not otherwise
defined herein shall have the meaning ascribed to them in the Agreement. In the event of a conflict between the provisions of this Purchase Order and the Agreement, the Agreement shall govern. 
 Comments: 
 Product shall be prepared in accordance with the
Specifications. 
 [...] 
  

			
	PDL BioPharma, Inc.
		
	Name:	 	 
		
	Print Name:	 	 
		
	Date:	 	 
	
	Accepted by Genmab MN, Inc.
		
	Name:	 	 
		
	Print Name:	 	 
		
	Date:	 	 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ANNEX D 
 TECHNICAL AGREEMENT 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 TECHNICAL AGREEMENT 
 between 
 GMN, Inc. 
 c/o Genmab, Inc. 
 457 North Harrison Street, Princeton, NJ 08540 
 - hereinafter referred to as “GMN” - 
 and 
 PDL BioPharma Inc., 
 1400 Seaport Boulevard, Redwood City, CA 94063 
 - hereinafter referred to as “PDL” - 
 Whereas this Technical Agreement forms an integral part of that certain Clinical Drug Substance Supply Agreement effective as of the Effective Date between the
Parties (“CDSSA”), pursuant to which the Parties wish to contract with each other with respect to the manufacture and quality control of certain humanized antibody products; 
 Whereas the Parties are aware of the fact that abidance to generally accepted pharmaceutical principles and rules in the production, manufacture and quality control of humanized antibody products as well as the
pharmaceutical-technical quality of said products are of vital importance; 
 Whereas the parties intend to determine their obligations and
responsibilities with regard to their co-operation in manufacturing and controlling pharmaceutical products recognizing that it is imperative to clearly define the responsibilities of each party and to define, in particular, the observance of GMP as
defined in the CDSSA. 
 Now, therefore, for and in consideration of the above-described recitals, the mutual promises and covenants of the parties
hereinafter contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties, the parties hereto (the “Parties”), intending to be legally bound, enter into the agreements
contained herein: 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

	1.	Subject of this Agreement 

  

	 	1.1	This Technical Agreement is an Annex to that certain CDSSA concerning the production of the Products at the Facility in order to supply PDL with Products for its clinical
development programs. 

  

	 	1.2	All defined terms within the CDSSA shall, unless specifically stated otherwise, have the same meaning when used in this Technical Agreement. 

  

	 	1.3	The obligations and responsibilities of each Party hereto with regard to the manufacture and quality control of the Products are specified in Annex 1 hereto.

  

	 	1.4	The names of contact persons are listed in Annex 2 hereto. 

  

	 	1.5	The Technical Information necessary for proper manufacture, quality control and storage of the Products are supplied by PDL. 

  

	2.	Manufacturing, Quality Control 

 Subject to the
terms of the CDSSA, the Parties shall ensure that the Products are manufactured and quality controlled in compliance with the Technical Information, the Specifications, GMP and applicable Laws. 
 Appendix 1 contains a detailed outline of the duties and obligations of GMN and PDL with respect to manufacture and quality control. 
  

	3.	Changes, Deviations 

 Any changes or deviations from
the content of the Technical Information may be performed only after prior written approval by PDL. GMN will undertake the following items: 
  

	 	•	 	 Evaluate and define follow up actions and final approval of deviations and failure investigations 

  

	 	•	 	 Notify PDL of all critical deviations within [****]* of the event being assigned as critical, or in emergency situations where prior notice is not practicable,
within [****]* after such deviation. (A critical deviation is defined as one which may affect Product quality or requires additional processing steps, testing or monitoring to ensure Product quality is not affected) 

  

	 	•	 	 Provide a list of all other Product related deviations with the consolidated Batch Record 

  

	 	•	 	 Notify PDL of failed runs within [****]* of failure being identified 

  

	 	•	 	 Notify PDL of any events which may materially impact batches previously shipped as soon as possible after the event has been identified.

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

	4.	Responsible Persons 

 Either Party shall notify the
other of the persons responsible for the manufacturing and/or the quality control of the Products, such persons to meet legally required qualifications, and shall keep the other Party informed of changes in such persons. 
  

	5.	Product Release 

 Complete copies of the completed
Batch Record, along with supporting documents (including in-process and raw material test results and product release results) produced in accordance with current procedures, as requested by PDL, will be provided by GMN to PDL within [****]* after
final release of Product. GMN shall furnish PDL for each batch of the corresponding Product with a certificate of analysis, a certificate of conformance and, on request of PDL, with samples and further information and documentation regarding the
manufacture and quality control of the Products. The certificate of analysis shall be signed by the person responsible for the release of the Product. The certificate of analysis and certificate of conformance shall serve as evidence for the proper
release of such batch and shall state that the Product meets the Specifications and was manufactured in accordance with GMP. The certificates may be electronically signed. 
 Annex 2 specifies the responsibilities in relation to release of Products. 
  

	6.	Facilities and Inspections 

 GMN shall permit PDL
authorized representatives, during normal working hours and upon reasonable written notice to GMN to (a) inspect that portion of its facilities utilized and records maintained for the manufacture, preparation, processing, storage or quality
control of any Product and (b) be on-site at GMN during the manufacture of Product. PDL’s authorized representatives shall be accompanied by personnel of GMN at all times, shall be qualified to conduct such manufacturing audits or be
present during manufacturing, and shall comply with all applicable rules and regulations relating to facility security, health and safety. PDL shall ensure that such authorized representatives conduct each manufacturing audit and site visit in such
a manner as to not interfere with the normal and ordinary operation of GMN. PDL acknowledges and agrees that it shall remain fully liable to GMN in respect of any negligent acts or omissions of its authorized representatives during the conduct of
such audits or site visits. PDL’s audit rights shall be limited as follows: (i) [****]* without cause, (ii) [****]* per batch of Products without cause, and (iii) [****]* audits per year for cause. 
 GMN shall make its facilities available for inspection by representatives of Regulatory Authorities in compliance with all applicable Laws. GMN will, to
the extent permitted by applicable Laws, promptly, and in any event within [****]*, notify PDL in writing of its receipt of any correspondence, notice or any other indication whatsoever of any FDA or other Regulatory Authority inspection,
investigation or other inquiry, or other notice or communication from any Regulatory Authority of any type, that could reasonably be expected to affect the continuity of supply of Product to PDL hereunder in a material way. Such notice shall include
a copy of any related correspondence. PDL shall have the right to be present at the inspection as permitted by applicable Law. PDL’s representative shall not interact with the Regulatory Authorities during such inspection unless permitted by
GMN. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 GMN shall provide written notice to PDL of any use of animal-sourced raw materials in the Facility (such
as, without limitation, serum, BSA, etc.). GMN shall also provide written notice of any observed “in-process” contamination within the Facility (such as, without limitation, microbial, mycoplasma, spiroplasma, virus), or during tests of
cell banks or EPC tests of material manufactured at the Facility, provided that such notification shall only be made in those cases where such contamination has not been previously disclosed in the environmental reports provided to PDL. 

 

	7.	Drug Safety, Complaints 

 Subject to applicable Law,
GMN shall promptly inform PDL, and vice-versa, on any peculiar event, finding and/or complaint which may have a bearing on drug safety or pharmaceutical quality in relation to the Products, and supply all necessary information and co-operation for
the investigation of such events. In cases where patient or investigative staff safety may be concerned, GMN shall inform PDL immediately by telephone and in writing, and vice-versa. 
  

	8.	Validations 

 GMN is responsible for providing
validated or qualified equipment, facilities and utilities for the manufacture of the Products per GMP. 
  

	9.	Miscellaneous 

 This Agreement and its annexes
supplement the CDSSA and the provisions of the CDSSA are hereby incorporated by reference. To the extent that any inconsistencies exist between the quality and GMP contents of this Technical Agreement and the CDSSA, the stipulations in this
Technical Agreement shall prevail. In all other matters the CDSSA shall prevail. 
  

	10.	Term, Termination, Effects Upon Termination 

 This
Agreement shall enter into force upon signature by the last Party to do so and shall remain valid for an indefinite period of time. Either Party shall be entitled to terminate this Agreement according to the CDSSA. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 In Witness whereof this Technical Agreement has been duly executed in two originals. 
  

			
	GMN INC.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  

			
	PDL BIOPHARMA INC.
		
	By:	 	 
	Name:	 	L. Patrick Gage
	Title:	 	Chief Executive Officer

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Annex 1 
 Responsibilities 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Annex 2 
 Key Contacts 
  

							
	 GMN [Name] Inc.
	  	Name	 	 	Contact Details	 
	 Project Manager
	  	[****]	*	 	[****]	*
	 Analytical Development
	  	[****]	*	 	[****]	*
	 Process Technology
	  	[****]	*	 	[****]	*
	 QA and Regulatory
	  	[****]	*	 	[****]	*
			
	 PDL BIOPHARMA INC.
	  	Name	 	 	Contact Details	 
	 Analytical and Process Development
	  	[****]	*	 	[****]	*
	 QA and Regulatory Affairs
	  	[****]	*	 	[****]	*
	 Others (please specify)
	  	[****]	*	 	[****]	*

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ANNEX E 
 PRELIMINARY PURCHASE PRICE 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ANNEX F 
 STABILITY TESTING 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ANNEX G 
 PDL-PROVIDED MATERIALS 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT G 
 TRANSITION SERVICES AGREEMENT 
 This TRANSITION SERVICES AGREEMENT (“Agreement”),
dated as of [                    ], 2008 is made by and between PDL BioPharma, Inc., a Delaware corporation (“Seller”), and
GMN, Inc., a Delaware corporation (“Buyer”). Seller and Buyer are together referred to herein as the “Parties”. 
 RECITALS 
 WHEREAS, Seller and Buyer have entered into that certain Asset Purchase Agreement (the “Purchase
Agreement”) dated as of February [    ], 2008, pursuant to which (i) Seller is selling and Buyer is purchasing certain Assets of Seller, as more fully set forth in the Purchase Agreement, and (ii) Seller
and Buyer have agreed to enter into and perform their obligations under this Agreement; and 
 WHEREAS, pursuant to the Purchase Agreement,
the Parties have agreed to enter into an agreement setting forth the terms pursuant to which Seller will render certain services to Buyer and Buyer will render certain services to Seller on an interim basis after the Closing. 
 NOW, THEREFORE, in consideration of the agreements and covenants contained in the Purchase Agreement, and the premises and mutual covenants hereinafter
set forth, and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 
 ARTICLE I 
 Definitions 
 All terms used herein without definition shall have the meanings assigned to them in the Purchase Agreement. 
 ARTICLE II 
 Agreement to Provide and Accept
Services 
 SECTION 2.01. Provision of Services. On the terms and subject to the conditions contained herein, Buyer shall provide
to Seller the services set forth in Schedule A to this Agreement (the “Seller Services”), and Seller shall provide to Buyer the services set forth in Schedule B to this Agreement (the “Buyer
Services”). Each Seller Service shall be provided in accordance with the provisions set forth herein and in Schedule A and each Buyer Service shall be provided in accordance with the provisions set forth herein and in Schedule
B. 
 SECTION 2.02. Information. Seller shall make available on a timely basis to Buyer all information and materials reasonably
requested by Buyer to enable Buyer to provide the Seller Services, and Buyer shall make available on a timely basis to Seller all information and materials reasonably requested by Seller to enable Seller to provide the Buyer Services. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 SECTION 2.03. Employees. 
 (a) Certain employees of Buyer who may perform Seller Services on behalf of Buyer (the “Transition Service Employees”)
are listed on Schedule C hereto, along with each Transition Service Employee’s primary area of responsibility and maximum commitment of time to the provision of Seller Services. Notwithstanding anything herein to the contrary, all
Transition Service Employees and any other employees of Buyer who may perform Seller Services on behalf of Buyer pursuant to the terms of this Agreement shall at all times be and remain employees of Buyer. Buyer shall be solely responsible for the
payment of all wages, bonuses, commissions, benefits and any other direct or indirect compensation for the Transition Service Employees, and for Buyer’s insurance costs and expenses. Buyer shall be responsible for directing and supervising the
activities of the Transition Service Employees in their performance of any Seller Services hereunder. At no time shall any of the Transition Service Employees be deemed to be employees of Seller. 
 (b) Notwithstanding anything herein to the contrary, all employees of Seller whose activities include performance of any Buyer Services on
behalf of Seller (the “Seller’s Employees”) shall at all times be and remain employees of Seller. Seller shall be solely responsible for the payment of all wages, bonuses, commissions, benefits and any other direct or indirect
compensation for the Seller’s Employees, and for all Seller’s insurance costs and expenses. Seller shall be responsible for directing and supervising the activities of the Seller’s Employees in their performance of any Buyer Services
hereunder. At no time shall any of Seller’s Employees be deemed to be employees of Buyer. 
 ARTICLE III 
 Standard of Performance of Services; Use of Services; Payment 
 SECTION 3.01. Standard of Performance and Use of Services. Each Party shall devote reasonable resources to support the transition of the Assets from Seller to Buyer, including but not limited to the provision
of the Seller Services by Buyer to Seller and provision of the Buyer Services by Seller to Buyer (including without limitation, those Buyer Services necessary to support the performance of Buyer’s responsibilities under the Clinical Drug
Substance Supply Agreement). 
 (a) Buyer shall provide Seller Services in a manner that is similar in all material respects
to the manner in which such services were performed by Seller immediately prior to the Closing Date [Performance standard of parties to be negotiated prior to the Closing Date], and Seller shall use the Seller Services for substantially the same
purpose and in substantially the same manner as such services were used by Seller immediately prior to the Closing Date; provided, however, that in no event shall (i) the scope of the Seller Services required to be performed hereunder
exceed that described in Schedule A, or (ii) Buyer be required to cause any of its employees other than the Transition Service Employees specifically designated on Schedule C hereto to provide Seller Services, except in respect of
the IT Services identified on Schedule A. 
 (b) Seller shall provide Buyer Services in a manner that supplies
sufficient resources to support the transition, and with a degree of care and level of performance no less than it provides with respect to similar services it provides for its own purposes; provided, however, that in no event shall the scope
of the Buyer Services required to be performed hereunder exceed that described in Schedule B. 
 (c) As soon as is
reasonably practicable, Seller agrees to use its reasonable efforts to reduce or eliminate its dependency on the Seller Services, and Buyer agrees to use its reasonable efforts to reduce or eliminate its dependency on the Buyer Services. 

(d) If it is necessary for Buyer to make any investments or capital expenditures or otherwise incur any incremental expenses to provide
any Seller Service (other than the salary, benefits and administrative costs associated with the Transition Service Employees or other employees of Buyer), then Seller agrees to reimburse Buyer for all reasonable costs and expenses incurred by the
Buyer in connection 

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 
therewith within [****]* of receipt of a written invoice from Buyer and in accordance with the payment provisions set forth in Section 3.02 below.
[Parties to negotiate prior to the Closing Date a notice requirement for such expenses and Seller option to not continue receiving the applicable Seller Services] 
 (e) If it is necessary for Seller to make any investments or capital expenditures or otherwise incur any incremental expenses to provide
any Buyer Service (other than the salary, benefits and administrative costs associated with Seller’s Employees), then Buyer agrees to reimburse Seller for all reasonable costs and expenses incurred by the Seller in connection therewith within
[****]* of receipt of a written invoice from Seller, and in accordance with the payment instructions contained therein. 
 SECTION 3.02.
Payments. 
 (a) All Buyer Services (which the Parties agree consist solely of the IT Services set forth on Schedule
B) shall be provided at no charge hereunder to Buyer. 
 (b) All Seller Services performed by Transition Service Employees
will be charged at the standard hourly rate of $[****]*, to be calculated in [****]*. In addition, all travel-related costs incurred by any Transition Service Employees or other employees of Buyer in performance of the Seller Services [****]*
(“Travel Expenses”), shall be paid by Seller to Buyer. 
 (c) IT Services and Storage as set forth on
Schedule A shall be provided by Buyer at no charge hereunder to Seller. 
 (d) Certain Taxes. The applicable
consideration due to Buyer for performance of each Seller Service does not and shall not include any sales tax, value added tax, goods and services tax, withholding tax or similar tax. Any such amounts required to be paid by Buyer in connection with
this Agreement or the performance hereof will be promptly reimbursed to Buyer by Seller, and such reimbursement shall be in addition to the amounts required to be paid by Seller pursuant to Section 3.02(b). 
 (e) Payment Procedure. An invoice will be delivered each month by Buyer to Seller for Seller Services provided by Buyer (including
any Travel Expenses) during the preceding month. The total amount set forth in each invoice shall be payable to Buyer within [****]* after the date such invoice is received by Seller. Any invoice amounts not paid within [****]* after the due date
shall be subject to late charges. Late charges are defined as the [****]* of the amount due, compounded each subsequent [****]* period that invoices remain unpaid, or the [****]*. 
 (f) Payments to Buyer will be sent to the following: [wire transfer instructions to be inserted by Buyer prior to the Closing Date]

 ARTICLE IV 
 Term of Services

 The provision of Seller Services by Buyer and Buyer Services by Seller shall commence on the date hereof and, unless terminated sooner
pursuant to Article VII, shall terminate on the date indicated for termination of each Seller Service in Schedule A or each Buyer Service in Schedule B, provided, that Buyer may cancel any Buyer Service and Seller may
cancel any Seller Service, upon at least [****]* written notice to the other Party of such cancellation. 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 ARTICLE V 
 Force Majeure 
 Neither Seller nor Buyer shall be liable for any interruption of any Service or delay
or failure to perform under this Agreement if such interruption, delay or failure results from causes beyond its reasonable control, including but not limited to, any strikes, lockouts or other labor disputes, acts of any government, riot,
terrorism, insurrection or other hostilities, embargo, fuel or energy crisis, fire, flood, lightning, earthquake, storm, hurricane, tornado, explosion, acts of God or act of any public enemy (each, a “Force Majeure Event”). Upon the
occurrence of a Force Majeure Event, any obligations hereunder affected by such Force Majeure Event shall be postponed for such time as performance is suspended or delayed on account thereof. Upon the cessation of such Force Majeure Event, Seller or
Buyer (as the case may be) will use reasonable efforts to resume performance of the affected Buyer or Seller Service(s) (as the case may be) with the least practicable delay. 
 ARTICLE VI 
 Disclaimer of Warranties; Liabilities 
 SECTION 6.01. THE SERVICES TO BE PROVIDED UNDER THIS TRANSITION SERVICES AGREEMENT ARE FURNISHED AS IS, WHERE IS, WITH ALL FAULTS AND WITHOUT WARRANTY OF
ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, ANY WARRANTY OF NON-INFRINGEMENT, NON-INTERFERENCE, MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 SECTION 6.02. Consequential and Other Damages. Neither Party shall be liable to the other Party, whether in contract, tort (including negligence
and strict liability) or otherwise, for any special, indirect, incidental, punitive or consequential damages which arise out of, relate to or are a consequence of, the performance or nonperformance hereunder or the provision of, or failure to
provide, any Service hereunder. 
 SECTION 6.03. Indemnity. [Indemnification terms to be negotiated prior to the Closing Date]

 ARTICLE VII 
 Termination

 SECTION 7.01. Termination. Notwithstanding anything herein to the contrary, this Agreement shall terminate, and the obligations
of the Parties to provide or cause to be provided any Service shall cease, on the earliest to occur of (i) the date on which the provision of all Buyer Services and Seller Services has terminated or been cancelled pursuant to Article IV,
(ii) the date on which this Agreement is terminated pursuant to Section 7.02, or (iii) [            , 2008]. 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 SECTION 7.02. Breach of Agreement. If either Party shall cause or suffer any material breach of
any of its obligations under this Agreement, including, but not limited to, any failure to make payments when due, and such Party does not cure such default in all material respects within [****]* after receiving written notice thereof from the
non-breaching Party, the non-breaching Party may terminate this Agreement immediately by providing written notice of termination. 
 SECTION
7.03. Employee Termination. If Buyer’s employment of any Transition Service Employee is terminated for any reason, or any Transition Service Employee is unable to work for any reason, Buyer shall be under no obligation to provide that
portion of the Seller Services that such Transition Service Employee provided on behalf of Buyer. 
 SECTION 7.04. Effect of
Termination. In the event of a termination of this Agreement: 
 (a) Buyer’s obligations to provide Seller Services
shall cease; 
 (b) Seller’s obligations to provide Buyer Services shall cease; and 
 (c) Buyer shall be entitled to the immediate payment of, and the Seller shall immediately pay to Buyer, all accrued amounts due to Buyer
under the terms of this Agreement as of the date of termination. Seller shall be entitled to the immediate payment of, and the Buyer shall immediately pay to Seller, all accrued amounts due to Seller under the terms of this Agreement, if any, as of
the date of termination. 
 SECTION 7.05. Survival. Section [****]*, [****]*, Articles [****]* and [****]* shall survive any
termination of this Agreement. 
 ARTICLE VIII 
 Miscellaneous 
 SECTION 8.01. Construction. For purposes of this Agreement, whenever the
context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall
include the masculine and feminine genders. Except as otherwise indicated, all references in this Agreement to “Articles,” “Sections,” and “Schedules” are intended to refer to Articles and Sections of and Schedules to
this Agreement. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
 SECTION 8.02. Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the Party to be
notified, (ii) when sent by confirmed facsimile, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid or (iv) one (1) day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the respective Parties at the addresses set forth below (or at such other addresses as shall be specified by notice
given in accordance with this Section 8.01): 
  

					
	 As to Seller:
	  	 PDL BioPharma, Inc.
	  	
		  	 Attention: General Counsel
	  	
		  	 1400 Seaport Boulevard
	  	
		  	 Redwood City, CA 94063
	  	
		  	 Facsimile: (650) 454-1468
	  	

  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

					
	 Copy to:
	  	 DLA Piper US LLP
	  	
		  	 Attention: Howard Clowes
	  	
		  	 153 Townsend Street, Suite 800
	  	
		  	 San Francisco, CA 94107-1957
	  	
		  	 Facsimile: (415) 659-7410
	  	
			
	 As to Buyer:
	  	 GMN, Inc.
	  	
		  	 Attention: President
	  	
		  	 c/o Genmab, Inc.
	  	
		  	 457 North Harrison Street
	  	
		  	 Princeton, NJ 08540
	  	
		  	 Facsimile: [______________]
	  	
			
	 Copies to:
	  	 Lisa Drakeman, President
	  	
		  	 Genmab A/S
	  	
		  	 c/o Genmab, Inc.
	  	
		  	 457 North Harrison Street
	  	
		  	 Princeton, NJ 08540
	  	
		  	 Facsimile: (609) 524-0847
	  	
			
		  	 Howard A. Neuman, Esq.
	  	
		  	 Satterlee Stephens Burke & Burke LLP

		  	 230 Park Avenue
	  	
		  	 Suite 1130
	  	
		  	 New York, New York 10169
	  	
		  	 Facsimile: (212) 818-9606
	  	

 SECTION 8.03. Severability. If any provision of this Agreement is held by a court of
competent jurisdiction to be invalid or unenforceable, it shall be modified, if possible, to the minimum extent necessary to make it valid and enforceable or, if such modification is not possible, such provision shall be stricken and the remaining
provisions shall remain in full force and effect. If any of the terms or provisions of this Agreement is in conflict with any applicable statute or rule of law in any jurisdiction, then such term or provision shall be deemed inoperative in such
jurisdiction to the extent of such conflict and the parties will renegotiate the affected terms and conditions of this Agreement to resolve any inequities. 
 SECTION 8.04. Entire Agreement. This Agreement, including any schedules hereto, along with the Purchase Agreement, constitutes the entire agreement of the parties hereto with respect to the subject matter
hereof and supersedes all prior agreements, covenants, representations, warranties, undertakings and understandings, written or oral, among the parties hereto with respect to the subject matter hereof. 
 SECTION 8.05. Assignment. Except as otherwise provided in this Section 8.05, neither Party shall assign its rights or obligations under
this Agreement, or any part hereof, without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may assign its rights and corresponding obligations under this Agreement to any one or more of its Affiliates or an
acquiror of all or substantially all of its assets or an entity into which it merges or consolidates, so long as such assignee party agrees in writing to assume and fully perform all of the assignor’s obligations under this Agreement;
provided, that in no event shall Seller assign its rights or obligations under this Agreement to any Person who is or who may be engaged in a business which is in competition with Buyer, without Buyer’s prior written consent. 

 

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 SECTION 8.06. No Third Party Beneficiaries. Nothing in this Agreement, express or implied, is
intended to or shall (i) confer on any Person other than the Parties and their respective successors or permitted assigns any rights (including third party beneficiary rights), remedies, obligations or liabilities under or by reason of this
Agreement, or (ii) constitute the Parties hereto as partners or as participants in a joint venture. This Agreement shall not provide third parties with any remedy, claim, liability, reimbursement, cause of action or other right in excess of
those existing without reference to the terms of this Agreement. No third party shall have any right, independent of any right which may exist irrespective of this Agreement, under or granted by this Agreement, to bring any suit at law or equity for
any matter governed by or subject to the provisions of this Agreement. 
 SECTION 8.07. Amendment. This Agreement may not be
amended, restated, supplemented or otherwise modified except by an instrument in writing signed by both parties hereto. 
 SECTION 8.08.
Governing Law. This Agreement will be governed by and construed under the laws of the State of [Minnesota] without regard to conflicts-of-laws principles that would require the application of the law of any other jurisdiction.

 SECTION 8.09. Confidentiality. The Parties acknowledge that each Party has disclosed, and may hereafter from time to time in the
course of the performance of this Agreement disclose, information to the other Party which is of a confidential and/or proprietary nature. Any such information received by either Party, including the terms of this Agreement and the identity of the
Parties, shall be considered Confidential Information and shall be treated as such under the terms of the Purchase Agreement. 
 [remainder of
page intentionally blank] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 IN WITNESS WHEREOF, the parties have executed this Transition Services Agreement as of the date first
above written. 
  

			
	 SELLER:
  
 PDL BIOPHARMA, INC.

		
	By:	 	 
	Title:	 	 
	Name:  	 	 
		 	

  

			
	 BUYER:
  
 GMN, INC.

		
	By:	 	 
	Title:	 	 
	Name:  	 	 
		 	

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 EXHIBIT H 
 [PDL LETTERHEAD] 
 [                    ], 2008 
  

	
	  
	  
	  
	Attn:                                      

 Via:                                       
        
  

	 	Re:	Consent to Assignment 

 Dear
                                : 
 PDL BioPharma, Inc. (“PDL”) has entered into that certain Asset Purchase Agreement dated February
[            ], 2008 (the “Asset Purchase Agreement”) with GMN Inc., a Delaware corporation (“Buyer”) pursuant to which PDL has agreed to sell to
Buyer certain Assets as defined in the Asset Purchase Agreement (the “Acquisition”). The Acquisition is expected to close in
[                    ], 2008 (the “Closing”). 
 In connection with the Acquisition, PDL intends to assign to Buyer that certain
                                 [insert agreement name] Agreement dated
                                ,
             between PDL and
                                     [insert name of
company] (the “Company”) (the “Agreement”). Pursuant to Section              of the Agreement, PDL hereby requests the consent of the Company to
the assignment of the Agreement, and to each and all of the terms and conditions of such Agreement and of PDL’s rights and obligations thereunder, to Buyer in connection with the Acquisition (the “Assignment”). 
 [Note: Some agreements require Buyer to expressly assume the agreement, so this letter may have to be modified accordingly. In addition, some agreements cover
more than one compound, so the letter may have to be modified to limit the assignment to rights and obligations related to the particular compound.] 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Please provide your consent to the Assignment by co-signing this letter where indicated below. By
co-signing this letter you acknowledge that all of the terms and conditions of the Agreement shall remain in full force and effect as of and following the Acquisition. 
 This Consent to Assignment shall be construed and enforced in accordance with the laws of the State of Minnesota, without regard to conflicts of laws principles. 
 Please fax an executed copy of this letter to
                             attention at
                             as soon as possible, but in no event later than
                            , 2008, and send the original via courier to
                             attention at the following address: DLA Piper US LLP, 153 Townsend
Street, Suite 800, San Francisco, CA 94107. 
 Feel free to contact me at
                         or
                         with any questions regarding this consent. 
  

	
	Sincerely,
	
	  
	[Name/title]

 ACKNOWLEDGED AND AGREED 
 this          day of                     , 2008 
                                        
      [Insert name of company] 
 By:
                                         
                        
 Name:
                                         
                   
 Title:
                                         
                      
             (Please print name and title) 
  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Attachment 1.30 
 Environmental Governmental Authorizations 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Attachment 1.52 
 Knowledge Employees 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Attachment 2.1(d) 
 Equipment with Book Value in Excess of $10,000 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Attachment 2.1(e) 
 List of Assumed Contracts 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Attachment 4.2(a) 
 List of Third Party Consents 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 SCHEDULE 5.3 
 Seller’s Required Consents 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.4(a) 
 Status of Assumed Contracts 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.4(b) 
 Third Party Consents 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.4(c) 
 Compliance with Contracts/Leases 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.5(a) 
 Compliance with Legal Requirements 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.5(b) 
 Governmental Authorizations 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.6(a) 
 Proceedings 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.6(b) 
 Orders 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.7 
 Environmental Matters 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.8(a) 
 Description of Tangible Personal Property 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.8(d)(i) 
 Description of Real Property 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.8(d)(ii) 
 Title to Real Property 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.9 
 Sufficiency of Assets 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.10 
 Ownership of Tangible Personal Property 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.12 
 Employee Inventions, etc. 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.13 
 Seller’s Brokers 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.18 
 Suppliers 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 5.19 
 Operations Employees 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 6.3 
 Buyer’s Required Consents 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 6.8 
 Buyer’s Brokers 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTED

 Schedule 7.8(a) 
 Seller’s Retained Employees 
 [****]* 
  

	*	Certain information on this page has been omitted and filed separately with the SEC. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  		  	CONFIDENTIAL TREATMENT REQUESTEDSummary Description of Alphatec Holdings, Inc 2009 Bonus Plan

 Exhibit 10.1 
 Summary Description of the Alphatec Holdings, Inc. 2009 Bonus Plan For Named Executive Officers 
 Under the Alphatec
Holdings, Inc. (the “Company”) 2009 Bonus Plan (the “2009 Plan”), each of the Named Executive Officers (as such term is defined in the Company’s 2009 Proxy Statement on Schedule 14A, as filed with the Securities and Exchange
Commission on April 30, 2009), based on the recommendation of the President and Chief Executive Officer of the Company and approval by the Compensation Committee of the board of directors (the “Board”), is eligible for cash bonuses
after its 2009 fiscal year end as further described below. One of the executives listed below, Stephen Lubischer, the Company’s Vice President, Sales, is also eligible for cash bonuses during the 2009 fiscal year. 
 Except with respect to Mr. Lubischer and Mitsuo Asai, the President of the Company’s subsidiary, Alphatec Pacific, Inc. (“API”), each Named Executive
Officer is eligible to receive a cash bonus based on the Company’s achievement of certain EBITDA goals, which comprises 100% of the potential award. The EBITDA goals have been determined by the Compensation Committee of the Board. 

2009 Plan for Messrs. Kuyper, Wulff, and Garner 
 With respect to
each of Dirk Kuyper, Peter Wulff and Ebun Garner, the target cash bonuses will be determined according to a formula expressed as percentages of the respective Named Executive Officer’s base salary, and will be subject to adjustments based on
the percentage to which the targeted applicable performance criteria is achieved. In the event the Company exceeds a certain threshold, the Named Executive Officers listed below will be entitled to receive cash bonuses based on higher percentages of
their respective base salaries. The bonuses will be payable after the end of the Company’s 2009 fiscal year. The Compensation Committee of the Board approved the applicable EBITDA targets. The table below sets forth for each of the Named
Executive Officers listed therein, the percentage of the base salary that such Named Executive Officer is eligible to receive as a cash bonus under the 2009 Plan upon the achievement of the target level of EBITDA. 
  

							
	 Name and Title
	  	2009 Base
Salary	  	Bonus Percentage Upon 100%
Achievement of EBITDA
Performance Criteria	 
	 Dirk Kuyper, President and CEO
	  	$	375,000	  	100	%
	 Peter Wulff, Chief Financial Officer and VP
	  	$	260,000	  	50	%
	 Ebun Garner, Esq., General Counsel and VP
	  	$	230,000	  	50	%

 2009 Plan with Respect to Mr. Asai 
 With respect to Mitsuo Asai, the target cash bonus will be determined according to a formula expressed as up to 35% of his base salary of 26 million Japanese Yen, and will be subject to adjustments based on the
percentage to which the targeted applicable performance criteria is achieved. Mr. Asai is eligible to receive a cash bonus based on the achievement of the following goals: (i) a goal based upon API’s total consolidated sales (which
represents 50% of such bonus amount); (ii) a goal based upon API’s total spine sales (which represents 25% of such bonus amount); and (iii) a goal based upon API’s profits before taxes (which represents 25% of such bonus amount).
In the event that API’s profits before taxes exceed certain target levels, Mr. Asai will be entitled to receive a cash bonus based on a higher percentage of his base salary. The bonus will be payable after the end of the Company’s
2009 fiscal year. The Compensation Committee of the Board approved the applicable total sales, spine sales and profits before taxes targets with respect to Mr. Asai. 
 2009 Plan with Respect to Mr. Lubischer 
 With respect to Mr. Lubischer, the target cash bonus amount will be
determined based upon the Company’s achievement of certain sales goals in the U.S. Upon 100% achievement of all of such sales targets, Mr. Lubischer’s bonus would be equal to approximately 100% of his base salary of $245,000. In the
event that U.S. sales exceed certain target levels, Mr. Lubischer will be entitled to receive a cash bonus that is higher then the percentage of his base salary set forth above. Two-thirds of Mr. Lubischer’s bonus is payable
quarterly, based on the achievement of quarterly sales targets and one-third of Mr. Lubishcer’s bonus is payable following the end of the Company’s 2009 fiscal year, based on the achievement of annual sales targets. The Compensation
Committee of the Board approved the applicable sales targets with respect to Mr. Lubischer. 
 For all Named Executive Officers, the Company (or API,
with respect to Mr. Asai) must first achieve a threshold of financial performance that has been established by the Compensation Committee of the Board, before an eligible Named Executive Officer may receive any cash bonuses under the 2009 Plan.
In addition, an eligible Named Executive Officer must be employed by the Company at the time the payment is made in order to receive any bonus payment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]